2011 - Mental Health Research Institute
2011 - Mental Health Research Institute
2011 - Mental Health Research Institute
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
We’re helping to put the pieces together<br />
<strong>2011</strong><br />
Annual Report
2<br />
Annual report <strong>2011</strong>
Contents<br />
4 Vision, Mission and Structure<br />
6 Board of Directors<br />
10 Chair’s Report<br />
13 Executive Director’s Report<br />
14 Behavioural Neuroscience Laboratory<br />
16 Molecular Psychopharmacology Laboratory<br />
18 Molecular Psychiatry Laboratory<br />
20 Neuropathology Laboratory<br />
22 Oxidation Biology Laboratory<br />
27 Synaptic Neurobiology Laboratory<br />
28 Clinical <strong>Research</strong> Group<br />
32 Clinical Discovery Unit<br />
34 Victorian Brain Bank Network<br />
36 Psychotropic Drug Advisory Service<br />
38 The Dax Centre<br />
42 Development and Communications<br />
44 <strong>2011</strong> Publications<br />
50 Concise Financial Operating Summary <strong>2011</strong><br />
52 Personnel and Collaborators <strong>2011</strong><br />
62 Donations <strong>2011</strong><br />
70 A Brief History<br />
72 Further Information<br />
“The new building, and the collaboration it<br />
enables, positions the Melbourne Neuroscience<br />
Centre as one of the top five centres for brain<br />
research internationally.”<br />
3
Vision<br />
To be a global leader in research that improves the lives of<br />
people affected by mental illness including psychotic illness<br />
(schizophrenia and depression) and neurodegenerative<br />
diseases (dementia and Alzheimer’s disease).<br />
Mission<br />
• To undertake sustainable, high quality, basic scientific,<br />
clinical and public health research<br />
• To promote understanding of, and investment in, research<br />
through advocacy<br />
• To educate clinicians and researchers<br />
• To provide expert commentary on the scientific basis of<br />
mental/psychiatric illness and dementia<br />
Structure<br />
The <strong>Institute</strong> is governed by a Board which is legally<br />
responsible for ensuring that the <strong>Institute</strong>’s work is directed<br />
towards its stated objectives. This Board comprises the<br />
Deans from the Medical Faculties of Monash University and<br />
The University of Melbourne, the <strong>Institute</strong>’s Executive Director,<br />
and up to 12 other voluntary members.<br />
The <strong>Institute</strong> is affiliated with Monash University, Melbourne<br />
<strong>Health</strong> and the University of Melbourne in addition to being a<br />
Department of The University of Melbourne (the Department<br />
of <strong>Mental</strong> <strong>Health</strong> in Neuroscience).<br />
4<br />
Annual report <strong>2011</strong><br />
“Our new premises in the Parkville<br />
precinct provides our researchers with<br />
state-of-the-art laboratories as well as<br />
new core services and equipment.”
Board of Directors<br />
6<br />
Annual report <strong>2011</strong><br />
CHAIR – Dr Sandra Hacker AO<br />
MBBS, DPM, FRANZCP, FAICD<br />
Sandra Hacker is a psychiatrist. She works in private practice and as Liaison<br />
Psychiatrist at the Heart/Lung Transplant Unit, Alfred Hospital. She is Chair of the<br />
Australian <strong>Health</strong> Ethics Committee of the National <strong>Health</strong> and Medical <strong>Research</strong><br />
Council and a Director of the Dax Centre.<br />
Dr Hacker was appointed to the MHRI Board in 2000 and became Chair in 2008.<br />
She is Chair of the <strong>Institute</strong>’s Nominations Committee and a member of the Audit<br />
and Risk Management Committee.<br />
DEPUTY CHAIRMAN – Mr Trevor Clark OAM<br />
ACIS, FAMI, FAICD, CPM<br />
Trevor Clark is the Director of management consultancy, TM Clark & Associates.<br />
He has been awarded a Medal of the Order of Australia, recognising his<br />
outstanding contribution to the community.<br />
Mr Clark was appointed to the MHRI Board in 1998 and became Deputy Chair<br />
in 2002. He is Chair of the <strong>Institute</strong>’s Development Council and a member of the<br />
Nominations Committee.<br />
EXECUTIVE DIRECTOR – Laureate Professor Colin Masters<br />
BMedSc (Hons), MBBS, MD, Hon DLitt WAust, FRCPath,<br />
FRCPA, FAA, FTSE<br />
Colin Masters is a Laureate Professor at The University of Melbourne and a former<br />
Director of Prana Biotechnology. He is one of the world’s best known authorities<br />
on Alzheimer’s disease.<br />
Professor Masters was appointed as the <strong>Institute</strong>’s Executive Director in 2007.<br />
He is a member of the <strong>Institute</strong>’s Audit and Risk Management, Nominations,<br />
Intellectual Property and Commercialisation, and Scientific Advisory Committees.
Professor James Angus AO<br />
BSc, PhD, FAA<br />
James Angus is Dean of the Faculty of Medicine, Dentistry and <strong>Health</strong> Sciences at<br />
The University of Melbourne. He is also a Fellow and former Member of Council at<br />
the Australian Academy of Science.<br />
Professor Angus was appointed to the MHRI Board in 2003. He is Chair of the<br />
<strong>Institute</strong>’s Scientific Advisory Committee and a member of the Nominations Committee.<br />
Mr Rob Gerrand<br />
BA, FAMI, FAICD<br />
Rob Gerrand heads the marketing and communications consultancy Gerrand & Associates<br />
and is Chair of <strong>Health</strong>y Parks <strong>Health</strong>y People Global Ltd. He is a former General Manager<br />
of Group Public Affairs at ANZ. Previous board appointments include the Financial<br />
Planning Association of Australia, the Koorie Heritage Trust, the Melbourne Convention<br />
and Marketing Bureau, Alfred Hospital and Parks Victoria where he chaired the Board.<br />
He was the Founding President of the Monash Alumni Association, and in 1994 was<br />
appointed Adjunct Professor at Deakin University. He is a published author.<br />
Mr Gerrand was appointed to the MHRI Board in 1995 and is a member of the Audit<br />
and Risk Management Committee. He is a member of the <strong>Institute</strong>’s Development<br />
Council and represented the MHRI Board on the Project Committee of the Melbourne<br />
Neuroscience Project.<br />
Ms Jennifer Labourne<br />
BBus, FCPA<br />
Jennifer Labourne is the Director of Finance & Business Services at Colac Area<br />
<strong>Health</strong>. She was previously a partner at Ernst & Young, Deputy Chair of <strong>Health</strong><br />
Purchasing Victoria, Director of Parks Victoria and has been involved on various<br />
committees of the Australian Society of Certified Practicing Accountants (CPAs).<br />
Ms Labourne was appointed to the MHRI Board in 2007. She is Chair of the<br />
<strong>Institute</strong>’s Audit and Risk Management Committee.<br />
7
Board of Directors<br />
8<br />
Annual report <strong>2011</strong><br />
Mr Andrew Stripp<br />
MSc (Clin Psychol), BBSc(Hons)<br />
Andrew Stripp is the Deputy Chief Executive Officer and Chief Operating Officer at Alfred<br />
<strong>Health</strong>. He chairs the organisation’s <strong>Health</strong> Services Operations and Leadership<br />
Committee. Previous roles include Director, Strategic Projects, Department of Human<br />
Services (DHS) and Director, Southern Metropolitan Region (DHS).<br />
Mr Stripp was appointed to the MHRI Board in July 2009.<br />
Professor Steve Wesselingh<br />
MBBS, FRACP, PhD (until 30 September <strong>2011</strong>)<br />
Steve Wesselingh was Dean of the Faculty of Medicine, Nursing and <strong>Health</strong> Sciences at<br />
Monash University until his appointment as the inaugural Executive Director of the South<br />
Australian <strong>Health</strong> and Medical <strong>Research</strong> <strong>Institute</strong> in October <strong>2011</strong>. Previously, Professor<br />
Wesselingh was Director of the Burnet <strong>Institute</strong>. From 1994 to 1997 he was on the Board<br />
of the Australian Society for Medical <strong>Research</strong> (ASMR), acting as President in 1998. He is<br />
recognised internationally as an expert in viruses that affect the human brain.<br />
Professor Wesselingh was appointed to the MHRI Board in 2007 until his resignation<br />
this year as a result of his move to South Australia. He was a member of the <strong>Institute</strong>’s<br />
Scientific Advisory Committee.<br />
Professor Ingrid Winship<br />
MBChB, MD, FRACP, FACD<br />
Ingrid Winship is Professor of Adult Clinical Genetics at The University of Melbourne and<br />
Executive Director of <strong>Research</strong>, Melbourne <strong>Health</strong>. She is a Director at the Walter and Eliza<br />
Hall <strong>Institute</strong>, Chair of the Victorian Cooperative Oncology Group (VCOG) Committee, Chair of<br />
the Clinical Services Committee and the Cancer Special Interest Group of the Human Genetic<br />
Society of Australasia and a member of the Victorian Cancer Agency, a consultative council for<br />
Victoria for cancer research.<br />
Professor Winship’s previous appointments include Head, Adult and Cancer Genetics, Genetic<br />
<strong>Health</strong> Services Victoria (2004-2006) and Associate Dean, <strong>Research</strong>, Faculty of Medical and<br />
<strong>Health</strong> Sciences, University of Auckland (1999-2004) and Clinical Director, Northern Regional<br />
Genetic Service, Auckland District <strong>Health</strong> Board (1994-2004).<br />
Professor Winship was appointed to the MHRI Board in June 2009.
Organisational Groups<br />
Development Council<br />
The <strong>Institute</strong>’s Development Council supports the<br />
<strong>Institute</strong>’s fundraising activities.<br />
• Chairman, Trevor Clark OAM<br />
• Peter Bennell<br />
• David Dean<br />
• Rob Gerrand<br />
• Doug George AM<br />
• Roger Flynn<br />
• Geoff Marshall<br />
• George McMaster<br />
Scientific Advisory Committee<br />
• Chair, Professor James Angus AO<br />
• Professor Steve Wesselingh<br />
• Professor Sam Berkovic<br />
• Professor John Furness<br />
• Professor Bruce Tonge<br />
• Professor Assen Jablensky<br />
• Professor Tony Burgess<br />
• Professor Colin Masters<br />
Organisational Memberships<br />
• Australian Association of Medical <strong>Research</strong> <strong>Institute</strong>s<br />
(AAMRI - includes The Australian Synchrotron)<br />
• Australia Israel Chamber of Commerce<br />
• BioMelbourne Network<br />
• Bio21<br />
• <strong>Mental</strong> <strong>Health</strong> Council of Australia<br />
• <strong>Mental</strong> Illness Fellowship of Victoria<br />
• National Neuroscience Facility<br />
• Neurosciences Victoria<br />
• <strong>Research</strong> Australia<br />
Annual General Meeting<br />
The <strong>Mental</strong> <strong>Health</strong> <strong>Research</strong> <strong>Institute</strong>’s Annual<br />
General Meeting will be held on 24 May, 2012.<br />
9
Chair’s Report: Dr Sandra Hacker AO<br />
After six years of planning and implementation<br />
of the Melbourne Neuroscience Project, one of<br />
this year’s most exciting events for the <strong>Mental</strong><br />
<strong>Health</strong> <strong>Research</strong> <strong>Institute</strong> (MHRI) was the much<br />
awaited move to the purpose built Kenneth<br />
Myer Building in Parkville. This move has<br />
provided our scientists with state-of-theart<br />
laboratories and the opportunity to work<br />
alongside other like-minded researchers from<br />
our partner organisations.<br />
The Kenneth Myer Building was officially opened by the<br />
Premier Ted Baillieu and Federal MP Michael Danby in<br />
October <strong>2011</strong>. The name of the building recognises the<br />
significant contribution by the Myer Family to both the<br />
building project and to medical research over many years.<br />
Also opening during the year, were two further facilities<br />
developed as part of the Melbourne Neuroscience Project -<br />
the Melbourne Brain Centres at the Austin and Royal<br />
Melbourne Hospitals. These facilities enable our basic<br />
research to be translated into outcomes for the benefit<br />
of those suffering from a mental illness. These combined<br />
facilities will house over 700 scientists. The <strong>Mental</strong> <strong>Health</strong><br />
<strong>Research</strong> <strong>Institute</strong> will also retain its Oak Street premises<br />
to continue its vital clinical research work.<br />
This year has also been a year of change for the<br />
Cunningham Dax Collection. First, we have given the<br />
collection independence by establishing it as an incorporated<br />
entity known as ‘The Dax Centre’. The Centre has also<br />
moved into the ground floor of the Kenneth Myer Building<br />
providing further opportunities to promote mental health<br />
through art and educate the general public of people’s<br />
experiences with mental illness. The State Minister for <strong>Mental</strong><br />
<strong>Health</strong>, Ms Mary Wooldridge, opened the new Dax Centre at<br />
an event that showcased the spectacular new public gallery<br />
and was attended by the many supporters of the Collection.<br />
Another highlight for <strong>2011</strong> was the launch of the Cooperative<br />
<strong>Research</strong> Centre (CRC) for <strong>Mental</strong> <strong>Health</strong>. The <strong>Institute</strong><br />
10<br />
Annual report <strong>2011</strong><br />
played a pivotal role in the establishment of the CRC and<br />
will have an equally important role in the ongoing research<br />
conducted under the umbrella of the CRC. The CRC brings<br />
together twenty research and commercial organisations to<br />
develop tools for the early diagnosis and prevention of mental<br />
health disorders.<br />
The inaugural Culinary Charity Challenge was a great success,<br />
not only raising vital funds but it was also a fantastic and<br />
fun event celebrating and promoting mental health research.<br />
This major event, along with direct mail campaigns, seminars,<br />
and lectures raised a total of $1.12M. Thank you to all our<br />
incredibly generous donors and philanthropic supporters for<br />
your ongoing involvement and support.<br />
I would like to thank the Board for their tireless efforts during<br />
this busy year. Particular thanks goes to Rob Gerrand and<br />
Andrew Stripp who have participated in regular meetings<br />
to assess the merits of a likely amalgamation with the Florey<br />
Neuroscience <strong>Institute</strong>s. Professor James Angus has acted<br />
as a facilitator for these discussions and as such has stepped<br />
down from his duties as a Director of MHRI whilst negotiations<br />
continue. In addition, Professor Steve Wesselingh resigned<br />
as a Director due to his move to Adelaide to establish the<br />
South Australian <strong>Health</strong> and Medical <strong>Research</strong> <strong>Institute</strong>.<br />
I would also like to congratulate MHRI’s Executive Director<br />
Colin Masters on being awarded the CSIRO Medal for<br />
<strong>Research</strong> Achievement for his research efforts in the area of<br />
Alzheimer’s disease and to extend my thanks to him, to the<br />
Chief Operating Officer Lisa Keam and to all staff for their<br />
contribution in a very challenging year.<br />
Our work continues thanks to funding provided by the<br />
Victorian State Government’s Department of <strong>Health</strong> and the<br />
Department of Business and Innovation who provide recurrent<br />
funding including Operational Infrastructure Support.<br />
Dr Sandra Hacker AO
Tony<br />
Rich<br />
Passionate volunteer<br />
Board Member and the Secretary and<br />
Treasurer for the One in Five Association<br />
“One in Five supports mental<br />
health research. I am a<br />
volunteer Board Member and<br />
the Secretary and Treasurer for<br />
the One in Five Association.<br />
The highlight for me this year<br />
was our Extreme Challenge<br />
that took the form of the<br />
Melbourne Marathon.<br />
Supporting people who<br />
push themselves to the<br />
extreme to support our<br />
cause is a very valuable<br />
and rewarding experience.”<br />
11
12<br />
Derek<br />
Clapton &<br />
Chris Yena<br />
Corporate supporters<br />
“Sailing for Sanity, an annual<br />
event that Warringal Financial<br />
Services have gladly supported<br />
since 2008. Aimed at raising<br />
funds for the <strong>Mental</strong> Heath<br />
<strong>Research</strong> <strong>Institute</strong> (MHRI) this<br />
corporate event provides us the<br />
opportunity to not only support<br />
a very worthwhile cause but to<br />
also participate in an exhilarating<br />
race across Hobsons Bay.”<br />
“As part of the process the awareness<br />
of mental Illness and the research<br />
undertaken in finding a cure has<br />
increased amongst our staff and<br />
our clients many of whom have seen<br />
family members or friends diagnosed<br />
with various forms of mental illness.”<br />
Annual report <strong>2011</strong>
Executive Director’s Report:<br />
Professor Colin L. Masters MD<br />
The highlight of <strong>2011</strong> has undoubtedly been<br />
MHRI’s long awaited relocation to the Kenneth<br />
Myer Building in Parkville. In October of this<br />
year, around 80 of our staff members packed<br />
up their offices and laboratories to move to<br />
one of three floors in the six storey building<br />
that was built under the Melbourne<br />
Neuroscience Project.<br />
The Kenneth Myer Building was designed by Lyons<br />
Architects and provides our researchers with state-of-the-art<br />
laboratories as well as new core services and equipment<br />
also purchased under the Project.<br />
The move to the Kenneth Myer Building enables our<br />
researchers to be co-located with neuroscience researchers<br />
from the Florey Neuroscience <strong>Institute</strong>s and The University<br />
of Melbourne and will facilitate intellectual debate and<br />
collaborations to advance our understandings of many<br />
neurological disorders. Although the majority of MHRI staff<br />
have relocated we will still have staff located at the Alan<br />
Gilbert Building and at our Oak Street site.<br />
As the year drew to a close, we cemented our relationship<br />
with The University of Melbourne by joining with them in<br />
an ‘Enhanced <strong>Research</strong> Collaboration Agreement’ under<br />
which formed a new Department of <strong>Mental</strong> <strong>Health</strong> in<br />
Neuroscience within the Facility of Medicine, Dentistry<br />
and <strong>Health</strong> Science.<br />
MHRI’s research income has continued to grow steadily over<br />
the last few years. Contributing to this growth in income has<br />
been the successful establishment of the CRC for <strong>Mental</strong><br />
<strong>Health</strong>, which over the next seven years will invest funding<br />
into research conducted at MHRI. MHRI will lead projects to<br />
develop biomarkers for the diagnosis of Alzheimer’s disease<br />
and psychiatric disorders such as schizophrenia, depression<br />
and bipolar disorder. The CRC is an excellent vehicle for<br />
building on collaborations with other research organisations<br />
and is encouraging interest from pharmaceutical companies<br />
in developing new tools for the diagnosis and treatment of<br />
neurological disorders.<br />
This year we were very fortunate to have Dr Thomas Insel,<br />
the Director of the National <strong>Institute</strong> of <strong>Mental</strong> <strong>Health</strong> (USA),<br />
to give our 19th Annual John Cade Lecture. Tom gave an<br />
insightful presentation as to the problems facing us in relation<br />
to developing new treatments for mental illness.<br />
A number of our researchers received awards for their<br />
outstanding research efforts including:<br />
• Professor Ashley Bush received one of six National <strong>Health</strong><br />
and Medical <strong>Research</strong> Australia Fellowships, which provides<br />
$4 million of research funding over the next five years.<br />
• Dr Olivia Dean was awarded a <strong>2011</strong> Lilly Young Investigator<br />
Fellow in Bipolar Disorder at the International Conference<br />
on Bipolar Disorder.<br />
• Dr Rachel Hill received a travel award from the World<br />
Federation of Societies of Biological Psychiatry.<br />
• Former Director of MHRI, Professor David Copolov, was<br />
awarded a Medal of the Order of Australia in the Australia<br />
Day Honours List this year for his service to medical research,<br />
to professional organisations, and to higher education.<br />
To mark the transition from Oak St to the new Parkville precinct<br />
we’ve written a brief history of MHRI which you can find on<br />
page 70.<br />
Colin L. Masters MD<br />
13
Behavioural Neuroscience Laboratory<br />
Head: Associate Professor Maarten van den Buuse<br />
The Behavioural Neuroscience Laboratory<br />
uses behavioural animal models to study<br />
brain neurotransmitter mechanisms involved<br />
in schizophrenia. We use state-of-the-art<br />
automated equipment for in vivo experiments,<br />
including photocell activity meters, automated<br />
video analysis of behaviour, prepulse inhibition<br />
of startle and models of learning and memory<br />
in rodents. This in vivo work is complemented<br />
with human studies, receptor binding<br />
autoradiography, and molecular studies.<br />
Highlights<br />
BDNF and schizophrenia<br />
The ‘two hit’ hypothesis of schizophrenia states that stress<br />
early in development increases vulnerability to later stressful<br />
events, leading to a higher risk of developing psychosis and<br />
other psychiatric illnesses. Previous work in the laboratory<br />
established animal models to study this interaction and<br />
suggested an important role of the neurotrophic factor, BDNF.<br />
Using molecular and neurochemical analysis, Rachel Hill<br />
characterised in mice sex differences in the levels of BDNF<br />
and associated proteins during adolescent and young-adult<br />
development. Particularly in male animals, these changes<br />
were correlated with circulating testosterone levels, an<br />
observation which provides important insight into times<br />
during development when there is increased vulnerability<br />
to environmental stress. Candace Wu and Rachel Hill also<br />
studied the interaction of BDNF and the serotonin-1A<br />
receptor using novel, double-mutant mouse models.<br />
The PhD project of Maren Klug focused on the effects of<br />
neurodevelopmental stress in rats or mice. In these animals,<br />
the long-term effects of additional treatment with stress<br />
hormone or a cannabis-like drug is characterised in a battery<br />
14<br />
Annual report <strong>2011</strong><br />
of behavioural tests, including learning and memory. Maren<br />
found significant cognitive changes in the animals after ‘two<br />
hit’ neurodevelopmental stress. Initial molecular analysis<br />
revealed effects on the levels of a key protein in the brain, the<br />
NMDA receptor. Szerenke Kiss von Soly and Rachel Hill are<br />
further characterising molecular changes in the forebrain of<br />
these animals in an attempt to understand the mechanisms<br />
involved in the effects of neurodevelopmental stress.<br />
In contrast, the long-term effects of a cannabis-like treatment<br />
were seen more in tests for anxiety and mood. Natasha<br />
Pracejus commenced a PhD project to continue studying<br />
the role of BDNF in neurodevelopmental stress and the<br />
development of schizophrenia and depression.<br />
Using a similar ‘two hit’ approach, Elizabeth Manning<br />
continued her PhD project looking at chronic treatment<br />
with methamphetamine, which may induce psychosis in<br />
vulnerable individuals. She observed alterations in the longterm<br />
behavioural effects of methamphetamine in male mice<br />
with reduced BDNF levels.<br />
Collectively, these studies provide important new insight into<br />
the brain changes and mechanisms involved in the effect of<br />
one or more developmental ‘hits’ and how these could play<br />
a role in the development of psychiatric illness.<br />
This work is supported by a Project Grant from the National<br />
<strong>Health</strong> and Medical <strong>Research</strong> Council (NHMRC).
Reelin and behaviour<br />
Another protein involved in brain development is reelin.<br />
Mice with only half the normal reelin levels showed markedly<br />
sex-specific behavioural changes. Previous work in the<br />
laboratory demonstrated that removing the source of sex<br />
steroid hormones could influence the behavioural deficits<br />
seen in these mice, as studied in behavioural tests of<br />
psychosis-like behaviour and of sensory gating (the process<br />
by which the brain responds to external stimuli). Rachel Hill<br />
investigated sex-specific changes in the levels of BDNF and<br />
associated proteins in the brains of these animals. Anand<br />
Gururajan, Laetitia Buret and Sally Martin are currently<br />
assessing the effect of stress hormone treatment in these<br />
reelin-deficient mice.<br />
The work on the role of reelin in schizophrenia is supported<br />
by a project grant from the NHMRC which started in <strong>2011</strong>.<br />
Sex steroid hormones and neurodevelopment<br />
Andrea Gogos continued pharmacological studies on how<br />
estrogen and testosterone can modulate behaviour and<br />
central neurotransmitter activity. Prepulse inhibition is a<br />
model of sensory gating that is disrupted in schizophrenia.<br />
Andrea showed that estrogen blocks disruption of prepulse<br />
inhibition by an action on the dopamine system in the brain.<br />
More recently, she extended these observations by showing<br />
additional effects of estrogen on the NMDA receptor. Andrea<br />
Gogos was awarded a prestigious Australian <strong>Research</strong><br />
Council, Discovery Early Career <strong>Research</strong>er Award (ARC<br />
DECRA) fellowship which will enable her to continue<br />
these studies.<br />
Shane Thwaites used an EEG-based model of sensory<br />
gating in rats to assess the effect of different acute and<br />
chronic treatments relevant to schizophrenia. This novel<br />
methodology will be used to investigate the role of<br />
sex steroids in information processing in the brain<br />
and the effects of neurodevelopmental factors in<br />
schizophrenia-like behaviour.<br />
Staff achievements<br />
Maarten van den Buuse was invited to present at seminars<br />
at the John Curtin School of Medicine, Canberra, NeuRA,<br />
Sydney, the Centre for Cancer Biology, Adelaide, the School<br />
of Psychology, Wellington, NZ, and at the Australasian<br />
Cognitive Neuroscience Conference, Sydney.<br />
Conferences & presentations<br />
Australian Neuroscience Society Meeting<br />
Auckland, New Zealand (January <strong>2011</strong>)<br />
World Congress of Biological Psychiatry<br />
Prague, Czech Republic (May/June <strong>2011</strong>)<br />
European College of Neuropsychopharmacology<br />
Paris, France (September <strong>2011</strong>)<br />
First Scientific Meeting of Biological Psychiatry Australia<br />
Melbourne, Australia (November <strong>2011</strong>)<br />
Australasian Society for Psychiatric <strong>Research</strong><br />
Dunedin, New Zealand (December <strong>2011</strong>)<br />
Australasian Cognitive Neuroscience Conference<br />
Sydney (December <strong>2011</strong>)<br />
15
Molecular Psychopharmacology Laboratory /<br />
Northern Psychiatry <strong>Research</strong> Centre<br />
Head: Associate Professor Suresh Sundram<br />
The Molecular Psychopharmacology Laboratory<br />
is dedicated to understanding the molecular<br />
pathology of psychotic disorders such as<br />
schizophrenia, bipolar disorder and major<br />
depression. We aim to develop better and more<br />
effective markers and interventions for these<br />
illnesses. We do this by investigating how<br />
psychotropic medications and drugs interact<br />
with receptors and intracellular signalling<br />
mechanisms in nerve cells (neurons).<br />
The understanding gained from this work can then be tested in<br />
clinical populations through the Northern Psychiatry <strong>Research</strong><br />
Centre (NPRC) leading to the development of new treatments<br />
and markers. Moreover, the NPRC can collect clinical material<br />
and biological samples that can be examined in the laboratory<br />
to better understand these disorders.<br />
Highlights<br />
We are continuing our work to reveal how antipsychotic<br />
drugs work; these are the mainstay of treatment for psychotic<br />
disorders including schizophrenia, bipolar disorder and major<br />
depression. Although these agents have been in use for over<br />
50 years there is still a lot to learn about how they work.<br />
In particular, we continue research into why one antipsychotic<br />
drug, clozapine, is effective in people for whom other<br />
antipsychotic drugs are not. From this we hope to gain<br />
insight into the pathology of psychotic disorders and more<br />
effective ways of treating them.<br />
We have been continuing to investigate our novel findings<br />
about the involvement of a growth factor signalling system<br />
in the brain, the epidermal growth factor (EGF) system, in<br />
the pathology of psychotic disorders.<br />
Avril Pereira and her team have carried on with their work<br />
investigating which proteins are activated in the brain<br />
16<br />
Annual report <strong>2011</strong><br />
consequent to clozapine treatment, in collaboration with Peter<br />
Crouch from The University of Melbourne, this work was also<br />
funded by a NHMRC Project Grant (commenced in 2010). Vaidy<br />
Swaminathan, in collaboration with Cyndi Shannon-Weickert<br />
from University of New South Wales, is looking at how these<br />
genes and proteins of the EGF system may be disturbed in the<br />
brains of people with schizophrenia. These data are currently<br />
being published in scientific journals and will be presented<br />
at the International Congress on Neuropsychopharmacology<br />
(CINP) in Stockholm in mid-2012.<br />
In parallel with the laboratory-based aspects of the project,<br />
Sujeevan Sinnatamby and the NPRC, in collaboration with<br />
Michael Berk from Deakin University, have been collecting<br />
clinical data and biological samples from people who are<br />
receiving treatment with clozapine. We are currently using<br />
these samples to determine if there are specific genetic<br />
variants and blood proteins that can predict response to<br />
clozapine treatment. Biological samples are being collected<br />
with the help of funding from the Marian and EH Flack Trust.<br />
The aim of this type of screening test is to help prevent<br />
unnecessary exposure to the toxic effects of clozapine for<br />
many people, and streamline potential responders to earlier<br />
and more effective intervention.<br />
This work will enable us to understand the pathology of<br />
schizophrenia and hopefully develop more effective<br />
interventions. Our preliminary data have demonstrated<br />
results strongly supporting our hypothesis that the EGF system<br />
correlates with symptoms in people with treatment-resistant<br />
schizophrenia treated with clozapine.
Sensory integration in schizophrenia<br />
With the continued collaboration of Olivia Carter and students<br />
from The University of Melbourne, the group is examining<br />
sensory deficits in schizophrenia. Previous research showed<br />
that healthy individuals are both accurate and fast when it<br />
comes to integrating visual information in different areas of<br />
visual space. In contrast, people with schizophrenia tend<br />
to be selectively impaired on tasks that assess visual<br />
integration. This study has demonstrated that integration of<br />
sensory information is affected across a number of psychotic<br />
disorders and shows some correlation with symptoms.<br />
The group have progressed this research and have now<br />
tested this deficit in other sensory modalities and are<br />
currently analysing these data. They have developed an<br />
auditory version of the test in conjunction with Dr Ken<br />
McAnally from Defence Science and Technology Organisation<br />
(DSTO). Such findings will inform us about the changes in<br />
brain function with reference to specific symptoms across<br />
the range of psychotic disorders.<br />
Improved health care delivery<br />
The two major studies examining new treatments for<br />
people with schizophrenia, in particular, a new long acting<br />
medication that may assist many patients intolerant of<br />
current treatments continues with the NPRC, through<br />
Russell D’Souza.<br />
Suresh Sundram and the Northern Clinical <strong>Research</strong> Centre<br />
have demonstrated that acculturation is a significant<br />
mediator of major depression and anxiety in people with<br />
chronic physical disorders and these data are currently<br />
being prepared for publication. This work is able to continue<br />
thanks to grant funding from beyondblue.<br />
A special thank you<br />
The generous and ongoing support of One in Five continues<br />
to make much of our research possible. The One in Five group<br />
was formed by the friends and family of Matthew Wardlaw<br />
who lost his battle with mental illness on New Years Eve 2001.<br />
An entirely voluntary group and now formally established as<br />
an organisation they provide much needed funds for our work.<br />
Staff achievements<br />
Suresh Sundram continues his work as an external consultant<br />
to the Australian Human Rights Commission on mental<br />
health issues and is currently preparing a report for the<br />
Commission on the mental health problems within<br />
Immigration Detention Centres.<br />
Suresh Sundram was appointed to the Executive of the<br />
World Psychiatric Association Section on Developing<br />
Countries, and was appointed Chair of the Scientific<br />
Committee of the 3rd World Congress of Asian Psychiatry.<br />
Conferences & presentations<br />
IndoGlobal Psychiatry Initiative Annual Meeting<br />
New Delhi, India (January <strong>2011</strong>)<br />
Asian Schizophrenia Congress<br />
Seoul, Korea (February <strong>2011</strong>)<br />
World Congress of Asian Psychiatry (August <strong>2011</strong>)<br />
Biological Psychiatry Australia Meeting<br />
Melbourne, Australia (November <strong>2011</strong>)<br />
17
Molecular Psychiatry Laboratory<br />
Head: Professor Brian Dean<br />
Overview<br />
The mission of the Molecular Psychiatry<br />
Laboratory is to identify the causes of<br />
schizophrenia, bipolar disorder and major<br />
depressive disorders as well as how drugs<br />
used to treat these disorders reduce symptom<br />
severity. Understanding the causes of<br />
schizophrenia, bipolar disorder and major<br />
depressive disorders is the first step in<br />
facilitating the rationale-based drug design<br />
that is needed to develop better treatments<br />
for psychiatric disorders.<br />
Our research to understand how current drugs work is<br />
designed to separate the actions of drugs that reduce<br />
symptoms from those that cause unwanted side-effects,<br />
again as a basis to facilitating the development of improved<br />
drug treatments.<br />
18<br />
Annual report <strong>2011</strong><br />
Highlights<br />
Having made the seminal breakthrough of identifying a<br />
subgroup within patients with schizophrenia who have lost<br />
approximately 75% of their cortical muscarinic M1 receptors,<br />
using microarray technology to further investigate both the<br />
group with normal levels of M1 receptors and those with the<br />
deficit, we have shown:<br />
1. There are marked differences in changes to the genes that<br />
are affected in people who have that deficit and those that<br />
do not and,<br />
2. Different molecular pathways in the brain of the two groups<br />
of people with schizophrenia.<br />
In addition, in collaboration with Professor Ian Everall and<br />
his group in the Department of Psychiatry, The University<br />
of Melbourne, we have shown widespread changes in the<br />
expression of selenium binding protein in the brains of<br />
people with schizophrenia, but not in the brains of people<br />
with depression or bipolar disorder.<br />
Finally, we have shown the changes in selenium binding<br />
protein observed in the cortex of people with schizophrenia<br />
are not present in the cortex of rats that have been treated<br />
with antipsychotic drugs. These findings suggest that<br />
selenium binding protein is not a target of current drug<br />
treatments and the changes in expression of this gene in<br />
brain tissue from people with schizophrenia has not resulted<br />
from such treatments.
Pro-inflammatory pathways<br />
and mood disorders<br />
Our group was the first to show increased levels of transmembrane<br />
tumour necrosis factor in the cortex of subjects<br />
with depression. We have now shown that levels of that<br />
protein are not increased in the cortex of subjects with<br />
schizophrenia but are changed in the cortex of people with<br />
bipolar disorder. We now have data that suggests that<br />
changes in transmembrane tumour necrosis factor related<br />
pathways are present in the cortex of people with major<br />
depressive disorders, bipolar disorders and schizophrenia.<br />
What is interesting is that the changes in schizophrenia are in<br />
pathways that increase cell death whilst the changes in major<br />
depressive disorders and bipolar disorders are in pathways<br />
that are neuroprotective.<br />
Staff achievements<br />
A special presentation by Brian Dean at the Australian<br />
Embassy in Washington DC highlighted the important role of<br />
MHRI research supporting the development of drugs which<br />
target the muscarinic M1 receptor to treat schizophrenia.<br />
Professor Jeffrey Conn, from Vanderbilt University, Nashville<br />
also outlined his progress in developing such drugs.<br />
Brian Dean was invited to join the Editorial Boards of Current<br />
Psychopharmacology, Open Neuropsychopharmacology<br />
Journal, World Journal of Psychiatry, World Journal of<br />
Pharmacology and International Review of Psychiatric<br />
<strong>Research</strong>, and he joined the Board of the Rebecca Cooper<br />
Medical <strong>Research</strong> Foundation.<br />
Brian Dean and Andrew Gibbons were invited speakers at<br />
national and international conferences.<br />
Myoung Suk Seo was awarded the prize for best abstract<br />
submitted by a student to the 1st Annual Scientific Meeting<br />
Biological Psychiatry Australia.<br />
Nahed Tawadros won a poster prize form the 1st Annual<br />
Scientific Meeting Biological Psychiatry Australia.<br />
Conferences & presentations<br />
5th CINP Pacific-Asia Regional Meeting<br />
Kuala Lumpur, Malaysia (June <strong>2011</strong>)<br />
2nd Asian College of Neuropsychopharmacology<br />
Annual meeting<br />
Seoul, Korea (September, <strong>2011</strong>)<br />
Students of Brain <strong>Research</strong><br />
Melbourne, Australia (October <strong>2011</strong>)<br />
First Annual Scientific Meeting of Biological Psychiatry<br />
Melbourne, Australia (November <strong>2011</strong>)<br />
Diplomatic Corps Lecture Series<br />
Australian embassy, Washington DC, USA<br />
World Federation of Biological Psychiatry<br />
Societies Congress<br />
Prague, Czech Republic (May <strong>2011</strong>)<br />
ComBio<br />
Melbourne, Australia<br />
19
Neuropathology Laboratory<br />
Head (Group Leader): Professor Colin L. Masters<br />
Characterisation of the toxic principle for<br />
Alzheimer’s disease<br />
This year has been a very productive year in our effort to<br />
understand the principle cause of neurodegeneration that<br />
occurs in Alzheimer’s disease. The main highlights have been<br />
our discovery of how to control the oligomeric status of<br />
amyloid beta (Aß). Amyloid beta is a 42 amino acid peptide<br />
that causes Alzheimer’s disease.<br />
Our discovery of how to modulate the self assembly of this<br />
neurotoxic peptide has allowed us to solve the first ever<br />
solution structure of oligomeric amyloid beta. This is a major<br />
advance in our understanding of Alzheimer’s disease and has<br />
provided us with a target to develop therapeutic compounds.<br />
The lab is feverishly screening drugs against our target that<br />
we hope will prove to be effective against the progression<br />
of Alzheimer’s disease. Post-doctoral researchers Blaine<br />
Roberts and Tim Ryan pioneered this work along with<br />
post-doctoral researcher Gawain McColl from the Oxidation<br />
Biology Laboratory.<br />
Metallo-proteomics<br />
Proteins that have iron, copper or zinc bound to them make<br />
up about 40% of all proteins and are vital for a variety of<br />
biological functions including oxygen transport, DNA repair,<br />
metabolism and neurodegenerative processes. Despite the<br />
importance of metal cofactors, techniques to measure metal<br />
status in a proteomic fashion are not available. Thus, we have<br />
been developing tools that will allow the direct measurement<br />
of the metal status of proteins. Using our recently developed<br />
techniques we have discovered that iron is dramatically<br />
changed in both the plasma and brain of Alzheimer’s patients.<br />
The identification of the iron proteins that change in<br />
Alzheimer’s disease may allow the future development of<br />
rapid diagnostic tests and increase our understanding of the<br />
role of iron in Alzheimer’s disease.<br />
20<br />
Annual report <strong>2011</strong><br />
Biomarker discovery for Alzheimer’s disease<br />
As the principle proteomic biomarker group involved in the<br />
Australian Imaging Biomarker Lifestyle Flagship Study of<br />
Ageing (AIBL) we have made great progress towards<br />
identifying candidate biomarkers that may one day be used<br />
as diagnostic tests for Alzheimer’s disease.<br />
The AIBL study is a longitudinal study following 1100 people<br />
(approximately 600 controls, 250 with cognitive impairment,<br />
250 with Alzheimer’s disease) over 5 to 10 years. Currently,<br />
our main focus is to identify a unique protein signature from<br />
people with Alzheimer’s disease that can be used as an<br />
early diagnostic. So far we have succeeded in identifying<br />
17 proteins that are unique to Alzheimer’s disease. We are<br />
currently validating this unique protein signature to determine<br />
if it meets the international criteria for a useful diagnostic test.<br />
The biomarker research is led by Scott Laffoon and Blaine<br />
Roberts in international collaboration with Professor<br />
Edward Dratz from Montana State University.
YeeWen<br />
Candace<br />
Wu<br />
Dedicated staff<br />
PhD Student<br />
“I started my PhD at the MHRI’s Behavioural<br />
Neuroscience Laboratory in 2010. Since then,<br />
I have been studying sex differences in<br />
neurodevelopmental animal models of<br />
schizophrenia and depression. I am passionate<br />
about my research as it will give us more insight<br />
into why sex differences occur in these major<br />
mental disorders and this may ultimately<br />
lead us closer to understanding their cause.’’<br />
21
Oxidation Biology Laboratory<br />
Head: Professor Ashley Bush<br />
Overview<br />
The Oxidation Biology Laboratory conducts<br />
research into Alzheimer’s disease and other<br />
neurodegenerative illnesses including<br />
Parkinson’s disease and Huntington’s disease<br />
Directed by National <strong>Health</strong> and Medical <strong>Research</strong> Council<br />
(NHMRC) Australia Fellow Professor Ashley Bush, the<br />
laboratory examines three major themes in order to develop<br />
new therapeutic approaches based on insights gained:<br />
• Oxidative stress in neurological disorders;<br />
• The molecular and cellular basis of neurotoxicity<br />
associated with the deposition of aggregating proteins in<br />
neurodegenerative disorders;<br />
• Understanding the interactions between cellular proteins<br />
and biologically important metals.<br />
Oxidation Biology Laboratory researchers have generated<br />
evidence that the hallmark proteins associated with<br />
Alzheimer’s disease - the Amyloid Precursor Protein (APP)<br />
and its cleavage product amyloid beta (Aß) influence the<br />
import and export of the vital nutrient metals - copper, zinc<br />
and iron - within the brain. Even a subtle imbalance in the<br />
normally tight regulation of these metals resulting from age<br />
or disease-related changes can permit these proteins to<br />
interact abnormally with deleterious effects on multiple<br />
cellular pathways.<br />
22<br />
Annual report <strong>2011</strong><br />
Highlights<br />
Senior <strong>Research</strong> Fellow James Duce has followed up on his<br />
groundbreaking work published in 2010 which identified a<br />
novel role for the Alzheimer’s amyloid precursor protein (APP)<br />
as a ferroxidase involved in regulating iron levels within cells.<br />
This has led to a subsequent discovery describing the role<br />
in iron for tau; another protein heavily involved in Alzheimer’s<br />
disease (AD). Tau appears to be important for the trafficking of<br />
APP to the neuronal cell surface and therefore, mislocalisation<br />
of tau (as evident in a number of neurodegenerative diseases)<br />
leads to an increase in iron. Lead author, PhD student Peng<br />
Lei presented those results in talks at several international<br />
conferences including The Alzheimer’s Association<br />
International Conference and the Annual Meeting of<br />
Neuroscience <strong>2011</strong>. This work has culminated in acceptance<br />
for publication in the high impact journal, Nature Medicine,<br />
and continued NHMRC support for a further 3 years.<br />
Peng also co-authored a review entitled ‘GSK-3 in<br />
neurodegenerative diseases’ which was published in the<br />
International Journal of Alzheimer’s Disease.<br />
Parallel research in the oxidase role of APP has also led<br />
the team to discover that this function is not restricted to<br />
just iron. Recently published in another high impact journal,<br />
Molecular Psychiatry, we show that APP is able to degrade<br />
catecholamines; a group of monoamines that are required<br />
as neurotransmitters within the nervous system. This has<br />
major implications for neurodegenerative diseases such as<br />
Alzheimer’s disease and Parkinson’s disease, but also the<br />
disorders associated with mood such as schizophrenia and<br />
major depression - where catecholamines are thought to be<br />
misregulated. Through MHRI’s unique collection of research<br />
teams in all fields of mental health, cross-group collaboration<br />
has promoted research on APP, traditionally a protein<br />
associated with neurodegeneration, to diversify into the<br />
mood disorders such as depression and bipolar disorder.<br />
<strong>Research</strong> in both these areas has led to invitations to present<br />
this data to the scientific community in a number of national<br />
and international arenas throughout the year.
Caroline<br />
Storm<br />
Passionate supporter<br />
“Philanthropists, businesses,<br />
corporations and small donors,<br />
such as I am, are needed to fund<br />
and expand research which<br />
will eventually conquer brain<br />
destruction. That is why<br />
I support the <strong>Mental</strong> <strong>Health</strong><br />
<strong>Research</strong> <strong>Institute</strong>...a body<br />
of dedicated people who<br />
work to prevent the ravages<br />
of brain disorders such<br />
as schizophrenia, bipolar,<br />
affective disorders, Alzheimer’s<br />
and Parkinson’s diseases.”<br />
23
Oxidation Biology Laboratory<br />
continued<br />
Ya Hui Hung continued to investigate the interaction of copper<br />
and cholesterol and how these interactions may impact on<br />
the neurodegenerative process. Last year Ya Hui established<br />
a novel line of research for our laboratory into Niemann-Pick<br />
Disease Type C (NP-C or ‘Childhood Alzheimer’s’). This fatal<br />
neurodegenerative disorder shares a number of pathological<br />
features with Alzheimer’s disease. The project now underway<br />
investigates the role of metals in the pathogenesis of NP-C<br />
and related diseases. Preliminary findings showed that,<br />
in parallel to Alzheimer’s disease, there are indeed changes<br />
in metal content in the brain tissue and blood plasma from<br />
human NP-C cases and a mouse model of NP-C.<br />
Translational Medicine Unit<br />
In partnership with Melbourne pharmaceutical company Prana<br />
Biotechnology Ltd, Robert Cherny, David Finkelstein and<br />
Jessica George have continued to oversee a team responsible<br />
for biological evaluation of a novel drug PBT434 for the<br />
treatment of Parkinson’s disease. In <strong>2011</strong> the team’s efforts<br />
were critical in obtaining a highly competitive grant from the<br />
Michael J Fox Parkinson’s Disease Foundation for further<br />
preclinical evaluation of the drug. In collaboration with Paul<br />
Adlard and Kevin Barnham, work continues on studying the<br />
mechanism of action of the Alzheimer’s drug PBT2 which<br />
was developed in this laboratory. Dr Cherny presented animal<br />
data on the beneficial effects of PBT2 in the genetic neurodegenerative<br />
disorder Huntington’s disease (HD) at the World<br />
Huntington’s Disease Congress in Melbourne. These results<br />
were central to the recent decision to undertake a clinical trial<br />
of PBT2 in human HD patients.<br />
24<br />
Annual report <strong>2011</strong><br />
C. elegans Ageing and<br />
Neurodegeneration Unit<br />
Gawain McColl operates our invertebrate laboratory<br />
in which he is developing transgenic models of<br />
neurodegeneration and investigating the underlying role<br />
that metals play in biological ageing. He established a<br />
roundworm ‘C. elegans’ model of Alzheimer’s disease<br />
in which he plans to discover and evaluate new drugs<br />
to treat this neurodegenerative condition. He is also<br />
developing new rapid methods to identify potential<br />
therapeutics to treat Parkinson’s disease. In addition,<br />
through collaboration with CSIRO and the Australian<br />
Synchrotron, he has published the first 3-dimensional,<br />
high-definition map of the location of biological metals<br />
in C. elegans. This pioneering work, published in PLoS<br />
One, is expected to lead to many new insights into how<br />
biological metals contribute to the processes of ageing<br />
and neurodegeneration.<br />
Scott Ayton successfully completed his PhD studies in<br />
which he investigated the causes of iron dysregulation<br />
in Parkinson’s disease. Work undertaken during his<br />
candidature was presented at the AD/PD conference in<br />
Barcelona in <strong>2011</strong> and was recently featured in papers<br />
accepted by the highly ranked journals Molecular<br />
Psychiatry and Nature Medicine. Scott was awarded a<br />
grant from the Bethlehem Griffiths research foundation<br />
to further investigate the role of cell-signalling<br />
molecule, nitric oxide, in causing iron dys-regulation in<br />
Parkinson’s disease. By understanding the pathways<br />
that lead to toxic iron dys-regulation in Parkinson’s<br />
disease, new drug targets might be possible. Indeed,<br />
emerging from Scott’s recent work, a patent was<br />
obtained for a potential new Parkinson’s disease drug.<br />
Future work by Scott will investigate how the brain<br />
manages iron in health, Parkinson’s and other diseases,<br />
to determine new therapeutic opportunities.
Conferences & presentations<br />
Metals in the Pathogenesis of Alzheimer’s disease.<br />
Master Class in Alzheimer’s disease Brisbane, Australia.<br />
ß-amyloid Metal Interactions in Alzheimer’s disease:<br />
Physiological and Pathological.<br />
Gordon <strong>Research</strong> Conference on Oxidative Stress<br />
Ventura, CA, USA.<br />
Metals and blood abnormalities in Alzheimer’s disease.<br />
Amgen, Thousand Oaks, CA, USA.<br />
The Metals Theory of Alzheimer’s Disease: an update.<br />
Barwon <strong>Mental</strong> <strong>Health</strong>, Drug & Alcohol Services <strong>2011</strong><br />
Colloquium, Geelong, Australia.<br />
Current and Future State of Alzheimer’s disease Treatments.<br />
Alfred Hospital Grand Rounds. Melbourne, Australia.<br />
Synaptic Zinc as a Pharmacological Target in<br />
Alzheimer’s disease.World Pharma Congress<br />
Philadelphia, USA.<br />
Iron, Tau and DJ-1: Insights into the Mechanism of Action<br />
of PBT434 in Parkinson’s Disease Mouse Models.<br />
World Pharma Congress, Philadelphia, USA.<br />
Alzheimer’s disease: Is a Cure Possible?<br />
Victorian Division of the Australian Academy of Science<br />
Technology and Engineering. Melbourne, Australia.<br />
Plenary Lecture: APP, tau and presenilin: The metal ion<br />
regulatory proteins of Alzheimer’s disease. International<br />
Conference on Alzheimer’s disease, Paris, France.<br />
Alzheimer’s disease: The search for the cure. <strong>Institute</strong> of<br />
<strong>Health</strong> and Biomedical Innovation, Queensland University<br />
of Technology, Brisbane, Australia.<br />
Metallostasis in Alzheimer’s Disease and Parkinson’s Disease.<br />
5th International Conference on Metals and Genetics,<br />
Hyogo, Japan.<br />
Metals and Alzheimer’s disease. National Center of Neurology<br />
and Psychiatry, Tokyo, Japan.<br />
Metallostasis in Alzheimer’s Disease and Parkinson’s Disease.<br />
4th Protein Misfolding and Neurological Disorders Meeting,<br />
Heron Island, Australia.<br />
Metals and Alzheimer’s disease: from bench to clinic. John<br />
Curtin School of Medical <strong>Research</strong>, Canberra, Australia.<br />
Zinc in Alzheimer’s disease. Minisymposium: The<br />
Neurophysiology and Pathology of Brain Zinc. Annual<br />
Meeting, 41st Annual Meeting of Neuroscience, Washington<br />
DC, USA (November <strong>2011</strong>)<br />
Tau-mediated amyloid precursor protein trafficking and iron,<br />
14th International Symposium on Trace Elements in Man and<br />
Animals, Enshi, China (September, <strong>2011</strong>)<br />
Alzheimer’s Association International Conference on<br />
Alzheimer’s Disease, Paris, France (July, <strong>2011</strong>)<br />
Loss of tau induces age-dependent neurodegeneration”,<br />
41st Annual Meeting of Neuroscience <strong>2011</strong><br />
Washington DC, USA (November <strong>2011</strong>)<br />
PBT434, a novel neuroprotective drug for Parkinson’s<br />
Disease. Alzheimer’s Disease/Parkinson’s Disease<br />
conference, Barcelona, Spain (March <strong>2011</strong>)<br />
Loss of tau induces age-dependent neurodegeneration”,<br />
Alzheimer’s Association International Conference on<br />
Alzheimer’s Disease <strong>2011</strong>, Paris, France (July <strong>2011</strong>)<br />
2D-LC-ICP-MS as a confirmation method for LA-ICP-<br />
MS” Agilent-UTS biological laser ablation ICP-MS Workshop.<br />
Sydney, Australia (October <strong>2011</strong>)<br />
Purification of Aß ‘dimers’ from human Alzheimer’s disease<br />
brain.” 4th Protein misfolding and neurological disorders<br />
meeting. Heron Island, Australia (November <strong>2011</strong>)<br />
Investigating the role of metals and membranes in<br />
Alzheimer’s Disease: Why does amyloid ß have to be<br />
soluble to be toxic?” Montana State University-Bozeman,<br />
MT, USA (November <strong>2011</strong>)<br />
Characterising the interaction between tau and metals in<br />
rTg4510 mice. International Conference on Alzheimer’s<br />
Disease Paris, France (July <strong>2011</strong>)<br />
25
26<br />
Andrea<br />
Gogos<br />
Dedicated staff<br />
Postdoctoral Scientist<br />
Annual report <strong>2011</strong><br />
“This year I returned to work from<br />
maternity leave and I was successful<br />
in receiving the Australian <strong>Research</strong><br />
Council Discovery Early Career<br />
<strong>Research</strong>er Award which will provide<br />
funds for me and my research for the<br />
next three years. I am excited about<br />
my research which investigates the<br />
effects of sex hormones on schizophrenia.
Synaptic Neurobiology Laboratory<br />
Heads: Dr Paul Adlard and<br />
Associate Professor David Finkelstein<br />
This laboratory focuses on understanding the<br />
role of metals in both normal and pathological<br />
aging, with a specific focus on understanding<br />
the basic cellular requirements for normal<br />
learning and memory. These studies will help<br />
provide direction for future drug therapy into<br />
conditions such as Alzheimer’s disease and<br />
normal age-related cognitive decline.<br />
Work in this Unit is funded by the Joan and Peter Clemenger<br />
Trust, The National <strong>Health</strong> and Medical <strong>Research</strong> Council<br />
(NHMRC) and The Alzheimer’s Association (USA).<br />
Highlights<br />
Paul Adlard and David Finkelstein demonstrated that one<br />
of the novel compounds they are examining (PBT2, Prana<br />
Biotechnology) has a profound effect on the brains of<br />
‘Alzheimer’s disease’ mice. The short-ter m treatment of<br />
these mice with PBT2 significantly improved the brain<br />
biochemistry and anatomy, which may help explain the<br />
cognitive benefits of this drug.<br />
Paul Adlard was awarded a Travel Fellowship to attend the<br />
Alzheimer’s Association <strong>2011</strong> International Conference on<br />
Alzheimer’s disease, held in Paris, France. Paul Adlard was<br />
also awarded two NHMRC Project Grants, an ARC Discovery<br />
Project Grant and an Alzheimer’s Association (USA) New<br />
Investigator Grant. These Grants will fund investigations into<br />
the role of metals in both normal and pathological ageing<br />
(such as Alzheimer’s disease).<br />
David Finkelstein co-authored a study that investigates<br />
how the compound CopperII (ATSM) prolongs survival in<br />
an amyotrophic lateral sclerosis mouse model (Soon et al,<br />
J Biological Chemistry, <strong>2011</strong>) and was awarded a NHMRC<br />
Project Grant on the role of Copper in Parkinson’s disease,<br />
a Bethlehem Griffiths <strong>Research</strong> award and an ARC<br />
Discovery Project Grant on the role of metals in diseases<br />
of the ageing brain.<br />
Conferences & presentations<br />
Alzheimer’s disease and Parkinson’s disease<br />
Barcelona, Spain (March <strong>2011</strong>)<br />
International Conference on Alzheimer’s disease<br />
Paris, France (July <strong>2011</strong>)<br />
Society for Neuroscience, Washington DC<br />
USA (November <strong>2011</strong>)<br />
Dementia Ageing and Neurodegeneration Diseases Group,<br />
Invited speaker (January <strong>2011</strong>)<br />
Australian Neuroscience Soc (Panel chair)<br />
New Zealand (January <strong>2011</strong>)<br />
Australia-China Biomedical <strong>Research</strong> Conference<br />
Invited speaker (April <strong>2011</strong>)<br />
27
Clinical <strong>Research</strong> Group<br />
Head: Dr Kathryn Ellis<br />
Overview<br />
The Clinical <strong>Research</strong> Group aims to detect<br />
and understand biological, clinical and<br />
cognitive differences between healthy ageing<br />
and dementia, including Alzheimer’s disease.<br />
The group collects, stores and analyses<br />
data from human participants and human<br />
tissue samples.<br />
The multi-disciplinary team includes neuropsychologists,<br />
research nurses, molecular biologists, neuroimagers and<br />
bioinfomaticians. The group is currently involved in the:<br />
• Australian Imaging, Biomarkers and Lifestyle (AIBL)<br />
Flagship Study of Ageing<br />
• Dominantly Inherited Alzheimer’s Network (DIAN) study<br />
• Rates of Change in Cognition (ROCS) study<br />
• AIBL Active Clinical Trial<br />
• Older Australian Twin Study (OATS)<br />
• AIBL - Women’s <strong>Health</strong>y Aging Study (aibl WHAP)<br />
• Dementia Collaborative <strong>Research</strong> Centre -<br />
Early Risk Diagnosis and Prevention<br />
28<br />
Annual report <strong>2011</strong><br />
Highlights<br />
The AIBL Study<br />
In <strong>2011</strong> the group completed the third time point (36 month)<br />
assessment of all study volunteers and has begun assessment<br />
of the fourth time point (54 month). As the study grows, AIBL<br />
has re-opened the cohort to accept some new volunteers.<br />
The data collected from the three time points have been<br />
analysed and some early results are suggesting promising<br />
areas to explore further. These data and analysis are presented<br />
at multiple international conferences and have been published<br />
as numerous manuscripts in international journals; information<br />
on the AIBL study can be found at the new AIBL website<br />
(www.aibl.csiro.au).<br />
The study has also been granted funding from the Science<br />
and Industry Endowment Fund (SIEF) until 2013 which will<br />
assist to fund our operation of the study’s second phase.<br />
AIBL Active Study<br />
This study builds on previous work from AIBL to investigate the<br />
effectiveness of physical activity in delaying the progression<br />
of cognitive decline and cardiovascular disease (as measured<br />
by brain imaging). The group is collaborating with Professor<br />
Nicola Lautenschlager’s team at the National Ageing <strong>Research</strong><br />
<strong>Institute</strong> to carry out neuropsychological assessment,<br />
and sample collection. The group will be continuing this<br />
collaboration throughout 2012.
Justine<br />
Sloane-Lees<br />
Loyal donor<br />
Having studied psychology as my<br />
second major at uni, and being<br />
interested in matters of social<br />
justice are probably why I<br />
decided to become a supporter<br />
of the MHRI. And then there<br />
is the fact that those with<br />
such illnesses don’t just suffer<br />
the effects of the illness<br />
itself but also the stigma<br />
our society still attaches<br />
to it. As someone who is<br />
financially comfortable,<br />
I heed the call the<br />
ethicist Peter Singer makes<br />
in his book, The Life You<br />
Can Save, to do something<br />
to try and help those in<br />
less fortunate circumstances.<br />
29
Clinical <strong>Research</strong> Group<br />
continued<br />
Rate of Change Study<br />
This study aims to improve future research design, so that<br />
studies are easier for participants and for assessors, as well<br />
as to improve our ability to detect even very small changes<br />
in memory at an earlier time point. The study measured<br />
cognitive function over the short (1-3 months) and long<br />
(18 months) term with repeated assessments conducted at<br />
relatively brief re-test intervals in a sub group of 205 well<br />
characterised patients currently enrolled in the AIBL cohort.<br />
We are in the final stages of this study, which is scheduled<br />
to be complete at the end of November 2012. As the study<br />
nears completion, data from these repeated assessments are<br />
being analysed under the direction of study leader Professor<br />
Paul Maruff.<br />
Dominantly Inherited Alzheimer’s<br />
Network (DIAN)<br />
Since its inception in 2008 DIAN has enrolled over 200<br />
participants across sites in the USA and the UK, as well as<br />
in Australia, making it the largest study worldwide examining<br />
familial Alzheimer’s disease. Results from the study have<br />
shown that in this population there are measurable changes<br />
in brain chemistry up to 20 years before clinical symptoms<br />
are detectable.<br />
Registration for the DIAN Therapeutic Trials Unit is open and<br />
DIAN was recently the recipient of the largest ever research<br />
grant from the Alzheimer’s Association in America for its<br />
innovative drug and biomarker trials.<br />
The Clinical <strong>Research</strong> Group at MHRI is leading Melbourne’s<br />
contribution to this important study.<br />
30<br />
Annual report <strong>2011</strong><br />
Internal growth<br />
Due to growth in research activity, the group has now<br />
expanded its office and laboratory area, which has<br />
doubled the capacity to collect and process samples. A new<br />
neuropsychology research assistant has joined the group<br />
to assist with the ongoing assessment of AIBL participants.<br />
The Women’s <strong>Health</strong>y Ageing Study (WHAP)<br />
The Clinical <strong>Research</strong> Group is working with Associate<br />
Professor Cassandra Szoeke’s team at the National Ageing<br />
<strong>Research</strong> <strong>Institute</strong> to re-assess the WHAP cohort, including<br />
administration of the AIBL battery. WHAP is an extension of<br />
the Melbourne Women’s Midlife <strong>Health</strong> Project, undertaken<br />
between 1991-1998, and is an exciting opportunity to<br />
reassess participants 20 years after their first assessments.<br />
Dementia Collaborative <strong>Research</strong> Centres<br />
The group continues to play a key role in phase two of the<br />
Dementia Collaborative <strong>Research</strong> Centres (DCRC), and being<br />
a partner of DCRC - Early Risk Diagnosis and Prevention.<br />
We have a number of projects focusing on blood biomarkers<br />
for Alzheimer’s disease, in addition to a study of a brain<br />
imaging compound which may have clinical utility in the coming<br />
years. This exciting work is being conducted in collaboration<br />
with the Australian National University, Austin <strong>Health</strong> and<br />
Edith Cowan University among other DCRC partners.
Knowledge transfer<br />
The information from the research is disseminated to both<br />
the scientific community and the general public. The Clinical<br />
<strong>Research</strong> Group has presented its research at numerous<br />
scientific conferences through <strong>2011</strong>.<br />
The website AIBL (www.aibl.csiro.au) will further assist with<br />
sharing our research findings with other colleagues and with<br />
the general public.<br />
The group holds a yearly function in conjunction with<br />
Alzheimer’s Australia, Victoria for participants in the AIBL<br />
study. The session includes presentations from leading<br />
scientists and provides a forum for questions and discussion.<br />
Also, participants are updated with regular mail-outs<br />
and newsletters.<br />
Conferences & presentations<br />
Alzheimer’s Association International Conference on<br />
Alzheimer’s Disease (ICAD) and Related Disorders<br />
Paris, France (July <strong>2011</strong>)<br />
DCRC National Dementia Forum<br />
Sydney, Australia (September <strong>2011</strong>)<br />
The 10th International Conference on Alzheimer’s<br />
and Parkinson’s Disease (AD/PD)<br />
Barcelona, Spain (March <strong>2011</strong>)<br />
Science of AIBL Day<br />
Melbourne, Australia (November <strong>2011</strong>)<br />
31
Clinical Discovery Unit<br />
Head: Professor Michael Berk<br />
The Clinical Discovery Unit aims to further<br />
understand the underlying pathology of mental<br />
illness and to assist in the discovery of better<br />
treatments for people with these illnesses.<br />
Collaboration between Deakin University, Barwon <strong>Health</strong><br />
and the <strong>Mental</strong> <strong>Health</strong> <strong>Research</strong> <strong>Institute</strong> investigates novel<br />
pathways to provide new treatment targets, and to<br />
understand the underlying factors involved in the<br />
development of psychiatric disorders. The current research<br />
focuses on oxidative stress, inflammation, mitochondrial<br />
dysfunction and psychiatric illnesses. At present, the group<br />
is conducting clinical trials investigating adjunctive treatments<br />
for psychiatric illnesses and working together on laboratory<br />
based projects aimed at clarifying the underlying<br />
mechanisms. As part of the Cooperative <strong>Research</strong> Centre<br />
for <strong>Mental</strong> <strong>Health</strong> (CRC), a number of trials developing novel<br />
therapies based on these pathways are pending.<br />
The Unit continues to be involved in a range of trials to test<br />
the benefits of the antioxidant N-acetyl cysteine (NAC) on<br />
the symptoms of disorders including bipolar disorder,<br />
depression and autism. In conjunction with these trials,<br />
magnetic resonance spectroscopy is being used to<br />
investigate changes in biomarkers following NAC treatment.<br />
Highlights<br />
NAC in bipolar depression<br />
In this trial all participants were given NAC for two months,<br />
after which participants were randomised to either continue<br />
NAC treatment or receive a placebo. Participants continued<br />
on the trial for a further six months and regular interviews<br />
were conducted to assess changes in participants’<br />
symptoms. This study has been completed with the<br />
open label phase showing significant improvements in<br />
symptoms, quality of life and functioning. In the maintenance<br />
(randomised) phase, the improvements noted in participants<br />
were maintained, resulting in a lack of differentiation between<br />
NAC and placebo groups.<br />
32<br />
Annual report <strong>2011</strong><br />
NAC in major depression<br />
This clinical trial is using a double blind, randomised design.<br />
As with the bipolar depression trial, participants are maintained<br />
on their usual treatment and in addition were given either NAC<br />
or placebo. Participants took the trial medication for three<br />
months. Four weeks following the end of the trial, a follow-up<br />
visit was conducted to establish how participants’ symptoms<br />
changed following the discontinuation of NAC. The recruitment<br />
for this study exceeded the target of 180 participants with<br />
269 people taking part in the study. This study has been<br />
completed and results are currently being analysed.<br />
NAC in autism<br />
There is a still a lack of evidence clearly exploring the<br />
underlying pathophysiology of autism. This disorder not only<br />
has a debilitating effect on the child diagnosed, but also a large<br />
impact on the families and people who care for these children.<br />
Current treatments continue to be suboptimal and many have<br />
little supporting scientific evidence. There is however, evidence<br />
to suggest alterations in oxidative and inflammatory pathways<br />
in autism that may contribute to the disorder.<br />
This ongoing study is investigating NAC (compared to placebo)<br />
in a small group of children with newly diagnosed autism.<br />
A Simons Foundation grant was obtained to turn the Rotary<br />
funded pilot study into a substantive trial. The trial includes a<br />
six month treatment phase followed by two discontinuation<br />
visits to assess the child’s progress both while on NAC and<br />
after completion of the trial. This project is being undertaken<br />
by PhD student, Kristi Villagonzalo, who has been responsible<br />
for the recruitment of approximately 40 children to date.<br />
Recruitment for this study is ongoing.
Future directions<br />
In addition to our trial in autism, Michael Berk and his team<br />
are planning to explore alternative treatments to depression<br />
and early intervention in mood disorders. A series of projects<br />
examining the biological foundations of both psychiatric<br />
illness and the effect of NAC are planned. These include<br />
Magnetic Resonance Spectroscopy studies, the investigation<br />
of statins and aspirin as treatments for depression and<br />
investigation of the relationship of biological markers to<br />
changes in symptomatology. Studies of mitochondrialenhancing<br />
agents for bipolar disorder, and analysis of<br />
peripheral markers are planned as part of the Cooperative<br />
<strong>Research</strong> Centre (CRC).<br />
Staff Achievements<br />
In <strong>2011</strong>, the Unit received five National <strong>Health</strong> and Medical<br />
<strong>Research</strong> Council (NHMRC) Project Grants and has also<br />
received funding from the National <strong>Health</strong> <strong>Institute</strong>, Simons<br />
Foundation Autism <strong>Research</strong> Initiative and the Australasian<br />
Society for Bipolar and Depressive Disorders. Dr Dean was<br />
a Lilly Young Investigator Fellow in Bipolar Disorder in <strong>2011</strong><br />
and has been awarded the Alfred Deakin Postdoctoral<br />
<strong>Research</strong> Fellowship.<br />
In addition to funding success, the unit has had a successful<br />
year in disseminating research findings with several high<br />
impact articles including the Lancet, Molecular Psychiatry<br />
and the American and British Journals of Psychiatry.<br />
Conferences & presentations<br />
Australasian Society for Bipolar and Depressive<br />
Disorders Conference <strong>2011</strong><br />
Sydney, Australia (November <strong>2011</strong>)<br />
Biological Psychiatry Congress <strong>2011</strong><br />
Cape Town, South Africa (September <strong>2011</strong>)<br />
ISBD Korea Annual Meeting<br />
Seoul, Korea (September <strong>2011</strong>)<br />
Geelong Mood Support Group AGM<br />
Geelong, Victoria, Australia (October <strong>2011</strong>)<br />
24th ECNP Congress<br />
Paris, France (September <strong>2011</strong>)<br />
3rd World Congress of Asian Psychiatry <strong>2011</strong><br />
Melbourne, Australia (July <strong>2011</strong>)<br />
FEDERA Meeting <strong>2011</strong> – Chronic Inflammation:<br />
New insights and Challenges<br />
Leiden, The Netherlands (June <strong>2011</strong>)<br />
9th International Conference of Bipolar Disorder<br />
Pittsburgh, Pennsylvania, United States (June <strong>2011</strong>)<br />
INNOPSY 11 (Innovation in Psychiatry)<br />
Milan, Italy (May <strong>2011</strong>)<br />
Japan Speaking Tour<br />
Japan (March <strong>2011</strong>)<br />
33
Victorian Brain Bank Network<br />
Head: Professor Catriona McLean<br />
Aims<br />
The Victorian Brain Bank Network (VBBN)<br />
collects, processes and stores post-mortem<br />
human brains and related samples from<br />
individuals who have had neurological<br />
diseases (i.e. Alzheimer’s disease, motor<br />
neurone disease and Parkinson’s disease),<br />
psychiatric disorders (i.e. bipolar mood<br />
disorder, depression and schizophrenia) as<br />
well as normal ‘control’ cases.<br />
The VBBN facilitates research into the study of brain<br />
diseases by providing tissue to researchers who, using<br />
current technologies, aim to unlock our understanding of<br />
how brain diseases occur and this will hopefully lead to<br />
improvements in diagnosis, the development of early<br />
diagnostic tests, therapeutic interventions and development<br />
of preventative strategies.<br />
The VBBN also provides a vital neuropathological diagnostic<br />
service and supports continued education of medical and<br />
allied health professionals.<br />
Highlights<br />
Brain and or spinal cord donations<br />
The VBBN has a total of 966 cases available for research,<br />
with 74 new donations received in <strong>2011</strong>- that is 28 more<br />
cases than last year. The new donations included cases<br />
diagnosed with Alzheimer’s disease, Frontotemporal<br />
dementias, Huntington’s disease, Lewy body disease,<br />
motor neurone disease, multiple sclerosis, Parkinson’s<br />
disease, schizophrenia, and control ‘normal’ cases.<br />
The VBBN collection makes up 42% of the cases that are<br />
available for research within Australia.<br />
34<br />
Annual report <strong>2011</strong><br />
Tissues provided to researchers<br />
During <strong>2011</strong>, the VBBN provided tissue to 42 Australian and<br />
international new or continuing research projects, with the main<br />
research focus being Alzheimer’s disease, other dementias,<br />
motor neurone disease, schizophrenia and bipolar disorder.<br />
The Molecular Psychiatry Laboratory, and the Oxidation Biology<br />
Laboratory located at MHRI are among the recipients of tissue.<br />
This provision equates to 2,926 diseased and ‘control’ samples<br />
being provided to researchers.<br />
During <strong>2011</strong> research outcomes utilising tissue from the VBBN<br />
has resulted in 23 Australian and international publications<br />
and presentations.<br />
This year the Victorian Brain Bank received grants from<br />
Parkinson’s Victoria $6,000, Motor Neurone Disease <strong>Research</strong><br />
<strong>Institute</strong> of Australia $10,000 and Bethlehem Griffiths <strong>Research</strong><br />
Foundation $23,310.<br />
Acknowledgment<br />
The VBBN would like to acknowledge the generosity shown by<br />
the donors and donor families in donating tissue to the VBBN.<br />
It is an act of great foresight and kindness to give at a time of<br />
loss, so that others may be helped in the future. The clinicians<br />
and researchers who benefit from these donations are very<br />
grateful to the donors and their families who support them with<br />
these decisions.
Gawain<br />
McColl<br />
Dedicated staff<br />
Senior <strong>Research</strong> Officer<br />
“The highlight for me this year<br />
was realising the necessary tools<br />
are now available to start<br />
working out the molecular<br />
details of how ageing and<br />
neurodegenerative diseases<br />
disturb the body’s ability<br />
to maintain biological<br />
metals, like copper<br />
and iron. Using new<br />
synchrotron-based imaging<br />
and mass spectrometry<br />
techniques I believe we will be<br />
making significant medically<br />
relevant discoveries at the<br />
Melbourne Neuroscience Centre.”<br />
35
Psychotropic Drug Advisory Service<br />
Head: Professor Nicholas Keks<br />
The Psychotropic Drug Advisory Service<br />
(PDAS) is an independent source for<br />
information on medicines used to treat mental<br />
illnesses and other drugs that affect the<br />
way we think, feel and behave. Service users<br />
include individuals, medical practitioners,<br />
health care professionals, mental health<br />
care support organisations and their staff,<br />
carers and consumers. Though predominantly<br />
telephone based, the service is also accessed<br />
via email and facsimile.<br />
Professor Nicholas Keks, Deputy Chair of Rehabilitation,<br />
Psychiatry and Pain Clinical <strong>Institute</strong>, Epworth Hospital,<br />
provides clinical support to pharmacist Christine Culhane<br />
who manages the service. The service responds to<br />
approximately 2000 enquiries each year.<br />
Funding is provided by the Department of Human Services<br />
Victoria, <strong>Mental</strong> <strong>Health</strong> Division and is auspiced to the <strong>Mental</strong><br />
<strong>Health</strong> <strong>Research</strong> <strong>Institute</strong>.<br />
36<br />
Annual report <strong>2011</strong><br />
Highlights<br />
Each year many people, young and old, are diagnosed with<br />
a mental illness. For some, psychosocial interventions<br />
adequately control their symptoms. Others will require<br />
biological treatments which include medications. Many do<br />
not fully understand the implications of the treatments or<br />
their role in managing their disorder despite the provision<br />
of this information by their prescriber or other healthcare<br />
professionals. Others wonder about what to expect from<br />
their medication: their benefits, side effects and the possibility<br />
of interactions with other medications they may be taking.<br />
This service provides a forum for discussion of prescribed<br />
medication that is timely and tailored to the needs of the<br />
caller. People have the opportunity to talk about their<br />
medication concerns in a confidential setting and receive<br />
current information.<br />
This is also an important service for carers of people with a<br />
mental illness who are concerned about the effects of these<br />
drugs on the person with the illness. The service can answer<br />
the questions of carers regarding the potential benefits<br />
of medications, adverse effects, safety and tolerability and<br />
possible interactions with other medications. Enquiries from the<br />
general public are nearly half of those recorded by the service.<br />
A range of health care professionals also utilise this service:<br />
psychiatrists, other medical practitioners, health care<br />
professionals including nurses, pharmacists, psychologists<br />
and dieticians, as well as researchers. Electronic databases<br />
allow many professionals to research some of their own<br />
queries making their calls to PDAS when the clinical situation<br />
is complex or to gain extra insights when there are new<br />
medications or other complications involved. The provision<br />
of this information to service providers allows them to best<br />
manage the changing needs of their clientele.<br />
This service also provides vital information for practitioners<br />
and consumers who reside or practise in rural or remote<br />
communities as they may not have the immediate resources<br />
to provide this extra information.
Presentations<br />
Presentations to both professional and consumer groups<br />
are also part of the work undertaken by the service.<br />
Presentations have been requested by and provided to<br />
a number of professional and lay audiences. Christine<br />
has ongoing involvement with The Epworth Hospital<br />
Psychopharmacology master classes with Professor Nicholas<br />
Keks and Dr Judy Hope. These forums are held twice each<br />
year to update the knowledge of practising psychiatrists and<br />
trainees. Tutorials and online discussions for undergraduate<br />
and post graduate pharmacists have also been provided.<br />
Christine has also been to a number of carer and consumer<br />
support organisations to provide information on medications<br />
in a patient sensitive forum.<br />
Professional Development<br />
The Psychotropic Drug Advisory Service provides a much<br />
needed source of specialised information to the broader<br />
mental health community in Victoria. Its value is measured by<br />
consistency of enquiry numbers and timeliness of responses.<br />
In order to provide the best available information, professional<br />
development activities are undertaken including the<br />
requirements for continued registration as a pharmacist<br />
as well as attending psychiatry and pharmacy specific<br />
congresses and symposia.<br />
Conferences & presentations<br />
Society of Hospital Pharmacists of Australia<br />
Victorian Branch Summit<br />
Melbourne, Australia (August <strong>2011</strong>)<br />
Society of Hospital Pharmacists of Australia Annual Meeting<br />
Hobart, Australia (November <strong>2011</strong>)<br />
37
The Dax Centre<br />
Director: Dr Eugen Koh<br />
A new identity<br />
<strong>2011</strong> marked the first year of The Dax Centre,<br />
a newly incorporated entity that has grown<br />
out of the Cunningham Dax Collection (which<br />
had its beginnings in 1946). The Cunningham<br />
Dax Collection began life as an organisation<br />
within the <strong>Mental</strong> <strong>Health</strong> <strong>Research</strong> <strong>Institute</strong><br />
(MHRI) and has continued as such for the past<br />
20 years. While the Cunningham Dax Collection<br />
is now The Dax Centre, an independent<br />
organisation with its own Board of Management,<br />
<strong>Mental</strong> <strong>Health</strong> <strong>Research</strong> <strong>Institute</strong> will retain its<br />
interest as the majority member.<br />
The relocation to the much more accessible, purpose-built<br />
premises in the Kenneth Myer Building in Parkville was a<br />
success thanks to the dedication of The Dax Centre’s staff, and<br />
the strong support of its Advisory Committee members, the<br />
Board of Management and the Council of Reference.<br />
38<br />
Annual report <strong>2011</strong>
The Dax Centre<br />
continued<br />
The Collection<br />
The Cunningham Dax Collection completed the cataloguing<br />
of approximately 2000 works by children who received<br />
psychotherapy at the Royal Children’s Hospital from the early<br />
1950s to the mid-1980s (known as the Margaret Ericksen<br />
Collection), and over 130 works by an artist who painted her<br />
experience of postnatal depression following multiple stillbirths.<br />
We are also most grateful to the staff and students<br />
at the Centre for Cultural Materials Conservation at<br />
The University of Melbourne for providing some of the<br />
conservation required for the latter group of works.<br />
The Collection also began the process of acquiring works<br />
by children from Kosovo and East Timor who were brought<br />
to Victoria in 1999 for safe haven from their war-torn<br />
environment, as well as works by children from the Yarra<br />
Valley who survived the 2009 bushfires.<br />
The high standard of The Dax Centre’s curatorial work was<br />
recognised when it successfully gained full accreditation<br />
from Museums Australia.<br />
Education<br />
One of The Dax Centre’s main objectives is education.<br />
The Education Unit, led by Emma Last, continues to<br />
consolidate its position as the major provider of resources<br />
for the teaching of mental health in VCE Psychology. Over<br />
3000 students attended the on-site exhibitions this past year.<br />
The ‘Mindfields’ program has been particularly successful.<br />
This program begins with students being encouraged to<br />
explore mental health issues through the current exhibition,<br />
followed by presentations by a person who has a mental<br />
illness (an advocate from the <strong>Mental</strong> Illness Fellowship<br />
of Victoria), and a neuroscientist from the <strong>Mental</strong> <strong>Health</strong><br />
<strong>Research</strong> <strong>Institute</strong>.<br />
40<br />
Annual report <strong>2011</strong><br />
Public Programs and Professional Development Programs,<br />
coordinated by Penelope Lee are aimed at building on the<br />
exhibition program by exploring related themes and issues<br />
through artist talks, lectures and seminars. The program<br />
consolidated its introductory art therapy sessions for the<br />
general public and professional development workshops for<br />
art therapists. It also successfully trialled the use of film to<br />
explore issues related to the exhibition, this program will be<br />
launched next year.<br />
The ‘Art for Emotional Literacy’ project, led by Margaret<br />
Nixon, a teacher with many years of experience in teaching<br />
art and student wellbeing, aims to use art to enhance the<br />
development of emotional literacy in primary school children.<br />
This is a new model of teaching art in primary schools formed<br />
by a working party consisting of teachers, an art therapist, a<br />
child educational psychologist, child psychotherapists and<br />
psychiatrists. This new model was successfully trialled in four<br />
schools in <strong>2011</strong>, and it will be piloted in nine schools in 2012.<br />
The other major project is the ‘Emotional World of the Child’.<br />
Led by Pia Brous, a child psychiatrist, and supported by a<br />
small group of senior child psychotherapists, this project<br />
aims to develop a series of educational resources based on<br />
the Margaret Ericksen Collection.<br />
The Asia-Pacific Art and <strong>Mental</strong> <strong>Health</strong> Symposium was<br />
hosted by The Dax Centre in collaboration with Asia Australia<br />
<strong>Mental</strong> <strong>Health</strong>, a program of Asialink, in partnership with St<br />
Vincent’s <strong>Mental</strong> <strong>Health</strong> and the Department of Psychiatry<br />
at The University of Melbourne. This successful symposium,<br />
which was made possible by a generous grant from the<br />
Sidney Myer Fund, brought together about 40 leaders of<br />
art and mental health from 18 countries from the Asia-<br />
Pacific region.
Exhibitions<br />
Picturing Mother and Child and Melancholia.<br />
Living with Psychosis.<br />
Travelling Exhibitions<br />
Travelling exhibitions visited Geelong and Wodonga.<br />
Funding and support<br />
The Dax Centre wishes to acknowledge the continuing<br />
support of the Victorian government, the William Buckland<br />
Foundation, the Myer Foundation and the Sidney Myer Fund,<br />
and a most generous philanthropist who wishes to remain<br />
anonymous. We also wish to acknowledge the support of<br />
MHRI for the past 20 years in auspicing the Cunningham<br />
Dax Collection and in facilitating the relocation to our new<br />
premises. The Dax Centre would not have been what it is<br />
today without the <strong>Mental</strong> <strong>Health</strong> <strong>Research</strong> <strong>Institute</strong>’s support.<br />
We are most grateful for the support of the Board of the<br />
Management, led by Associate Professor Elizabeth Dax<br />
AM, and the Council of Reference, led by the Hon Robert<br />
Knowles AO.<br />
Last but not least, we would like to thank the artists who have<br />
donated their works to the Cunningham Dax Collection, and<br />
have contributed to The Dax Centre’s exhibitions. Without<br />
their support The Dax Centre would simply not exist.<br />
With the support of all the above, and that of the general<br />
community, The Dax Centre will be able to achieve its mission<br />
to promote mental health and wellbeing by fostering a greater<br />
understanding of the mind, mental illness and trauma through<br />
art and creativity.<br />
41
Development and Communications<br />
Head: Ross Johnstone<br />
The Development and Communications<br />
Unit works with businesses, individual<br />
donors, community groups and philanthropic<br />
trusts and foundations to ensure vital<br />
research into dementia, Alzheimer’s disease,<br />
Parkinson’s disease, Huntington’s disease,<br />
major depression, bipolar disorder, and<br />
schizophrenia continues.<br />
In <strong>2011</strong> the unit raised over $1.12 million<br />
from fundraising events, appeals, grants,<br />
trusts and bequests.<br />
Donors<br />
Once again our donors have provided fantastic support to<br />
our mission to improve the lives of people suffering from<br />
neurodegenerative diseases and psychiatric illnesses.<br />
Everyone at the <strong>Mental</strong> <strong>Health</strong> <strong>Research</strong> <strong>Institute</strong> is<br />
thankful for the generosity of our supporters.<br />
<strong>Research</strong> Funding<br />
<strong>Mental</strong> disorders and neurological disorders together account<br />
for 25% of the disease burden in Australia and account for<br />
nearly 10% of health system costs, and receive approximately<br />
9% of funding from the National <strong>Health</strong> and Medical <strong>Research</strong><br />
Council (NHMRC).<br />
That’s why we rely heavily on help from non-government<br />
sources to fund our research and improve the future for<br />
the one in five Australians who experience a mental illness,<br />
and the families and communities who support them.<br />
The generous support we receive from donations and<br />
philanthropic grants is vital to fund specialised equipment<br />
and to support our scientists.<br />
42<br />
Annual report <strong>2011</strong><br />
Events<br />
A new fundraising event for <strong>2011</strong> was the gala Culinary<br />
Charity Challenge - a black-tie battle for culinary supremacy<br />
at Crown Entertainment Centre, Melbourne. The Culinary<br />
Charity Challenge pitted the best Sydney chefs against<br />
Melbourne’s finest in a battle that raised funds to support<br />
research programs at the <strong>Mental</strong> <strong>Health</strong> <strong>Research</strong> <strong>Institute</strong>.<br />
The New South Wales team was captained by Matt Moran<br />
of Sydney’s iconic Aria restaurant. Shannon Bennett, of<br />
Melbourne’s fine dining destination Vue Du Monde, was<br />
captain of the Victorian team.<br />
The Masters of Ceremonies Matt Preston and Ann Peacock<br />
guided us smoothly through the evening, while Jacques<br />
Reymond and his expert panel of judges deliberated<br />
over the fantastic dishes. In the end, Team Victoria was<br />
announced the winner. Let’s see what happens next time.<br />
Warringal Financial Services proved that persistence is<br />
rewarded by winning the <strong>Mental</strong> <strong>Health</strong> Cup at Sailing for<br />
Sanity. This was the fourth consecutive year that Warringal<br />
Financial Services sponsored the yacht Galaxy to take part<br />
in this annual corporate sailing day raising funds for research.<br />
In 2nd place was Duckmobile, sponsored by Parks Victoria,<br />
followed by Audi Penfold Sport in 3rd place. Guests returned<br />
from the water to enjoy a BBQ lunch and live music on the<br />
deck of the Royal Yacht Club of Victoria after the race.
John Cade Lecture<br />
The John Cade lecture was held for the first time at the<br />
new Melbourne Neuroscience Centre and was a resounding<br />
success, with all the seats (and a few extras at the back)<br />
of the new 250 seat theatre taken. This year’s Kearney<br />
Visiting Professor was Dr Thomas Insel (Director of the<br />
National <strong>Institute</strong> of <strong>Mental</strong> <strong>Health</strong>, USA). Dr Insel’s lecture<br />
was very well received; he provided interesting viewpoints<br />
on mental health and challenged everyone to rethink<br />
attitudes to research into mental illnesses, its causes,<br />
and potential cures.<br />
One in Five<br />
Our wonderful supporters, One in Five, are a group of<br />
friends whose lives have been significantly affected by mental<br />
illness. One In Five raises funds to support research into the<br />
cause and treatment of mental illness and passes these funds<br />
on to the <strong>Mental</strong> <strong>Health</strong> <strong>Research</strong> <strong>Institute</strong>. Through their work<br />
they also raise awareness of the fact that one in five people<br />
will suffer some form of mental illness in their lives. One in Five<br />
has grown from a small group comprised of family and friends<br />
of the late Matthew Wardlaw into a professional organisation<br />
with an independent board supported by a growing number<br />
of volunteers.<br />
This hard working group organise great events including<br />
the ‘Long Lunch’ and ‘Extreme Challenge’ which fund the<br />
One in Five research project at the <strong>Institute</strong>. Also, since<br />
2006, a group of surfers formed the “Bolt Blowers” and<br />
have got together with One in Five to organise an annual<br />
fun surf event that also supports the work of the <strong>Institute</strong>.<br />
Dave Dowdle, supported by his wife Karen, cycled from Perth<br />
to Melbourne, within 36 days only taking seven days rest<br />
throughout, and raised over $26,000. At the finish line<br />
Associate Professor Suresh Sundram thanked Dave and<br />
Karen on behalf of the <strong>Mental</strong> <strong>Health</strong> <strong>Research</strong> <strong>Institute</strong> and<br />
congratulated them on their contribution to mental health<br />
research through One in Five.<br />
Education<br />
Once again the innovative and unique education program<br />
Mindfields, initiated by The Dax Centre, provides a great<br />
opportunity for schools to integrate teachings about art,<br />
mental health and neuroscience for Year 11 and Year 12<br />
students. This popular program for students of psychology<br />
caters for both regional and metropolitan schools.<br />
The program includes a presentation by a <strong>Mental</strong> <strong>Health</strong><br />
Advocate from the <strong>Mental</strong> Illness Fellowship and a<br />
presentation by a neuroscientist from the <strong>Mental</strong> <strong>Health</strong><br />
<strong>Research</strong> <strong>Institute</strong>. The students also tour the current<br />
exhibition at The Dax Centre.<br />
Development Council<br />
The Development Council provides advice, counsel and<br />
direct assistance to the <strong>Institute</strong>’s fundraising, marketing<br />
and public relations activities. The Council is chaired by the<br />
<strong>Institute</strong>’s Deputy Chair, Trevor Clark OAM, and includes<br />
fellow Board member, Rob Gerrand, as well as other<br />
volunteer members drawn from the business community.<br />
43
<strong>2011</strong> Publications<br />
Acevedo KM, Hung YH, Dalziel AH, Li QX, Laughton K, Wikhe K,<br />
Rembach A, Roberts B, Masters CL, Bush AI, Camakaris J: Copper<br />
promotes the trafficking of the amyloid precursor protein. Journal of<br />
Biological Chemistry <strong>2011</strong>, 286(10):8252-8262.<br />
Adams W, van den Buuse M: Hippocampal serotonin depletion<br />
facilitates the enhancement of prepulse inhibition by risperidone:<br />
Possible role of 5-HT(2C) receptors in the dorsal hippocampus.<br />
Neuropharmacology <strong>2011</strong>, 61(3):458-467.<br />
Adlard PA, Bica L, White AR, Nurjono M, Filiz G, Crouch PJ, Donnelly<br />
PS, Cappai R, Finkelstein DI, Bush AI: Metal ionophore treatment<br />
restores dendritic spine density and synaptic protein levels in a mouse<br />
model of Alzheimer’s disease. PloS One <strong>2011</strong>, 6(3):e17669.<br />
Adlard PA, Bush AI: The plasma membrane redox system in<br />
Alzheimer’s disease. Experimental Neurology <strong>2011</strong>, 228(1):9-14.<br />
Adlard PA, Engesser-Cesar C, Cotman CW: Mild stress facilitates<br />
learning and exercise improves retention in aged mice. Experimental<br />
Gerontology <strong>2011</strong>, 46(1):53-59.<br />
Ascher DB, Cromer BA, Morton CJ, Volitakis I, Cherny RA, Albiston<br />
AL, Chai SY, Parker MW: Regulation of insulin-regulated membrane<br />
aminopeptidase activity by its c-terminal domain. Biochemistry <strong>2011</strong>,<br />
50(13):2611-2622.<br />
Berk L, Jorm AF, Kelly CM, Dodd S, Berk M: Development of<br />
guidelines for caregivers of people with bipolar disorder: a Delphi<br />
expert consensus study. Bipolar Disorders <strong>2011</strong>, 13(5-6):556-570.<br />
Berk M, Brnabic A, Dodd S, Kelin K, Tohen M, Malhi GS, Berk L,<br />
Conus P, McGorry PD: Does stage of illness impact treatment<br />
response in bipolar disorder? Empirical treatment data and their<br />
implication for the staging model and early intervention. Bipolar<br />
Disorders <strong>2011</strong>, 13(1):87-98.<br />
Berk M, Johansson S, Wray NR, Williams L, Olsson C, Haavik J,<br />
Bjerkeset O: Glutamate cysteine ligase (GCL) and self reported<br />
depression: An association study from the HUNT. Journal of Affective<br />
Disorders <strong>2011</strong>, 131(1-3):207-213.<br />
Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes<br />
M, Yucel M, Gama CS, Dodd S, Dean B, Magalhães PV, Amminger P,<br />
McGorry P, Malhi GS: Pathways underlying neuroprogression in bipolar<br />
disorder: Focus on inflammation, oxidative stress and neurotrophic<br />
factors. Neuroscience and Biobehavioral Reviews <strong>2011</strong>, 35(3):804-817.<br />
Berk M, Malhi GS: Should antipsychotics take pole position in mania<br />
treatment? Lancet <strong>2011</strong>, 378(9799):1279-1281.<br />
Berk M, Munib A, Dean O, Malhi GS, Kohlmann K, Schapkaitz I,<br />
Jeavons S, Katz F, Anderson-Hunt M, Conus P, Hanna B, Otmar R,<br />
Ng F, Copolov DL, Bush Al: Qualitative methods in early-phase drug<br />
44<br />
Annual report <strong>2011</strong><br />
trials: Broadening the scope of data and methods from an RCT of<br />
N-acetylcysteine in schizophrenia. Journal of Clinical Psychiatry <strong>2011</strong>,<br />
72(7):909-913.<br />
Beyer N, Coulson DTR, Cherny R, Volitakis I, Bush AI, Heggarty S,<br />
Ravid R, Hellemans J, Irvine GB, Johnston JA: Reduced prion protein<br />
expression in Alzheimer’s disease post-mortem human brain may<br />
impair neuronal zinc uptake. Irish Journal of Medical Science <strong>2011</strong>,<br />
180:24.<br />
Bica L, Meyerowitz J, Parker SJ, Caragounis A, Du T, Paterson BM,<br />
Barnham KJ, Crouch PJ, White AR, Donnelly PS: Cell cycle arrest in<br />
cultured neuroblastoma cells exposed to a bis(thiosemicarbazonato)<br />
metal complex. Biometals <strong>2011</strong>, 24(1):117-133.<br />
Bora E, Yucel M, Pantelis C, Berk M: Meta-analytic review of<br />
neurocognition in bipolar II disorder. Acta Psychiatrica Scandinavica<br />
<strong>2011</strong>, 123(3):165-174.<br />
Boyd A, Klug G, Masters CL, Collins SJ: Iatrogenic Creutzfeldt-Jakob<br />
disease in Australia: time to amend infection control measures for<br />
pituitary hormone recipients? REPLY. Medical Journal of Australia <strong>2011</strong>,<br />
194(4):215.<br />
Callaly T, Trauer T, Hyland M, Coombs T, Berk M: An examination of<br />
risk factors for readmission to acute adult mental health services within<br />
28 days of discharge in the Australian setting. Australasian Psychiatry<br />
<strong>2011</strong>, 19(3):221-225.<br />
Camfield DA, Sarris J, Berk M: Nutraceuticals in the treatment of<br />
Obsessive Compulsive Disorder (OCD): A review of mechanistic and<br />
clinical evidence. Progress in Neuro-Psychopharmacology & Biological<br />
Psychiatry <strong>2011</strong>, 35(4):887-895.<br />
Chavez C, Gogos A, Hill R, Van Sinderen M, Simpson E, Boon WC,<br />
van den Buuse M: Differential effect of amphetamine on c-fos<br />
expression in female aromatase knockout (ArKO) mice compared to<br />
wildtype controls. Psychoneuroendocrinology <strong>2011</strong>, 36(5):761-768.<br />
Chetelat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G,<br />
O’Keefe GJ, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL,<br />
Rowe CC, Australian Imaging Biomarkers and Lifestyle Study of<br />
Ageing (AIBL) <strong>Research</strong> Group: Independent contribution of temporal<br />
beta-amyloid deposition to memory decline in the pre-dementia phase<br />
of Alzheimer’s disease. Brain <strong>2011</strong>, 134:798-807.<br />
Ciccotosto GD, Tew DJ, Drew SC, Smith DG, Johanssen T, Lal V, Lau<br />
TL, Perez K, Curtain CC, Wade JD, Separovic F, Masters CL, Smith JP,<br />
Barnham KJ, Cappai R: Stereospecific interactions are necessary for<br />
Alzheimer disease amyloid-beta toxicity. Neurobiology of Aging <strong>2011</strong>,<br />
32(2):235-248.
Corrigan F, Pham CLL, Vink R, Blumbergs PC, Masters CL, van den<br />
Heuvel C, Cappai R: The neuroprotective domains of the amyloid<br />
precursor protein, in traumatic brain injury, are located in the two<br />
growth factor domains. Brain <strong>Research</strong> <strong>2011</strong>, 1378:137-143.<br />
Crouch PJ, Savva MS, Hung LW, Donnelly PS, Mot AI, Parker SJ,<br />
Greenough MA, Volitakis I, Adlard PA, Cherny RA, Masters CL,<br />
Bush AI, Barnham KJ, White AR: The Alzheimer’s therapeutic PBT2<br />
promotes amyloid-beta degradation and GSK3 phosphorylation via a<br />
metal chaperone activity. Journal of Neurochemistry <strong>2011</strong>, 119(1):<br />
220-230.<br />
Darby DG, Brodtmann A, Pietrzak RH, Fredrickson J, Woodward M,<br />
Villemagne VL, Fredrickson A, Maruff P, Rowe C: Episodic memory<br />
decline predicts cortical amyloid status in community-dwelling older<br />
adults. Journal of Alzheimers Disease <strong>2011</strong>, 27(3):627-637.<br />
Davison SL, Bell RJ, Gavrilescu M, Searle K, Maruff P, Gogos A,<br />
Rossell SL, Adams J, Egan GF, Davis SR: Testosterone improves<br />
verbal learning and memory in postmenopausal women: Results from<br />
a pilot study. Maturitas <strong>2011</strong>, 70(3):307-311.<br />
Dean B: Understanding the role of inflammatory-related pathways in<br />
the pathophysiology and treatment of psychiatric disorders: evidence<br />
from human peripheral studies and CNS studies. International Journal<br />
of Neuropsychopharmacology <strong>2011</strong>, 14(7):997-1012.<br />
Dean B, Gibbons A, Scarr E, Thomas EA: In: Handbook of<br />
schizophrenia Spectrum Disorders, Volume I. Chapter 10: Changes<br />
in gene expression in subjects with schizophrenia associated with<br />
disease progression; <strong>2011</strong>, Published by Springer, Editor Michael S.<br />
Ritsner, Dordrecht Heidelberg, London, New York.<br />
Dean B, Tawadros N, Scarr E, Gibbons A: Regionally-specific<br />
changes in levels of tumour necrosis factor in the cortex obtained<br />
postmortem from subjects with mood disorder. Biological Psychiatry<br />
<strong>2011</strong>, 69(9):129S-129S.<br />
Dean O, Giorlando F, Berk M: N-acetylcysteine in psychiatry: current<br />
therapeutic evidence and potential mechanisms of action. Journal of<br />
Psychiatry & Neuroscience <strong>2011</strong>, 36(2):78-86.<br />
Dean OM, van den Buuse M, Berk M, Copolov DL, Mavros C, Bush<br />
AI: N-acetyl cysteine restores brain glutathione loss in combined<br />
2-cyclohexene-1-one and D-amphetamine-treated rats: Relevance<br />
to schizophrenia and bipolar disorder. Neuroscience Letters <strong>2011</strong>,<br />
499(3):149-153.<br />
Dodd S, Malhi GS, Tiller J, Schweitzer I, Hickie I, Khoo JP, Bassett DL,<br />
Lyndon B, Mitchell PB, Parker G, Fitzgerald PB, Udina M, Singh A,<br />
Moylan S, Giorlando F, Doughty C, Davey CG, Theodoros M, Berk M:<br />
A consensus statement for safety monitoring guidelines of treatments<br />
for major depressive disorder. Australian and New Zealand Journal of<br />
Psychiatry <strong>2011</strong>, 45(9):712-725.<br />
Drew SC, Barnham KJ: The heterogeneous nature of Cu2+<br />
interactions with Alzheimer’s amyloid-beta peptide.<br />
Accounts of Chemical <strong>Research</strong> <strong>2011</strong>, 44(11):1146-1155.<br />
Drew SC, Haigh CL, Klemm HMJ, Masters CL, Collins SJ, Barnham<br />
KJ, Lawson VA: Optical imaging detects apoptosis in the brain and<br />
peripheral organs of prion-infected mice. Journal of Neuropathology<br />
and Experimental Neurology <strong>2011</strong>, 70(2):143-150.<br />
Ellis KA, Rowe CC, Szoeke CEI, Villemagne VL, Ames D, Chetelat G,<br />
Martins RN, Masters CL, Fripp J, Acosta O, Raninga P, Bourgeat PT,<br />
Salvado O: Advances in structural and molecular neuroimaging in<br />
Alzheimer’s disease. Medical Journal of Australia <strong>2011</strong>, 194(4):S20-S23.<br />
Faux NG, Ellis KA, Porter L, Fowler CJ, Laws SM, Martins RN, Pertile<br />
KK, Rembach A, Rowe CC, Rumble RL, Szoeke C, Taddei K, Taddei T,<br />
Trounson BO, Villemagne VL, Ward V, Ames D, Masters CL, Bush AI:<br />
Homocysteine, vitamin B12, and folic acid levels in Alzheimer’s disease,<br />
mild cognitive impairment, and healthy elderly: Baseline characteristics<br />
in subjects of the Australian Imaging Biomarkers Lifestyle Study.<br />
Journal of Alzheimers Disease <strong>2011</strong>, 27(4):909-922.<br />
Fink G: Stress Controversies: Post-Traumatic Stress Disorder,<br />
Hippocampal Volume, Gastroduodenal Ulceration. Journal of<br />
Neuroendocrinology <strong>2011</strong>, 23(2):107-117.<br />
Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor AR,<br />
McLean CA, Cao DN, Rigopoulos A, Cartwright GA, O’Keefe G, Gong<br />
S, Adlard PA, Barnham KJ, Rowe CC, Masters CL, Kudo Y, Cappai R,<br />
Yanai K, Villemagne VL: 18F-THK523: a novel in vivo tau imaging ligand<br />
for Alzheimer’s disease. Brain <strong>2011</strong>, 134:1089-1100.<br />
Fodero-Tavoletti MT, Villemagne VL, Rowe CC, Masters CL, Barnham<br />
KJ, Cappai R: Amyloid-beta: The seeds of darkness. International<br />
Journal of Biochemistry & Cell Biology <strong>2011</strong>, 43(9):1247-1251.<br />
Fox JH, Connor T, Stiles M, Kama J, Lu Z, Dorsey K, Liebermann G,<br />
Sapp E, Cherny RA, Banks M, Volitakis I, DiFiglia M, Berezovska O,<br />
Bush AI, Hersch SM: Cysteine oxidation within N-terminal mutant<br />
Huntingtin promotes oligomerization and delays clearance of soluble<br />
protein. Journal of Biological Chemistry <strong>2011</strong>, 286(20):18320-18330.<br />
Gerlach M, Bartoszyk GD, Riederer P, Dean O, van den Buuse M: Role<br />
of dopamine D(3) and serotonin 5-HT(1A) receptors in L-DOPA-induced<br />
dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned<br />
rat model of Parkinson’s disease. Journal of Neural Transmission <strong>2011</strong>,<br />
118(12):1733-1742.<br />
Gerlach M, Beck J, Riederer P, van den Buuse M: Flibanserin<br />
attenuates L-DOPA-sensitized contraversive circling in the unilaterally<br />
6-hydroxydopamine-lesioned rat model of Parkinson’s disease. Journal<br />
of Neural Transmission <strong>2011</strong>, 118(12):1727-1732.<br />
45
<strong>2011</strong> Publications<br />
continued<br />
Gibbons AS, Udawela M, Jeon WJ, Seo MS, Brooks L, Dean B:<br />
The neurobiology of APOE in schizophrenia and mood disorders.<br />
Frontiers in Bioscience-Landmark <strong>2011</strong>, 16:962-979.<br />
Gogos A, Kwek P, van den Buuse M: The role of estrogen and<br />
testosterone in female rats in behavioural models of relevance to<br />
schizophrenia. European Neuropsychopharmacology <strong>2011</strong>, 21:<br />
S261-S262.<br />
Greenough MA, Volitakis I, Li QX, Laughton K, Evin G, Ho M, Dalziel<br />
AH, Camakaris J, Bush AI: Presenilins promote the cellular uptake of<br />
copper and zinc and maintain copper chaperone of SOD1-dependent<br />
copper/zinc superoxide dismutase activity. Journal of Biological<br />
Chemistry <strong>2011</strong>, 286(11):9776-9786.<br />
Guille V, Gogos A, Nathan PJ, Croft RJ, van den Buuse M: Interaction<br />
of estrogen with central serotonergic mechanisms in human sensory<br />
processing: loudness dependence of the auditory evoked potential<br />
and mismatch negativity. Journal of Psychopharmacology <strong>2011</strong>,<br />
25(12):1614-1622.<br />
Gupta VB, Laws SM, Villemagne VL, Ames D, Bush AI, Ellis KA, Lui JK,<br />
Masters C, Rowe CC, Szoeke C, Taddei K, Martins RN and the AIBL<br />
<strong>Research</strong> Group: Plasma apolipoprotein E and Alzheimer disease risk;<br />
The AIBL study of aging. Neurology <strong>2011</strong>, 76(12):1091-1098.<br />
Haigh CL, McGlade AR, Lewis V, Masters CL, Lawson VA, Collins SJ:<br />
Acute exposure to prion infection induces transient oxidative stress<br />
progressing to be cumulatively deleterious with chronic propagation<br />
in vitro. Free Radical Biology and Medicine <strong>2011</strong>, 51(3):594-608.<br />
Harel BT, Darby D, Pietrzak RH, Ellis KA, Snyder PJ, Maruff P:<br />
Examining the nature of impairment in visual paired associate<br />
learning in amnestic mild cognitive impairment. Neuropsychology<br />
<strong>2011</strong>, 25(6):752-762.<br />
Hickey JL, Crouch PJ, Mey S, Caragounis A, White JM, White AR,<br />
Donnelly PS: Copper(II) complexes of hybrid hydroxyquinolinethiosemicarbazone<br />
ligands: GSK3 beta inhibition due to intracellular<br />
delivery of copper. Dalton Transactions <strong>2011</strong>, 40(6):1338-1347.<br />
Hill RA, Murray SS, Halley PG, Binder MD, Martin SJ, van den Buuse<br />
M: Brain-derived neurotrophic factor expression is increased in the<br />
hippocampus of 5-HT(2C) receptor knockout mice. Hippocampus<br />
<strong>2011</strong>, 21(4):434-445.<br />
Hill RA, van den Buuse M: Sex-dependent and region-specific changes<br />
in TrkB signaling in BDNF heterozygous mice. Brain <strong>Research</strong> <strong>2011</strong>,<br />
1384:51-60.<br />
46<br />
Annual report <strong>2011</strong><br />
Ho M, Hoke DE, Chua YJ, Li Q-X, Culvenor JG, Masters CL, White<br />
AR, Evin G: Effect of metal chelators on y-secretase indicates that<br />
calcium and magnesium ions facilitate cleavage of Alzheimer amyloid<br />
precursor substrate. International Journal of Alzheimer’s Disease <strong>2011</strong>,<br />
doi.10.4061/<strong>2011</strong>/950932.<br />
Jacka FN, Kremer PJ, Berk M, de Silva-Sanigorski AM, Moodie M,<br />
Leslie ER, Pasco JA, Swinburn BA: A prospective study of diet quality<br />
and mental health in adolescents. PloS One <strong>2011</strong>, 6(9)e24805.<br />
Jacka FN, Mykletun A, Berk M, Bjelland I, Tell GS: The association<br />
between habitual diet quality and the common mental disorders in<br />
community-dwelling adults: The Hordaland <strong>Health</strong> Study.<br />
Psychosomatic Medicine <strong>2011</strong>, 73(6):483-490.<br />
Jacka FN, Pasco JA, Williams LJ, Leslie ER, Dodd S, Nicholson GC,<br />
Kotowicz MA, Berk M: Lower levels of physical activity in childhood<br />
associated with adult depression. Journal of Science and Medicine in<br />
Sport <strong>2011</strong>, 14(3):222-226.<br />
James SA, Volitakis I, Adlard PA, Duce JA, Masters CL, Cherny RA,<br />
Bush AI: Elevated labile Cu is associated with oxidative pathology in<br />
Alzheimer’s disease. Free Radical Biological Medicine <strong>2011</strong>,<br />
52(2):298-302.<br />
Karl T, Burne THJ, van den Buuse M, Chesworth R: Do transmembrane<br />
domain neuregulin 1 mutant mice exhibit a reliable sensorimotor gating<br />
deficit? Behavioural Brain <strong>Research</strong> <strong>2011</strong>, 223(2):336-341.<br />
Kenche VB, Barnham KJ: Alzheimer’s disease & metals: therapeutic<br />
opportunities. British Journal of Pharmacology <strong>2011</strong>, 163(2):211-219.<br />
Klug GM, Boyd A, McGlade A, Stehmann C, Masters CL, Collins SJ:<br />
Surveillance of Creutzfeldt-Jakob disease in Australia: update to<br />
December 2010. Communicable Diseases Intelligence Quarterly<br />
Reports <strong>2011</strong>, 35(2):149-153.<br />
Kusljic S, van den Buuse M. The effect of serotonergic lesions in the<br />
medial prefrontal cortex on psychotomimetic drug-induced locomotor<br />
hyperactivity and prepulse inhibition in rats. Serbian Journal of<br />
Experimental and Clinical <strong>Research</strong> <strong>2011</strong>, 21:11-19.<br />
Lambert JC, Dallongeville J, Ellis KA, Schraen-Maschke S, Lui J, Laws<br />
S, Dumont J, Richard F, Cottel D, Berr C, Ames D, Masters CL, Rowe<br />
CC, Szoeke C, Tzourio C, Dartiques JF, Buée L, Martins R, Amouyel<br />
P: Association of plasma A beta peptides with blood pressure in the<br />
elderly. Plos One <strong>2011</strong>, 6(4)e18536.<br />
Lawson VA, Klemm HM, Welton JM, Masters CL, Crouch P, Cappai R,<br />
Ciccotosto GD: Gene knockout of tau expression does not contribute<br />
to the pathogenesis of prion disease. Journal of Neuropathology and<br />
Experimental Neurology <strong>2011</strong>, 70(11):1036-1045.
Leyton CE, Villemagne VL, Savage S, Pike KE, Ballard KJ, Piguet O,<br />
Burrell JR, Rowe CC, Hodges JR: Subtypes of progressive aphasia:<br />
application of the international consensus criteria and validation using<br />
beta-amyloid imaging. Brain <strong>2011</strong>, 134:3030-3043.<br />
Lim NKH, Villemagne VL, Soon CPW, Laughton KM, Rowe CC,<br />
McLean CA, Masters CL, Evin G, Li QX: Investigation of matrix<br />
metalloproteinases, MMP-2 and MMP-9, in plasma reveals a decrease<br />
of MMP-2 in Alzheimer’s Disease. Journal of Alzheimers Disease<br />
<strong>2011</strong>, 26(4):779-786.<br />
Macneil CA, Hasty MK, Berk M, Henry L, Evans M, Redlich C, Daglas<br />
R, McGorry PD, Conus P: Psychological needs of adolescents in the<br />
early phase of bipolar disorder: implications for early intervention.<br />
Early Intervention in Psychiatry <strong>2011</strong>, 5(2):100-107.<br />
Maes M, Galecki P, Chang YS, Berk M: A review on the oxidative and<br />
nitrosative stress (O&NS) pathways in major depression and their<br />
possible contribution to the (neuro)degenerative processes in that<br />
illness. Progress in Neuro-Psychopharmacology & Biological<br />
Psychiatry <strong>2011</strong>, 35(3):676-692.<br />
Maes M, Ruckoanich P, Chang YS, Mahanonda N, Berk M: Multiple<br />
aberrations in shared inflammatory and oxidative & nitrosative stress<br />
(IO&NS) pathways explain the co-association of depression and<br />
cardiovascular disorder (CVD), and the increased risk for CVD<br />
and due mortality in depressed patients. Progress in Neuro-<br />
Psychopharmacology & Biological Psychiatry <strong>2011</strong>, 35(3):769-783.<br />
Magalhaes PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann<br />
K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M: Dimensions of<br />
improvement in a clinical trial of N-acetyl cysteine for bipolar disorder.<br />
Acta Neuropsychiatrica <strong>2011</strong>, 23(2):87-88.<br />
Magalhaes PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann<br />
K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M: N-acetyl<br />
cysteine add-on treatment for bipolar II disorder: a subgroup analysis<br />
of a randomized placebo-controlled trial. Journal of Affective<br />
Disorders <strong>2011</strong>, 129(1-3):317-320.<br />
Malhi GS, Berk M: Depolarizing bipolar disorder: both the illness and<br />
our views. Australian and New Zealand Journal of Psychiatry <strong>2011</strong>,<br />
45(11):909-910.<br />
Manso Y, Adlard PA, Carrasco J, Vasak M, Hidalgo J: Metallothionein<br />
and brain inflammation. Journal of Biological Inorganic Chemistry<br />
<strong>2011</strong>, 16(7):1103-1113.<br />
Masters CL. Colin Masters on Seeking the Natural History of<br />
Alzheimer’s Disease Special Topic of Alzheimer’s Disease Interview,<br />
May <strong>2011</strong>. www.sciencewatch.com http://sciencewatch.com/ana/st/<br />
alz2/11maySTAlz2Mast/.<br />
Masters CL, Kril JJ, Halliday GM, Pamphlett R, Collins S, Hill AF,<br />
McLean C: Overview and recent advances in neuropathology. Part 2:<br />
Neurodegeneration. Pathology <strong>2011</strong>, 43(2):93-102.<br />
Masters CL. Abeta toxicity - Part I and II. In: Hardy, J. (ed.),<br />
Alzheimer’s Disease: The Biomedical & Life Sciences Collection,<br />
Henry Stewart Talks Ltd, London (online at http://hstalks.com/bio).<br />
Masters CL, Beyreuther K. Amyloidβ production. In:<br />
Neurodegeneration: The Molecular Pathology of Dementia and<br />
Movement Disorders. Second edition. Edited by Dickson DW,<br />
Weller RO. Oxford: Wiley-Blackwell. <strong>2011</strong>; Chapter 11, p 92-96.<br />
Mattsson N, Andreason U, Persson S, Arai H, Batish D, Bernardini S,<br />
Bocchio-Chiavetto L, Blankenstein RA, Carrillo MC, Chalbot S, Coart<br />
E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan A, Forlenza O,<br />
Frisoni G, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka<br />
MT, Herskovitz AZ, Herukka S-K, Holtzman DM, Humpel C, Hyman<br />
B, Iqbal K, Jucker M, Kaeser S, Kaiser E, Kapaki E, Kidd D, Klivenyi<br />
P, Knudsen C, Kummer M, Liu J, Lladó A, Lewczuk P, Li Q-X, Martins<br />
R, Masters CL, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL,<br />
Montine T, Nowatzke W, O’Brien R, Otto M, Paraskevas GP, Parnetti L,<br />
Petersen R, Prvulovic D, de Reus HPM, Rissman RA, Scarpini E,<br />
Stefani A, Soininen H, Schroder J, Shaw LM, Skinningsrud A,<br />
Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H,<br />
Umek R, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM,<br />
Windisch M, Zhang J, Zetterberg H, Blennow K: The Alzheimer’s<br />
Association external quality control program for cerebrospinal fluid<br />
biomarkers. Alzheimer’s and Dementia <strong>2011</strong>, 7(4):386-395.<br />
McBride SJ, Szoeke CEI, Good NM, Ames D, Martins RN, Masters CL,<br />
Maruff PT, Rowe CC, Savage G, Ellis KA and the AIBL <strong>Research</strong> Group:<br />
A web-based normative data tool for assessing cognitive<br />
performance in healthy older Australians. Medical Journal of Australia<br />
<strong>2011</strong>, 194(4):S12-S14.<br />
Meyerowitz J, Parker SJ, Vella LJ, Ng DCH, Price KA, Liddell JR,<br />
Caragounis A, Li QX, Masters CL, Nonaka T, Haseg: C-Jun N-terminal<br />
kinase controls TDP-43 accumulation in stress granules induced by<br />
oxidative stress. Molecular Neurodegeneration <strong>2011</strong>, 6(1):57-78.<br />
Moylan S, Staples J, Ward SA, Rogerson J, Stein DJ, Berk M: The<br />
efficacy and safety of alprazolam versus other benzodiazepines in the<br />
treatment of panic disorder. Journal of Clinical Psychopharmacology<br />
<strong>2011</strong>, 31(5):647-652.<br />
Pasco JA, Jacka FN, Williams LJ, Brennan SL, Leslie E, Berk M: Don’t<br />
worry, be active: positive affect and habitual physical activity. Australian<br />
and New Zealand Journal of Psychiatry <strong>2011</strong>, 45(12):1047-1052.<br />
47
<strong>2011</strong> Publications<br />
continued<br />
Pike KE, Ellis KA, Villemagne VL, Good N, Chetelat G, Ames D, Szoeke<br />
C, Laws SM, Verdile G, Martins RN, Masters CL, Rowe CC: Cognition<br />
and beta-amyloid in preclinical Alzheimer’s disease: Data from the<br />
AIBL study. Neuropsychologia <strong>2011</strong>, 49(9):2384-2390.<br />
Price KA, Crouch PJ, Lim S, Paterson BM, Liddell JR, Donnelly<br />
PS, White AR: Subcellular localization of a fluorescent derivative of<br />
CuII(atsm) offers insight into the neuroprotective action of CuII(atsm).<br />
Metallomics <strong>2011</strong>, 3(12):1280-1290.<br />
Price KA, Crouch PJ, Volitakis I, Paterson BM, Lim S, Donnelly PS,<br />
White AR: Mechanisms controlling the cellular accumulation of<br />
copper Bis(thiosemicarbazonato) complexes. Inorganic Chemistry<br />
<strong>2011</strong>, 50(19):9594-9605.<br />
Ray S, Howells C, Eaton ED, Butler CW, Shabala L, Adlard PA, West<br />
AK, Bennett WR, Guillemin GJ, Chung RS: Tg2576 cortical neurons<br />
that express human Ab are susceptible to extracellular A beta-Induced,<br />
K+ efflux dependent neurodegeneration. PloS One <strong>2011</strong>, 6(4).<br />
Rogers AN, Chen D, McColl G, Czerwieniec G, Felkey K, Gibson BW,<br />
Hubbard A, Melov S, Lithgow GJ, Kapahi P: Life span extension via<br />
eIF4G inhibition is mediated by posttranscriptional remodeling of<br />
stress response gene expression in C. elegans. Cell Metabolism <strong>2011</strong>,<br />
14(1):55-66.<br />
Santosa C, Rasche S, Barakat A, Bellingham SA, Ho M, Tan JL, Hill AF,<br />
Masters CL, McLean C, Evin G: Decreased expression of GGA3<br />
protein in Alzheimer’s disease frontal cortex and increased<br />
co-distribution of BACE with the amyloid precursor protein.<br />
Neurobiology of Disease <strong>2011</strong>, 43(1):176-183.<br />
Scarr E, Money TT, Dean B: Decreased mu opioid receptor availability<br />
in subjects with schizophrenia who died by suicide. Biological<br />
Psychiatry <strong>2011</strong>, 69(9):158S-158S.<br />
Schnabel J: Little proteins, big clues. [Interviews with C.L. Masters, K<br />
Beyreuther and others]. Nature <strong>2011</strong>, 475:(supplement) 512-514.<br />
Sensi SL, Paoletti P, Koh JY, Aizenman E, Bush AI, Hershfinkel M: The<br />
neurophysiology and pathology of brain zinc. Journal of Neuroscience<br />
<strong>2011</strong>, 31(45):16076-16085.<br />
Singh A, Ng C, Byron K, Berk M, Osborne C, Dean B: Child abuse<br />
and depression severity not genotype predictive of response to<br />
antidepressants. Australian and New Zealand Journal of Psychiatry<br />
<strong>2011</strong>, 45:A52-A53.<br />
Sittironnarit G, Ames D, Bush AI, Faux N, Flicker L, Foster J, Hilmer S,<br />
Lautenschlager NT, Maruff P, Masters CL, Martins RN, Rowe C, Szoeke<br />
C, Ellis KA and the AIBL <strong>Research</strong> Group: Effects of anticholinergic<br />
drugs on cognitive function in older Australians: Results from the AIBL<br />
Study. Dementia and Geriatric Cognitive Disorders <strong>2011</strong>, 31(3):<br />
173-178.<br />
48<br />
Annual report <strong>2011</strong><br />
Soon CPW, Donnelly PS, Turner BJ, Hung LW, Crouch PJ, Sherratt NA,<br />
Tan JL, Lim NKH, Lam L, Bica L, Lim SC, Hickey JL, Morizzi J, Powell<br />
A, Finkelstein DI, Culvenor JG, Masters CL, Duce J, White AR,<br />
Barnham KJ, Li QX: Diacetylbis(N(4)-methylthiosemicarbazonato)<br />
Copper(II) (CuII(atsm)) protects against peroxynitrite-induced<br />
nitrosative damage and prolongs survival in amyotrophic lateral<br />
sclerosis mouse model. Journal of Biological Chemistry <strong>2011</strong>,<br />
286(51):44035-44044.<br />
Stafford L, Berk M: The use of statins after a cardiac intervention Is<br />
associated with reduced risk of subsequent depression: Proof of<br />
concept for the inflammatory and oxidative hypotheses of<br />
depression? Journal of Clinical Psychiatry <strong>2011</strong>, 72(9):1229-1235.<br />
Streltsov VA, Varghese JN, Masters CL, Nuttall SD: Crystal structure of<br />
the amyloid-β p3 fragment provides a model for oligomer formation in<br />
Alzheimer’s disease. Journal of Neuroscience <strong>2011</strong>, 31: 1419-1426.<br />
Udawela M, Scarr E, Hannan AJ, Thomas EA, Dean B: Phospholipase<br />
C beta 1 expression in the dorsolateral prefrontal cortex from patients<br />
with schizophrenia at different stages of illness. Australian and New<br />
Zealand Journal of Psychiatry <strong>2011</strong>, 45(2):140-147.<br />
van den Buuse M, Becker T, Kwek P, Martin S, Ruimschotel E,<br />
Risbrough V: Disruption of prepulse inhibition by 3,4-methylenedioxymethamphetamine<br />
(MDMA): comparison between male and female<br />
wild-type and 5-HT(1A) receptor knockout mice. International Journal<br />
of Neuropsychopharmacology <strong>2011</strong>, 14(6):856-861.<br />
van den Buuse M, Ruimschotel E, Martin S, Risbrough VB, Halberstadt<br />
AL: Enhanced effects of amphetamine but reduced effects of the<br />
hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT(1A) receptor<br />
knockout mice: Implications for schizophrenia. Neuropharmacology<br />
<strong>2011</strong>, 61(1-2):209-216.<br />
Villagonzalo KA, Dodd S, Ng F, Mihaly S, Langbein A, Berk M:<br />
The relationship between substance use and posttraumatic stress<br />
disorder in a methadone maintenance treatment program.<br />
Comprehensive Psychiatry <strong>2011</strong>, 52(5):562-566.<br />
Villemagne VL, Okamura N, Pejoska S, Drago J, Mulligan RS, Chetelat<br />
G, Ackermann U, O’Keefe G, Jones G, Gong S, Tochon-Danguy H,<br />
Masters CL, Skovronsky DM, Rowe CC: In vivo assessment of vesicular<br />
monoamine transporter type 2 in dementia with lewy bodies and<br />
Alzheimer disease. Archives of Neurology <strong>2011</strong>, 68(7):905-912.<br />
Villemagne VL, O’Keefe G, Mulligan RS, Rowe CC: Quantitative<br />
approaches to amyloid imaging. In: Molecular Imaging: Methods and<br />
Protocols. Methods in Molecular Biology, Volume 680. Edited by Shah<br />
K. Springer New York Dordrecht Heidelberg London: <strong>2011</strong>; 201-225.
Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G,<br />
O’Keefe G, Ackerman U, Tochon-Danguy H, Chan JG, Reininger CB,<br />
Fels L, Putz B, Rohde B, Masters CL, Rowe CC: Amyloid imaging with<br />
18F-florbetaben in Alzheimer disease and other dementias. Journal of<br />
Nuclear Medicine <strong>2011</strong>, 52(8):1210-1217.<br />
Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P,<br />
Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O’keefe G:<br />
Longitudinal assessment of Aβ and cognition in aging and Alzheimer<br />
disease. Annals of Neurology <strong>2011</strong>, 69(1):181-192.<br />
Wang YJ, Wang X, Lu JJ, Li QX, Gao CY, Liu XH, Sun Y, Yang MA,<br />
Lim Y, Evin G, Zhong JH, Masters CL, Zhou XF: p75NTR Regulates<br />
Aβ deposition by increasing Aβ production but inhibiting Aβ<br />
aggregation with its extracellular domain. Journal of Neuroscience<br />
<strong>2011</strong>, 31(6):2292-2304.<br />
Wang YM, Xiao ZJ, Liu XD, Berk M: Venlafaxine modulates<br />
depression-induced behaviour and the expression of Bax mRNA and<br />
Bcl-xl mRNA in both hippocampus and myocardium. Human<br />
Psychopharmacology-Clinical and Experimental <strong>2011</strong>, 26(2):95-101.<br />
Watt AD, Perez KA, Faux NG, Pike KE, Rowe CC, Bourgeat P, Salvado<br />
O, Masters CL, Villemagne VL, Barnham KJ: Increasing the predictive<br />
accuracy of amyloid-β blood-borne biomarkers in Alzheimer’s<br />
disease. Journal of Alzheimer’s Disease <strong>2011</strong>, 24(1):47-59.<br />
Williams LJ, Bjerkeset O, Langhammer A, Berk M, Pasco JA, Henry<br />
MJ, Schei B, Forsmo S: The association between depressive and<br />
anxiety symptoms and bone mineral density in the general population:<br />
The HUNT Study. Journal of Affective Disorders <strong>2011</strong>, 131(1-3):<br />
164-171.<br />
Yates PA, Sirisriro R, Villemagne VL, Farquharson S, Masters CL,<br />
Rowe CC and the AIBL <strong>Research</strong> Group: Cerebral microhemorrhage<br />
and brain beta-amyloid in aging and Alzheimer disease. Neurology<br />
<strong>2011</strong>, 77(1):48-54.<br />
49
Concise Financial Operating Summary <strong>2011</strong><br />
ABN 48 101 228 451<br />
STATEMENT OF COMPREHENSIVE INCOME<br />
FOR THE YEAR 1 JANUARY <strong>2011</strong> TO 31 DECEMBER <strong>2011</strong><br />
Revenue from ordinary activities 13,100,691<br />
Salary and employee benefits (7,616,061)<br />
Scientific consumables (955,479)<br />
Scientific equipment purchases (52,726)<br />
Scientific support (2,497,591)<br />
Infrastructure expenses (1,344,086)<br />
Depreciation (739,967)<br />
Amortisation (131,539)<br />
Net operating surplus/(deficit) after depreciation & amortisation (236,758)<br />
Revenue related to Building Project 25,976,040<br />
Expenses related to Building Project (5,977,363)<br />
Revenue related to Dax Centre Loan 562,467<br />
Expenses related to Dax Centre segregation (525,673)<br />
NET SURPLUS FOR THE YEAR 19,798,713<br />
50<br />
Annual report <strong>2011</strong><br />
Grants<br />
Contract <strong>Research</strong> Fees<br />
Public Support<br />
Interest<br />
Dividends<br />
Other Revenue<br />
$
BALANCE SHEET AS AT 31 DECEMBER <strong>2011</strong><br />
Current Assets<br />
Cash and cash equivalents 198<br />
Trade and other receivables 2,095<br />
Stock on Hand 23<br />
Financial assets - Term Deposit Funds 5,251<br />
MHRI accommodation relocation account 1,597<br />
Total Current Assets 9,164<br />
Non-Current Assets<br />
Financial assets 157<br />
Property, plant and equipment 13,744<br />
Equipment shared 740<br />
Intangible Asset 21,967<br />
Total Non-Current Assets 36,608<br />
TOTAL ASSETS 45,772<br />
Current Liabilities<br />
Trade and other payables 1,393<br />
Provisions for employee benefits 921<br />
MHRI accommodation relocation account 1,626<br />
Total Current Liabilities 3,940<br />
Non-Current Liabilities<br />
Provisions 172<br />
Total Non-Current Liabilities 172<br />
TOTAL LIABILITIES 4,112<br />
NET ASSETS 41,659<br />
Equity<br />
<strong>Research</strong> funds 1,165<br />
Capital reserves 37,917<br />
Asset revaluation reserve 2,526<br />
Unrealised gain on investment reserve 50<br />
Accumulated deficit -<br />
TOTAL FUNDS 41,659<br />
NOTES: This is a summary of operating activity for <strong>2011</strong>, for a full set of audited financial<br />
statements please contact MHRI on 03 9388 1633 or email accounts@mhri.edu.au.<br />
$’000<br />
51
Personnel and Collaborators <strong>2011</strong><br />
Behavioural Neuroscience Laboratory<br />
Head<br />
Associate Professor Maarten van den Buuse BSc (Hons), PhD<br />
Postdoctoral Scientists<br />
Dr Andrea Gogos BSc (Hons), PhD<br />
Dr Rachel Hill BSc (Hons), PhD<br />
Dr Anand Gururajan BSc (Hons), PhD<br />
Dr Laetitia Buret BSc (Hons), PhD<br />
Dr Sue Tye BSc (Hons), PhD<br />
<strong>Research</strong> Assistant<br />
Sally Martin BSc (Hons)<br />
PhD Students<br />
Maren Klug BSc (Hons)<br />
Shane Thwaites BSc (Hons)<br />
Yee Wen Candace Wu BSc (Hons)<br />
Elizabeth Manning BSc (Hons)<br />
Natasha Pracejus BSc (Hons)<br />
Masters/Honours students<br />
Szerenke Kiss Von Soly<br />
Michael O’Neill<br />
Collaborators<br />
Dr Simon Murray, Centre for Neuroscience, Melbourne<br />
Dr Tony Hannan, Florey Neuroscience <strong>Institute</strong>s, Melbourne<br />
Dr Olivia Dean, Barwon <strong>Health</strong>, Geelong<br />
Dr Quenten Schwarz, Centre for Cancer Biology, Adelaide<br />
Dr Tim Karl, NeuRA, Sydney<br />
Dr Adam Halberstadt, Department of Psychiatry, UCSD,<br />
San Diego, USA<br />
Dr Victoria Risbrough, Department of Psychiatry, UCSD,<br />
San Diego, USA<br />
Prof Manfred Gerlach, University of Wurzburg, Germany<br />
52<br />
Annual report <strong>2011</strong><br />
Molecular Psychopharmacology Laboratory<br />
Head<br />
Associate Professor Suresh Sundram MBBS, MMed,<br />
FRANZCP, PhD<br />
Senior Scientist Honorary Professorial Fellow<br />
Professor George Fink MBBS, DPhil, MD, FRCPE, FRSE<br />
Senior <strong>Research</strong> Officer<br />
Dr Avril Pereira BAppSc, MSc, PhD<br />
<strong>Research</strong> Assistant<br />
Peter Malcolm BSc (Hons)<br />
PhD Students<br />
Sujeevan Sinnatamby MD, FRANZCP<br />
Vaidy Swaminathan MD, FRANZCP<br />
Advanced Medical Sciences (AMS) Students<br />
Yuanna Zhou<br />
Honam Choi<br />
Postgraduate Student<br />
Hanneke Raaijmakers<br />
Molecular Psychiatry Laboratory<br />
Head of Laboratory / NHMRC Senior <strong>Research</strong> Fellow<br />
Professor Brian Dean HND ApplBiol, MSc, PhD, Fl Biol<br />
<strong>Research</strong> Officers<br />
Dr Andrew Gibbons BSc (Hons), PhD<br />
Dr Madhara Udawela BSc (Hons), PhD<br />
Dr Jung Yoon Um BSc, PhD<br />
Dr Jaclyn Neo BSc (Hons), PhD<br />
Graduate <strong>Research</strong> Assistant<br />
Geoffrey Pavey BSc (Hons)<br />
Doctoral Students<br />
Nahed Tawadros BSc (Hons)<br />
Ajeet Singh (MBBS)<br />
Myoung Suk Seo BSc, MSc<br />
Won Je Jeon BSc, MSc<br />
Natalie Paige Thomas BSc (Hons)
Collaborators<br />
Professor Galila Agam (Ben-Gurion University)<br />
Dr Andrew Aquilina (University of Wollongong)<br />
Professor Robert Belmaker (Ben-Gurion University)<br />
Professor Michael Berk (Barwon <strong>Health</strong> and The Geelong<br />
Clinic, The University of Melbourne)<br />
Dr. Chad Bousman (Department of Psychiatry, University<br />
of Melbourne).<br />
Dr Vanesa Cropley (Melbourne Neuropsychiatry Centre,<br />
The University of Melbourne)<br />
Ms Tiffany Cowie (Department of Pathology, University<br />
of Melbourne)<br />
Dr Olivia Dean (Barwon <strong>Health</strong> and The Geelong Clinic,<br />
The University of Melbourne)<br />
Dr Connie Darmanin (CSIRO)<br />
Professor Ian Everall (Cato Chair of Psychiatry, The University<br />
of Melbourne)<br />
Professor Vahram Haroutunian (Mount Sinai School of<br />
Medicine, New York, NY, USA)<br />
Professor James Meadow-Woodruff (Department of<br />
Psychiatry and Behavioral Neurobiology, University of<br />
Alabama at Birmingham, USA)<br />
Dr Robert McCullumsmith (Department of Psychiatry and<br />
Behavioral Neurobiology, University of Alabama at<br />
Birmingham, USA)<br />
Dr Tammie Money (Department of Psychiatry, University<br />
of Melbourne)<br />
Professor Christos Pantelis (Melbourne Neuropsychiatry<br />
Centre, The University of Melbourne)<br />
Northern Psychiatry <strong>Research</strong> Centre<br />
Head<br />
Associate Professor Suresh Sundram MBBS, MMed,<br />
FRANZCP, PhD<br />
Senior <strong>Research</strong> Physician<br />
Dr Russell D’Souza MPM, MD<br />
<strong>Research</strong> Coordinator<br />
Fiona Bole RN<br />
<strong>Research</strong> Nurse<br />
Sumathy Sathiyamoorthy RN (Div II)<br />
<strong>Research</strong> Physicians<br />
Dr Rohit Lodhi MD, MRCPsych, FRANZCP<br />
Dr Manish Sharma MD<br />
PhD Student<br />
Jody Stanley<br />
Postgraduate Students<br />
Daniel Bennett<br />
Amy Dluzniak<br />
Advanced Medical Sciences (AMS) Student<br />
Zexi Allan<br />
Collaborators<br />
Professor Michael Berk (The University of Melbourne)<br />
Dr Olivia Carter (The University of Melbourne)<br />
Dr Gursh Chana (The University of Melbourne)<br />
Dr Peter Crouch (The University of Melbourne)<br />
Professor Brian Dean (<strong>Mental</strong> <strong>Health</strong> <strong>Research</strong> <strong>Institute</strong>)<br />
Dr Seetal Dodd (The University of Melbourne)<br />
Professor Ian Everall (The University of Melbourne)<br />
Dr John Farhall (La Trobe University)<br />
Ms Marnie Graeco (Northern Hospital)<br />
Professor Brenda Happell (Central Queensland University)<br />
Ms Alison Harrington (Northern Area <strong>Mental</strong> <strong>Health</strong> Service)<br />
Dr Alexander Holmes (The University of Melbourne)<br />
Dr Ana Hutchinson (Northern Clinical <strong>Research</strong> Centre)<br />
Dr Nigel Jones (The University of Melbourne)<br />
A/Professor Gerard Kennedy (Victoria University)<br />
53
Personnel and Collaborators <strong>2011</strong><br />
continued<br />
Dr Ken McAnally (Defense Science Technology Organization)<br />
Professor Ralph Martins (Edith Cowan University)<br />
Professor Terence O’Brien (The University of Melbourne)<br />
Dr Meaghan O’Donnell (The University of Melbourne)<br />
Dr Elizabeth Scarr (The University of Melbourne)<br />
Dr Elizabeth Thomas (Scripps <strong>Institute</strong>, USA)<br />
Professor Cyndi Shannon-Weickert (Neurosciences Australia)<br />
Dr Anthony White (The University of Melbourne)<br />
Neuropathology Laboratory<br />
Head (Group Leader)<br />
Professor Colin L. Masters BMedSc (Hons), MBBS, MD,<br />
HonDLitt WAust, FRCPath, FRACPA, FAA, FTSE<br />
Post-doctoral Scientists<br />
Dr. Blaine R. Roberts, BSc, PhD<br />
Dr Tim M. Ryan, BSc, PhD<br />
Dr Scott Laffoon, BSc, PhD<br />
Dr Alan Rembach (Hons), PhD<br />
Dr Qiao-Xin Li, PhD<br />
<strong>Research</strong> assistant<br />
Monica Lind ChemEng, MBiotech<br />
Student<br />
Katherine Jones-Ganio BSc<br />
Volunteer<br />
Anne Roberts BSc<br />
International Collaborators<br />
Professor Edward A. Dratz<br />
(Montana State University, Bozeman, MT)<br />
Professor Joseph S. Beckman<br />
(Oregon State University, Corvallis, OR)<br />
54<br />
Annual report <strong>2011</strong><br />
Oxidation Biology Laboratory<br />
Head of Laboratory<br />
Professor Ashley Bush MBBS, DPM, PhD, FRANZCP, FTSE<br />
Principal <strong>Research</strong> Fellow and Deputy Head<br />
Associate Professor Robert Cherny BSc, PhD<br />
Personal & Administrative Assistant<br />
Suzie McNicol Dip Fin Plan<br />
Senior <strong>Research</strong> Fellow<br />
Dr Paul Adlard BSc (Hons), PhD<br />
Associate Professor David Finkelstein BSc, GradDip,<br />
MSc, PhD<br />
Dr James Duce BSc (Hons), PhD<br />
<strong>Research</strong> Fellows and Post-doctoral Scientists<br />
Dr Ya Hui Hung BMus, BSc (Hons), PhD<br />
Dr Gawain McColl BSc (Hons), PhD<br />
Dr Alan Rembach BSc (Hons), PhD<br />
<strong>Research</strong> Officer<br />
Dr Toni Lynch BAppSc, MSc, PhD<br />
<strong>Research</strong> Assistants<br />
Gulay Filiz BSc (Hons)<br />
Jessica George BSc (Hons), MSc<br />
Lydia Gunawan MappSc<br />
Linh Lam BSc (Hons)<br />
Elysia Robb BMedSc (Hons)<br />
Amelia Sedjahtera BSc (Hons)<br />
Irene Volitakis BSc (Hons)<br />
Technical Assistants<br />
Lisa Bray AssocDipAppSc (AnimTech)<br />
Nicole Critch (DipAnimTech)<br />
Bruce Etherton, Animal Technician<br />
Sarah Evans (DipAnimTech)<br />
Rinola Singh (DipAnimTech)
Postgraduate Students<br />
Scott Ayton BBNSc (Hons)<br />
Yif’at Biran BPharmSci, CertIV BusMgt, BSc (Hons)<br />
Mark Greenough BSc<br />
Adam Gunn BSc (Hons)<br />
Simon James BSc (Hons)<br />
Peng Lei BSc<br />
Rebecca Vaughan BSc (Hons)<br />
National Collaborators<br />
Professor James Camakaris (Department of Genetics,<br />
The University of Melbourne)<br />
Dr Roger Chung (University of Tasmania)<br />
Dr Tracey Dickson (University of Tasmania)<br />
Dr Philip Doble (University of Technology, Sydney)<br />
Dr John Forsythe (Materials Engineering, Monash University)<br />
Professor Brett Garner (Illawarra <strong>Health</strong> and Medical <strong>Research</strong><br />
<strong>Institute</strong>, University of Wollongong)<br />
Dr Melissa Gresle<br />
(Multiple Sclerosis Group, Howard Florey <strong>Institute</strong>)<br />
Professor Trevor Kilpatrick<br />
(Centre for Neuroscience/Howard Florey <strong>Institute</strong>, Melbourne)<br />
Professor Ralph Martins (University of Western Australia)<br />
Professor Julian FB Mercer<br />
(Director, Centre for Cellular and Molecular Biology,<br />
School of Biological and Chemical Sciences, Deakin<br />
University, Burwood)<br />
Associate Professor Christina Morganti-Kossmann<br />
(The Alfred, Melbourne)<br />
Dr David Nisbet (Materials Engineering, Monash University)<br />
Dr Melanie Pritchard (Department of Biochemistry and<br />
Molecular Biology, Monash University)<br />
Dr Tara Pukala (University of Adelaide)<br />
Professor James Vickers (University of Tasmania)<br />
Professor Adrian West (University of Tasmania)<br />
International Collaborators<br />
United States of America<br />
Professor Julie Anderson<br />
(Buck <strong>Institute</strong> for Age <strong>Research</strong>, Novato, CA)<br />
Dr Math Cuajungco (Massachusetts General Hospital and Harvard<br />
Medical School, Boston, MA)<br />
Dr M Flint Beal (Cornell University, New York, NY)<br />
Professor Joseph S Beckman<br />
(Linus Pauling <strong>Institute</strong>, Corvallis, OR)<br />
Professor Edward A Dratz (Montana State University,<br />
Bozeman, MT)<br />
Dr Jane Flinn (George Mason University, Fairfax VA)<br />
Dr Jonathan Fox (Neurology, Massachusetts General Hospital,<br />
Boston, MA)<br />
Dr Avi Friedlich (Bedford Veterans Affairs Hospital,<br />
Boston, MA)<br />
Dr Lee Goldstein (Brigham and Women’s Hospital, Harvard<br />
Medical School, Boston, MA)<br />
Professor Elizabeth Head<br />
(University of Kentucky, Lexington, KY)<br />
Assistant Professor Xudong Huang (Department of Psychiatry,<br />
Massachusetts General Hospital, Boston, MA)<br />
Dr Deepinder Kaur (Buck <strong>Institute</strong> for Age <strong>Research</strong>,<br />
Novato, CA)<br />
Dr Mahmoud Kiaei (Weill Medical College of Cornell University,<br />
New York, NY)<br />
Dr Lenore Launer (National <strong>Institute</strong> on Aging, Bethesda, MD)<br />
Associate Professor Christopher D Link (<strong>Institute</strong> for<br />
Behavioral Genetics; University of Colorado, Boulder, CO)<br />
Associate Professor Gordon J Lithgow (Buck <strong>Institute</strong> for Age<br />
<strong>Research</strong>, Novato, CA)<br />
Associate Professor Simon Melov (Buck <strong>Institute</strong> for Age<br />
<strong>Research</strong>, Novato, CA)<br />
Associate Professor Martha Clare Morris (Rush <strong>Institute</strong> for<br />
<strong>Health</strong>y Aging, Rush University Medical Center, Chicago, IL)<br />
Dr Dan Ory (Washington University School of Medicine,<br />
St Louis)<br />
Associate Professor Michael Petris (Department of<br />
Biochemistry, University of Missouri-Columbia, MO)<br />
Associate Professor Jack Rogers (Psychiatry, Massachusetts<br />
General Hospital, Boston, MA)<br />
55
Personnel and Collaborators <strong>2011</strong><br />
continued<br />
Professor Rudolph Tanzi (Director, Genetics and Aging<br />
<strong>Research</strong> Unit at Massachusetts General <strong>Institute</strong> for<br />
Neurodegenerative Disease, Boston, MA)<br />
Assistant Professor Robert Moir (Massachusetts General<br />
Hospital & Harvard Medical School, Boston, MA)<br />
Professor Dennis Thiele (Duke University Medical Center,<br />
Durham, NC)<br />
Dr Hui Zheng (Baylor College of Medicine, Houston, Texas)<br />
United Kingdom<br />
Dr Janet Johnston (Division of Psychiatry and Neuroscience,<br />
Queen’s University, Belfast, Ireland)<br />
Dr Craig W. Ritchie (Royal Free & University College Medical<br />
School, Hampstead)<br />
Professor Robert Evans (School of <strong>Health</strong> Sciences and Social<br />
Care, Brunel University, West London)<br />
Chile<br />
Professor Nibaldo Inestrosa, (Catholic University of Chile,<br />
Santiago)<br />
Dr Carlos Opazo (University of Concepcion)<br />
Republic of Korea<br />
Professor Jae Koh (University of Ulsan College of Medicine,<br />
Seoul)<br />
Assistant Professor Joo-Yong Lee (University of Ulsan College<br />
of Medicine, Seoul)<br />
Japan<br />
Assistant Professor Yoichi Kato (University of Hyogo)<br />
Dr Seiichi Nagano (Harvard Medical School, Massachusetts<br />
General Hospital)<br />
Spain<br />
Dr Juan Hidalgo (Universidad Autonoma de Barcelona)<br />
Hungary<br />
Dr Zsolt Datki (University of Szeged)<br />
Israel<br />
Professor Irit Sagi (The Weizmann <strong>Institute</strong> of Science,<br />
Rehovot, Israel)<br />
Dr Inna Solomonov (The Weizmann <strong>Institute</strong> of Science,<br />
Rehovot, Israel)<br />
56<br />
Annual report <strong>2011</strong><br />
Synaptic Neurobiology Laboratory<br />
Heads<br />
Dr Paul Adlard BSc, (Hons), PhD after Adlard<br />
Associate Professor David Finkelstein BSc, GradDip, MSc, PhD<br />
Clinical <strong>Research</strong> Group<br />
Head<br />
Dr Kathryn Ellis BSc (Hons), PhD<br />
Clinical and Neuropsychology researchers<br />
Adrian Kamer BSc (Hons), Candidate DPsych (ClinNeuropsych)<br />
Carolina Restrepo (Psych)<br />
Fiona Lamb BASc(Psych)(Hons), DPsych(ClinNeuro)<br />
Harriet Downing BA, PGrad Dip Psych, Candidate DPsych<br />
(ClinNeuropsych)<br />
Jo Robertson BA(Psych)(Hons)<br />
Karra Harrington BA<br />
Rachel Buckley BSc(Psych)(Hons)<br />
Stacey Walker<br />
Molecular Biology <strong>Research</strong>ers<br />
Brett Trounson BSc (Hons) - AIBL Blood Processing<br />
Laboratory Manager<br />
Dr Christopher Fowler BSc (Hons) - PhD<br />
Kelly Pertile BSc (Hons) - <strong>Research</strong> Assistant<br />
Rebecca Rumble BBioSc (Hons) - <strong>Research</strong> Assistant<br />
Postdoctoral Fellows<br />
Dr Alan Rembach BSc (Hons), PhD - Postdoctoral<br />
<strong>Research</strong> Fellow<br />
Dr Noel Faux BSc (Hons), Grad Dip Comp Sci, PhD<br />
DIAN Study<br />
Alicia Rooney BSc, BNurs, GCHumanFact<br />
Tabitha Nash BA (Psych)(Hons) DipEd (Secondary)<br />
<strong>Research</strong> Nurses<br />
Fairlie Hinton RN<br />
Alison Boyd<br />
Susan Dickie RN
Administration<br />
Yumiko Matsumoto<br />
Senior AIBL Study Scientists and Collaborators<br />
Professor David Ames (National Ageing <strong>Research</strong> <strong>Institute</strong>)<br />
Professor Kaarin Anstey (Australian National University)<br />
Associate Professor Marc Budge (Australian National<br />
University)<br />
Professor Ashley Bush (<strong>Mental</strong> <strong>Health</strong> <strong>Research</strong> <strong>Institute</strong>)<br />
Associate Professor David Darby (CogState)<br />
James Doecke (CSIRO Mathematical and Information<br />
Sciences)<br />
Dr Maree Farrow (Alzheimer’s Australia Victoria)<br />
Associate Professor Jonathan Foster (Edith Cowan University)<br />
Norm Good (CSIRO Mathematical and Information Sciences)<br />
Professor Richard Head (CSIRO)<br />
Professor Peter Hudson (AVIPEP)<br />
Professor Nicola Lautenschlager (The University of Melbourne)<br />
Dr Qiao-Xin Li (The University of Melbourne)<br />
Dr Lance Macaulay (CSIRO)<br />
Simon McBride (The Australian e-<strong>Health</strong> <strong>Research</strong> Centre)<br />
Professor Paul Maruff (<strong>Mental</strong> <strong>Health</strong> <strong>Research</strong> <strong>Institute</strong>)<br />
Professor Ralph Martins (Edith Cowan University)<br />
Professor Colin Masters (<strong>Mental</strong> <strong>Health</strong> <strong>Research</strong> <strong>Institute</strong>)<br />
Andrew Milner (Neurosciences Victoria)<br />
Lynette Moore (Alzheimer’s Australia Victoria)<br />
Dr Timothy O’Meara (CSIRO)<br />
Glenn Rees (Alzheimer’s Australia)<br />
Professor Chris Rowe (Austin <strong>Health</strong>)<br />
Olivier Salvado (CSIRO e-<strong>Health</strong>)<br />
Associate Professor Greg Savage (MACCS)<br />
Jack Sach (Alzheimer’s Australia Victoria)<br />
Dr Wichat Srikusalanukul (Australian National University)<br />
Dr Cassandra Szoeke (National Ageing <strong>Research</strong> <strong>Institute</strong>)<br />
Kevin Taddei (Edith Cowan University)<br />
Associate Professor Victor Villemagne (Austin <strong>Health</strong>)<br />
Associate Professor Michael Woodward (Austin <strong>Health</strong>)<br />
Associate Professor Olga Yatsrubetskaya (The University<br />
of Melbourne)<br />
Clinical Discovery Unit<br />
Head of Program<br />
Professor Michael Berk MBBCh, MMed, FF(Psych)SA,<br />
FRANZCP, PhD<br />
Co-Investigators<br />
Professor Ashley Bush MBBS, DPM, PhD, FRANZCP, FTSE<br />
Associate Professor Maarten van den Buuse PhD<br />
Professor Gin Malhi BSc Pharmacol (Hons), MBChB, MRC<br />
Psych, FRANZCP, MD<br />
Professor Flavio Kapczinki MD, PhD<br />
Professor Brian Dean HND ApplBiol, MSc, PhD, Fl Biol<br />
Professor Andy Nierenberg MD PhD<br />
Postdoctoral Scientist<br />
Dr Olivia Dean PhD<br />
Trial Clinicians<br />
Tanya Vick, BA BSc<br />
Dr Sue Jeavons BA Psych (Hons), MPhil (Clinical Psychology),<br />
PhD<br />
Karen Hewitt, RN<br />
Michelle Tanious BmedSci (Hons), GradDipPsych<br />
Postgraduate Students<br />
Kristi-Ann Villagonzalo BSc (Hons)<br />
Collaborators and Visiting Fellows<br />
Dr Tina Andreazza PharmD, PhD<br />
Dr Pedro Magalhaes PhD<br />
Dr Joao Data Franco MD<br />
Dr Sue Cotton PhD<br />
Dr Jerome Sarris PhD<br />
57
Personnel and Collaborators <strong>2011</strong><br />
continued<br />
Victorian Brain Bank Network<br />
Head<br />
Professor Catriona McLean BSc, MBBS, FRCPA, MD<br />
Director<br />
Professor Brian Dean HND ApplBiol, MSc, PhD, Fl Biol<br />
Consultants<br />
Professor Colin Masters BMedSc (Hons), MBBS, MD,<br />
HonDLitt WAust, FRCPath, FRACPA, FAA, FTSE<br />
Associate Professor Suresh Sundram MBBS, MMed,<br />
FRANZCP, PhD<br />
Coordinator<br />
Ms Fairlie Hinton<br />
<strong>Research</strong> Assistants<br />
Mr Geoff Pavey BSc (Hons)<br />
Ms Leanne Taylor BSc (Hons)<br />
Consultant Histologist<br />
Dr Ian Birchall BAppSc, MSc, PhD<br />
Collaborators<br />
Laboratory Manager and Mortuary Staff, The Alfred Hospital.<br />
Transplant and Family Liaison Coordinators (Donor Tissue<br />
Bank of Victoria).<br />
Forensic Pathologists and Mortuary Technicians (Victorian<br />
<strong>Institute</strong> of Forensic Medicine).<br />
Visitors<br />
Ms Susan Boyce - Head of Ethical Tissue, University of<br />
Bradford, West Yorkshire, England.<br />
58<br />
Annual report <strong>2011</strong><br />
Psychotropic Drug Advisory Service<br />
Head<br />
Professor Nicholas Keks MBBS, MPM, PhD, FRANZCP<br />
Staff<br />
Christine Culhane BPharm, Grad Dip Hosp Pharm<br />
The Dax Centre<br />
Director<br />
Dr Eugen Koh BSc (Hons), MBBS, MPM, FRACGP,<br />
FRANZCP, Senior Lecturer in Arts & Psychiatry (The University<br />
of Melbourne)<br />
Executive and <strong>Research</strong> Assistant<br />
Charlotte Adams BA (Hons) (Professional and Creative Writing)<br />
(From November <strong>2011</strong>)<br />
Personal Assistant to the Director<br />
Amy Middleton BA (Hons), MA (Arts Management)<br />
Julia Robinson Grad Dip Marketing<br />
Collection Unit<br />
Collection Manager<br />
Charlotte Christie BCA, DML, MA (Art Curatorship)
Curatorial Officer<br />
Georgina Adams BA (Hons) (Art History) MA (Art Curatorship)<br />
MA (History and Culture of Fashion)<br />
Lisa Gluck BA (Art History & Environmental Studies)<br />
Dip Modern Language (French) Postgraduate Dip<br />
(Arts Management) Masters (Art Curatorship)<br />
Curatorial Scholarship Student<br />
Brad Rusbridge BA (Professional Writing & Visual Art)<br />
MA (Art Curatorship)<br />
Curatorial Staff<br />
Alison Langley BSc, BA (Fine Art) (casual)<br />
Zoe Evershed BA (Hons Visual) (casual) (Until June <strong>2011</strong><br />
Exhibitions Unit<br />
Exhibition Manager<br />
Juliette Hanson BA (Art History & Philosophy), MA<br />
(Art Curatorship)<br />
Curatorial Officer<br />
Nikki Anderson BVA, MA (Art Curatorship)<br />
Curatorial Officer<br />
Clare Diamond BA (Art History), Grad Dip (Museum Studies),<br />
MA (Masters in Cultural Heritage)<br />
Education Unit<br />
Education Manager<br />
Emma Last BA, BSW, Grad dip (Family Therapy),<br />
Penelope Lee RN, RPN, BA (Hons), FPV Certificate<br />
Schools Coordinator<br />
Glenda Urquhart Grad Dip (Psychology)<br />
Megan Lee BBNsc, DipEd<br />
Education Officers<br />
Deb Zipper BA Occupational Therapy<br />
Eleni Kyrpigikidis BA Social Work<br />
Public Programs, Partnerships &<br />
Professional Development<br />
Manager<br />
Penelope Lee RN, RPN, BA (Hons), FPV Certificate<br />
Operations and Finance Unit<br />
Operations & Finance Manager<br />
Sherry Paddon BA Fine Art, Post Grad Dip<br />
(Heritage Studies), Grad Dip<br />
Administration Officers<br />
Lisa Gluck BA (Art History & Environmental Studies) Dip.<br />
Modern Language (French) Postgraduate Dip.<br />
(Arts Management) Masters (Art Curatorship)<br />
Clare Diamond BA (Art History), Grad Dip (Museum Studies),<br />
MA (Masters in Cultural Heritage)<br />
Development Unit<br />
Development Manager<br />
Amy Middleton BA(Hons), MA (Arts Management)<br />
Communications Officer<br />
Anna Zagala BA, B Design (Hons), MPhil<br />
Publication & Grants Officer<br />
Jessica Raschke PhD, BA<br />
59
Personnel and Collaborators <strong>2011</strong><br />
continued<br />
Other<br />
Project Managers<br />
Margaret Nixon DipEd DipArts<br />
Pia Brous (Honorary) MBBS, BMedSc, MPM, FRANZCP,<br />
Cert. Child Psychiatry<br />
Jennifer Harrison MBBS, FRANZCP, Specialist Training in<br />
Child Psychiatry<br />
Fundraising Consultant<br />
Stephanie Joseph<br />
Psychoanalyst in Residence<br />
Associate Professor Frances Salo, LlB, MCPP, PhD<br />
Art Therapist<br />
Victoria Schnaedelbach<br />
Consultant<br />
Loretta Shepherd BA (Psychology & Economics), Grad Dip<br />
Communications, Grad Dip Art History, MA (Art Curatorship)<br />
Executive Director’s Office<br />
Executive Director<br />
Professor Colin Masters BMedSc (Hons), MBBS, MD,<br />
HonDLitt WAust, FRCPath, FRCPA, FAA, FTSE<br />
Emily Cuningham BBiomedSci (Hons Sci) - Personal <strong>Research</strong><br />
Assistant<br />
Brenda Huckstepp – Secretary<br />
60<br />
Annual report <strong>2011</strong><br />
Administrative Services<br />
Chief Operating Officer and Company Secretary<br />
Lisa Keam GradDip IP Law, BSc<br />
Commercialisation and Business Development<br />
Michael Vovos<br />
Development and Communications<br />
Ross Johnstone MFIA – Development and Communications<br />
Manager<br />
Jane Standish MFIA – Marketing and Communications<br />
Anita Gowers - Trusts / Foundations and Bequests<br />
Gemma Turvey - Development Assistant & Donor Liaison<br />
Associate Professor Neil Cole – Consumer Consultant<br />
Finance and Administration<br />
Nick Catton LLB, BMS - Accountant<br />
Brian Fleming BBus(Acc) – Assistant Accountant<br />
Helen Gibbons - Receptionist<br />
Alistair Kittson - Administration Assistant<br />
Human Resources<br />
Rachel Mostacci - HR and Administrative Officer<br />
Information Technology<br />
Rik Casama BSc - IT Manager<br />
Gena Shoykhet BIS - IT Officer<br />
Andrew Crone – IT Officer
Laboratory Services<br />
Anna Sellens BSc (Hons) - Laboratory Facilities Manager<br />
Jason Verde Dip Animal Tech - Animal Facility Manager<br />
Melissa Cameron - Technical Assistant<br />
Elissa Wells Dip Animal Tech – Technical Assistant<br />
Elsa Tsui - Laboratory Assistant<br />
Liam Richardson - Tech Assistant<br />
Megan Haliday - Tech Assistant<br />
Dorian Watts - Technical Assistant<br />
Don Kuruppu, NDT, CGI (London) - Laboratory Assistant<br />
Michael Kent - Property & Maintenance Manager<br />
Governors<br />
Mr Charles Allen AO<br />
Dr Di Bresciani<br />
Mr Richard Buxton<br />
Mr Peter Clemenger AM<br />
Professor David Copolov OAM<br />
Mr Ian Farrington<br />
Professor George Fink<br />
Mr Roger Flynn<br />
Mr Doug George AM<br />
Dr David Greatorex AO<br />
Ms Caroline Hogg<br />
Mr John Kearney AM QC<br />
Dr Ben Lochtenberg<br />
Mr Geoff Marshall<br />
Mr George McMaster<br />
Dame Elisabeth Murdoch AC DBE<br />
Emeritus Professor Sir Gustav Nossal<br />
Mr Ross Oakley<br />
Mr Andrew Wardlaw<br />
Mrs Liz Wardlaw<br />
Ms Meredith Woods<br />
61
Donations <strong>2011</strong><br />
THANK YOU<br />
We are continually grateful to the many<br />
people, businesses, philanthropic trusts<br />
and foundations who support our work.<br />
We thank you and acknowledge your support.<br />
In Kind Supporters<br />
Mr Alf Caruana<br />
Audi Penfold<br />
Barbecues Plus<br />
Block Arcade<br />
Briner Signs<br />
Coopers<br />
Mr David Seaman<br />
Department of Human Services, <strong>Mental</strong><br />
<strong>Health</strong> Branch<br />
Mr Des Speakman<br />
Dr Di Bresciani<br />
Dulux<br />
Gerrand & Associates<br />
Ms Linda Karafilli<br />
Melbourne Theatre Company<br />
Middletons Lawyers<br />
Monash University<br />
Mutual Ltd<br />
One in Five Association<br />
Mr Ross Oakley<br />
Royal Yacht Club of Victoria<br />
Mr Ryan Wavish<br />
Sanpellegrino<br />
The Age<br />
The Egg<br />
The University of Melbourne<br />
Wardlaw Family<br />
Whybin/TBWA<br />
Woods Family<br />
Yering Station<br />
<strong>2011</strong> Culinary Charity Challenge<br />
Adam Gunn<br />
Annabelle Clark<br />
62<br />
Annual report <strong>2011</strong><br />
Anthony Puharich<br />
ARIA Restaurant<br />
Candace Wu<br />
Carlton & United Breweries<br />
Carolina Restrepo<br />
Cedar Hospitality<br />
Cory Campbell<br />
Crown Ltd<br />
Crowne Plaza Gold Coast<br />
Dizzy’s Jazz Club<br />
Disney<br />
Executive <strong>Health</strong> Management<br />
Fletcher Jones<br />
Four Seasons<br />
George & Therese McMaster<br />
George Calombaris<br />
Graeme Samuel<br />
Guillaume at Bennelong<br />
Guillaume Brahimi<br />
Hare and Grace<br />
Horseland<br />
HV Polo<br />
Jaques Reymond<br />
Judy Davenport<br />
Justin North<br />
Ladelle<br />
Larissa Dubecki<br />
Leanne Taylor<br />
Leigh Smith<br />
Luscious Affairs Cooking School<br />
Mark Best<br />
Marque Restaurant<br />
Matt Moran<br />
Melbourne Food and Wine Festival<br />
Miele<br />
Mitchell & Partners<br />
Mona Museum<br />
Montalto<br />
Natalie O’Brien<br />
Neil Perry<br />
Nespresso<br />
Nick Catton<br />
Nobu<br />
Penelope Clark<br />
Peninsula Hot Springs<br />
Petuna<br />
Pinc Pearls<br />
Quarter Twenty One<br />
Quay Restaurant<br />
Radisson Hotels<br />
Raymond Capaldi<br />
Senselle Foods<br />
Shannon Bennett<br />
Southern Star Observation Wheel<br />
Spice Temple<br />
Steve Abbott (Jellis Craig)<br />
Terry Durack<br />
The Australian Ballet<br />
The Good Guys<br />
Three Kings<br />
Tim & Janine Fredman<br />
Tim Hess<br />
Treasury Wine Estates<br />
Vic’s Meat<br />
Victor Churchill - The Family Butcher<br />
Victoria Racing Club<br />
Vue de Monde<br />
Walter Wagner<br />
Werribee Mansion Hotel and Spa<br />
Willie’s World Class Cacao<br />
Wolfgang Grimm AM<br />
$200,000+<br />
One in Five Association Inc<br />
$50,000 - $199,999<br />
Addi & Cassi Foundation<br />
Anonymous<br />
Joan and Peter Clemenger Trust<br />
Mr J F Kearney AM QC & Mrs M A Kearney<br />
Mr Jack Smorgon<br />
$10,000 - $49,999<br />
7-Eleven Stores Pty Ltd<br />
Mr & Mrs John & Lorraine Bates<br />
Estate Late Olga Mabel Woolger<br />
G W Vowell Foundation Ltd
Geoff & Helen Handbury Foundation<br />
Mrs Diana E Gibson AO<br />
Mr Pieter Huveneers<br />
Ian Potter Foundation<br />
Isabel & John Gilbertson Charitable Trust<br />
Jessica & Wallace Hore Foundation<br />
Lindsay & Heather Payne Medical <strong>Research</strong><br />
Charitable Foundation<br />
Rebecca L Cooper Medical <strong>Research</strong><br />
Reece Australia Ltd<br />
Stuart Leslie Foundation<br />
$2,000 - $9,999<br />
AFS Group Limited<br />
Mrs R Andre<br />
Australian Pacific Tours<br />
Berwick Opportunity Shop Incorporated<br />
Bill Kee & Associates<br />
Mr E Bladeni<br />
Bolt Blowers Surf Carnival<br />
Boral Clay Concrete<br />
Ms Lucy Bretherton<br />
Brookfield Multiplex Construction<br />
Mr John Bugg<br />
Carpet Court Australia<br />
Citi Power/Powercor<br />
Costa Exchange<br />
Coventry Group Limited<br />
Ms Kate Cowen<br />
CSR Lightweight Systems<br />
DCWC Management Pty Ltd<br />
Dulux Powder Industrial &<br />
Refinishing Coatings<br />
Energy Power Systems<br />
Mr Andrew Erikson<br />
Mrs Neilma Gantner<br />
Mrs Sylvia Gelman AM MBE<br />
Greatorex Foundation Pty Ltd<br />
Mr Jonathan P Green<br />
Mrs Lesley Griffin<br />
Dr Sandra Hacker AO<br />
Hart Charities Pty Ltd<br />
<strong>Health</strong> Super<br />
<strong>Institute</strong> of <strong>Health</strong> and Biomedical<br />
Innovation, QUT<br />
Jeffrey Thomas & Partners<br />
Mr Gerard Keeghan<br />
Mr A P Kelly<br />
Mrs Diana M Lowe<br />
Ms Regina McInnes<br />
Michael and Andrew Buxton Foundation<br />
Miss M O’Sullevan<br />
Mr R G Pitcher AM<br />
Pratt Family Foundation<br />
Mr & Mrs Robert & Faye Ramsay<br />
Recovery and Recycling Industries P/L<br />
Mr Martin E Ryan<br />
Sanpellegrino Asia Pacifc<br />
Say Family Foundation<br />
Ms Pauline Speedy<br />
Sutton Tools Pty Ltd<br />
The Age<br />
The Ideal Group<br />
Warringal Financial Services Pty Ltd<br />
William Angliss (Victoria) Charitable Fund<br />
Dr Robin Wilson<br />
Wilson Security<br />
Mrs Meredith Woods<br />
$200 - $1,999<br />
Ms Stephanie Aeuckens<br />
Mr Douglas Agnew<br />
Mrs M C Ainsworth<br />
Dr Ken Alexander AM<br />
Ms Nichole Alfreds<br />
Mr Andrew & Michelle Amarant<br />
Ms Elizabeth Angelatos<br />
Professor James Angus AO<br />
Mr & Mrs Ashcroft<br />
Mr D M Aston<br />
Mr Robert Audsley<br />
Mr Rita Avdiev<br />
Dr W J Bailey AO<br />
Mr Paul Bartlett<br />
The Honorable William R Baxter<br />
Dr Josephine Beatson<br />
Mrs & Mr Kerry & James Beer<br />
Mr G R Blair<br />
Mr Michael Blayney<br />
Professor & Mrs Sidney & Felicity Bloch<br />
Dr John P Bomford<br />
Mr John Bowen<br />
Mr & Dr Lino & Di Bresciani<br />
Ms Beth Brown & Mr Tom Bruce AM<br />
Mrs M J Bugg<br />
Mr D M Burke<br />
Mrs Ellen M Burt<br />
Mr Ronald Butlers<br />
Miss E M Butt<br />
Mr Jarrod Byham & Mrs Sally Emerson<br />
C R Kennedy & Company Pty Ltd<br />
Mr Ross Campbell<br />
Mrs Karen Carpentier<br />
Mrs Anne Carroll<br />
Ms M G Cavanagh<br />
The Hon S P & Mrs J J Charles<br />
Mrs Florence Clarridge<br />
Mr & Mrs J L & E S Cleland<br />
Mrs Christine Clough<br />
Mrs E M Coldwell<br />
Mr & Mrs Frank & Dorothy Colwell<br />
Dr & Mrs Geoffrey & Joan Conron<br />
Mr & Mrs B B & S H Cooling<br />
Mrs Heather Coombes<br />
Professor David Copolov & Assoc Professor<br />
Christine McDonald<br />
Mr Kevin J Cosgrave<br />
Mr Frank Cotela<br />
Cotton On<br />
Mrs Anne Cowan<br />
Ms Helen Cowan<br />
Mr L Gordon Darling AC CMG<br />
Mr Ernest F Dawes OBE FTS<br />
Ms Geraldine de Malet<br />
Decor Corporation<br />
Dr & Mrs C M Deeley<br />
Mr Matthew Delasey<br />
Mr & Mrs J & D Dixon<br />
Dixson Trust Pty Ltd<br />
Ms Billie Donaldson<br />
Dr Abe Dorevitch<br />
Mr David Dowdle<br />
Mrs Rose Downer<br />
63
Donations <strong>2011</strong><br />
continued<br />
Eastbeth Services Pty Limited<br />
Mr Carl Elliott<br />
Mr Z Elton & Dr Diana Elton<br />
Mr James O Fairfax AC<br />
Mr Jack Fajgenbaum<br />
The Rooke Family<br />
Mr Nick Farnell<br />
Farrow Wyatt Chartered Accountants<br />
Mr Julian Feller<br />
Finkel Foundation<br />
Mr Roger B Flynn<br />
Mr Clark Forbes<br />
Mr & Mrs Tim & Janine Fredman<br />
Dr A K Fryday<br />
Mrs J A Gabb<br />
Mr Stephen Gatt<br />
Mr James Gear<br />
Glenhuntly Bridge Club<br />
The Hon Alan Goldberg AO QC<br />
Mr R N Gotch<br />
Mrs L M Gourlay OAM<br />
Mrs M R Grady<br />
Mrs J B Guerin<br />
Dr James Guest AM OBE & Mrs Guest<br />
Mr Donald Haig<br />
Ms Olive M Hamilton<br />
Justice H R Hansen<br />
Mr Roy Hardcastle<br />
Miss Joan M Harman<br />
Mrs Lynette Harris<br />
Mr & Mrs Peter & Elaine Harris<br />
Mrs Kathleen Hatch<br />
Mr Ken Hill<br />
Lady Suzanne Holland<br />
Holmes <strong>Institute</strong><br />
Mrs I Y Hoolihan<br />
Ms Janet Hornidge<br />
Ms Brenda Huckstepp<br />
Mr Michael Hutchison<br />
Mr Rowan V Ingpen<br />
Interpath Services Pty Ltd<br />
Dr Brian D James<br />
Professor Norman James<br />
Dr Elcahnan H Januszewicz<br />
Ms Carolyn Jarrett<br />
64<br />
Annual report <strong>2011</strong><br />
Mr & Mrs L & R Johnson<br />
Johnstaff Projects<br />
Karingal Bowling Club Inc<br />
Mr & Mrs D & M Kaufmann<br />
Ms Lisa Keam<br />
Mr & Mrs P & J Keller<br />
Mr Graeme Kelly<br />
Bryan & June Keon-Cohen<br />
Mr John Kirkhope<br />
Ms Jodie Koch<br />
Mrs B M Kohane<br />
Professor Paul Korner<br />
Mrs Helen Kosky<br />
Mr N Kuperholz<br />
Ms Jennifer Labourne<br />
Ms Margaret Ladanyl<br />
Landman Foundation<br />
Mr R F Lauwers<br />
Mr Peter Lemon<br />
Leo & Mina Fink Fund<br />
Mr D W & Mrs W I Leslie<br />
Mr & Mrs J B & A Leslie AC<br />
Mr Lewis Lester<br />
Mr Ambrose Linke<br />
Mrs E Linton<br />
Ms Pearl Lubansky<br />
Mr Michael Lukis<br />
Mrs J A Lunt<br />
Ms Rosemary B S Macindoe<br />
Mr Don Maloney<br />
Mrs & Mr Prue & John Matthews<br />
Mr C M Maxwell<br />
Dr Ian W McCay<br />
Ms P T McColl<br />
Mr Andrew McComas<br />
Ms Patricia McKendrick<br />
Dr Ruth McMahon<br />
Mr Ian McNally<br />
Dr & Mrs A P & M S McPhate<br />
McPherson’s Limited<br />
Mrs Marsha Merory<br />
Metro Signs<br />
Mr John Michaux<br />
Mr Nicholas Miller<br />
Mr & Mrs G A & C R Morgan<br />
Kate Morris<br />
Mr & Mrs Tony & Sue Morrison<br />
Mr Richard Moshinsky<br />
Dr Bruce Munro<br />
Next Step Recruitment Company Pty Ltd<br />
Mr & Mrs John & June Nixon-Smith<br />
Mr Barry N Novy<br />
Ms H M Oakes<br />
Mrs Doreen O’Brien<br />
Mrs S Ohl<br />
Mrs Gail O’Reilly<br />
Mr Damien O’Shea<br />
Mr Jeremy Paterson<br />
Mr Guy Pearce<br />
Penfold Motors<br />
Ms Daniella Phillips<br />
Pipers Creek Pty Ltd<br />
Mrs Margaret Poh Kam Chan<br />
Mrs Jean Potter<br />
Mr Helmut Putz<br />
Mr John Ralph AC<br />
Mrs Ann Reid<br />
Mr Ralph Renard<br />
Mr Chris Richardson<br />
Ritchies Expense Company<br />
Mr Mark Robertson<br />
Rock’n Suzies<br />
Mr D W Rogers<br />
Rotary Club of Geelong East Inc<br />
Mrs Patricia D Rowe<br />
Mr & Mrs P & E Ryba<br />
Mr Quin Scalzo<br />
Ms Jane Schmeiszl<br />
Mr Ian Seymour<br />
Dr Garry Sheehan<br />
Mr Andrew Shenton<br />
Mr & Mrs M & J Simmons<br />
Mr Bardie Simpson<br />
Miss P Smart<br />
Mr A W Smith<br />
Dr Sylvia Solinski<br />
Ms Natalie Solopotias<br />
Somerville Lions Club<br />
Mr & Mrs Des & Margie Speakman<br />
Mr & Mrs A W Stephens
Mr Russell Stewart<br />
Mr Robert Stinson<br />
Mrs Fay Strachan<br />
Mr & Mrs Colin & Carolyn Stubbs<br />
Ms R E Swanson<br />
Mr Rowan Tatchell<br />
Mr Robin Taylor<br />
Mr & Mrs Peter & Debbie Thomas<br />
Mr & Mrs J G Thrum<br />
Mrs Marjorie Todd<br />
Dr Diana Tolhurst<br />
Dr Gad Trevaks AM<br />
Dr Kay Tudor<br />
Dr David Tyrwhitt<br />
Mr Roger van Assche<br />
Ms Sally van Doorn<br />
Mr David Vernon<br />
Mr Stan Wallis AC & Mrs Judith Wallis<br />
Mr & Mrs R N Walters<br />
Mr & Mrs Ralph & Barbara Ward-Ambler AM<br />
Mr Geoffrey N Webb<br />
Dr Peter J Webster<br />
Mr Philip Weickhardt<br />
Ms Rachela H West<br />
Mrs Kathleen Westlake<br />
Mr & Mrs John & Robyn Wilkins<br />
Mr Harry Williams<br />
Mrs Lyn Willis AM<br />
Mrs Margaret Wilson<br />
Mr Justin Wilson<br />
Dr Alex Wood<br />
Mr & Mrs L & E Yoannidis<br />
Dr Robin Zeidler<br />
$2 - $199<br />
Mr W J Absalom<br />
Mr & Mrs I D Ada<br />
Mr Peter Adams<br />
Ms Karen Allan<br />
Dr Glenison Alsop<br />
Mr & Mrs P Amato<br />
Ms Angela Anderson<br />
Mr Con Andronis<br />
Mrs Judith Anketell<br />
Ms Betty Appleton<br />
Mrs A M Arbuckle<br />
Mr Daniel Archer<br />
Miss E Arthur<br />
Ms Barbara Ashton<br />
Ms Chrissy Atkins<br />
Australian Productivity Council Pty Ltd<br />
Mrs V Baguley<br />
Mr Peter Baird<br />
Bakers Delight<br />
Mr Clive Baldwin<br />
Mr & Mrs John & Helen Baldwin<br />
Ms Caroline Banhidy<br />
Ms Debbie Banks<br />
Ms Veronica Barcelo<br />
Mr Melvyn Barnett<br />
Mrs Manola P Barrett<br />
Mrs A Barro<br />
Mr G Bartle<br />
Mr J L Bath<br />
Ms Sharon Beaumont<br />
Mrs Doreen Bell<br />
Mrs Diana F Benefield<br />
Miss B R Benjamin<br />
Mr & Mrs Ron & Margaret Benn<br />
Mr David Bennett<br />
Mrs Ruth M Benson<br />
Mr & Mrs L Best<br />
BHP Billiton<br />
Mrs V Bicknell<br />
Ms Margaret Birch<br />
Dr William Birch AM<br />
Dr Ian Birchall<br />
Mrs Annette Bird<br />
Mr & Mrs R D G & M J Birrell<br />
Mr & Mrs G J & S E Birt<br />
Ms Robin S Blair<br />
Mr & Mrs J Blaney-Murphy<br />
Mr Emilio Blasetti<br />
Mr Richard Blaze<br />
Miss Justine Bonello<br />
Ms Youle Bottomley<br />
Ms Margaret Bounader<br />
Ms C Bourke<br />
Mr David Bramley<br />
Mr & Mrs A Brecknell<br />
Mr B M Brennan<br />
Mrs Geni Brewster<br />
Mrs Jaaini Brinckerhoff<br />
Mrs Marietta Brinkley<br />
Mr Alan Brocklebank<br />
Ms Peta Brown<br />
Mr Gary Brown<br />
Mrs Pearl Bruhn<br />
Ms Jacqueline Bryan<br />
Ms Irene Buchanan<br />
Mr J A Buchanan<br />
Ms Mary Budd<br />
Ms Huong Bui<br />
Mr A B Bunnett OAM<br />
Miss R I Byers<br />
Ms Eliza Camera<br />
Mrs B M Campbell<br />
Mr D Capper<br />
Mr C M Carrigan<br />
Mr Dylan Carter<br />
Mrs Susan Carter<br />
Mr Lee Casey<br />
Mrs Tania Cecconato<br />
Mr Anthony E Chaloner<br />
Ms Susan Chapman<br />
Ms Jill Chapman<br />
Ms Amanda Chapman<br />
Mrs P A Chaston<br />
Mr & Mrs M Chatfield<br />
Dr I G Chenoweth<br />
Ms Mary Chester<br />
Mrs L T Christopherson AM<br />
Mr & Mrs R P Churchill<br />
Mr Ski Clark<br />
Mr Brian Clarke<br />
Miss Stacey Clayton<br />
Clayton Bowls Club Inc<br />
Miss Joanna Clements<br />
Mr John Xavier Clifton<br />
Mr James Coady<br />
Mr F J Coates<br />
Mrs Leanne Coburn<br />
Mr Dale Code<br />
Mr & Mrs George & Dot Coffield<br />
65
Donations <strong>2011</strong><br />
continued<br />
Mr Matt Coghlan<br />
Ms S M Cohen<br />
Mr & Mrs M& L Colabattista<br />
Mr & Mrs R & E Colabattsta<br />
Mr & Mrs Mark & Annie Cole<br />
Ms Helen Colla<br />
Mrs Julie Collins<br />
Mr & Mrs A Collins<br />
Mrs Mandy Collins<br />
Mr M.D. deB. Collins Persse<br />
Mr Ross Coniglione<br />
Mrs Augusta Conte<br />
Miss Sarah Cook<br />
Mr Harry Cooper<br />
Ms Noelene Copper<br />
Mrs N Costello<br />
Ms Katrina Cox<br />
Mr James Craven<br />
Ms Mary Crean<br />
Mr & Mrs Louis & Amanda Crema<br />
Mr & Mrs A & J Cresswell<br />
Ms T Cristiano<br />
Mr Andrew Crook<br />
Mrs Pamela Crosthwaite<br />
Dr Wendy Crouch<br />
Mr P Crowe OAM<br />
Mr & Mrs J & C Crutchfield<br />
Ms Bronwyn Culshaw<br />
Mr Peter Cummiskey<br />
Ms Anne Cunningham<br />
Mr Brian Cunningham<br />
Daimz Trading Pty Ltd<br />
Mrs Dall’ Olio<br />
Mr & Mrs G & N Dall ‘Ollio<br />
Ms Pam Dalrymple<br />
Gaylene and Mario D’Antini<br />
Mr Aldo D’Astoli<br />
Mrs Irene E Davidson<br />
Ms Irene Dawson<br />
Mrs R De Grandis<br />
Mrs S Deeves<br />
Mrs Edna Defina<br />
Mrs Pamela Delbridge<br />
Dr Bill Denholm<br />
Mrs Anne Dickinson<br />
66<br />
Annual report <strong>2011</strong><br />
Mrs June Donald<br />
Ms Alison Donovan<br />
Mr David Dowdle<br />
Mrs Rosemary Drenen<br />
Mrs I Duggan<br />
Ms Leonie Dunnachie<br />
Mrs Anne Dunstone<br />
East Devonport Fellowship Group<br />
Mrs Helen Edmonds<br />
Mrs Sandra Edwards<br />
Mr & Mrs F & M Eggleston<br />
Mr Earl Elpers<br />
Ms Sonia Elphick<br />
Mrs P A Fagg<br />
Ms Kaarin Fairfax<br />
Ms P K Falcinella<br />
The Edwards Family<br />
Felice and Maddalena Fattore<br />
Ms Ann Fernando<br />
Ms Fiona Ferrington<br />
Mr Paul Ferronato<br />
Mr & Mrs Mario & Elizabeth Ferronato<br />
Fitzroy Football Club<br />
Ms Tina Forbes<br />
Mrs Nives Forte<br />
Mr & Mrs FRB Forwood<br />
Mr George Fotakis<br />
Mrs Jane Fox<br />
Mrs Lyn Francis<br />
C.N. Fraser<br />
Vera Freidin<br />
Mrs Valmae Freilich<br />
Mr Frank Freschi<br />
Mrs Vera Friedrich<br />
Mr Fred Frohlich<br />
Mr Jordan Gallagher Lyon<br />
Mr & Mrs Sam Galloway<br />
Mr Desmond Gannon<br />
Ms Adriana Garbayo<br />
Ms Bronwyn Gardiner<br />
Garry Martin & Associates Pty Ltd<br />
Mr H Keith Gaze B.E.<br />
Mr R Gehrig<br />
Mr & Mrs D S & V I Gibb<br />
Mr John Gibbs<br />
Miss Belinda Gibson<br />
Mr Raymond Gilbert<br />
Mrs S Gleeson<br />
Glenroy Probus Club<br />
Mr & Mrs R R Goodes<br />
Mrs Doreen Gordon-Kirkby<br />
Ms Anna Gouttmann<br />
Ms Carla Gow<br />
Ms E M Graham<br />
Mrs M L Gray<br />
Ms Wilma Grogan<br />
Mr B J Grogan OAM<br />
Mr Andrew Grondow<br />
Ms Loris L Grote<br />
Mrs H Gulson<br />
H W I Electrical Ltd<br />
Mrs Alice Halasz<br />
Ms Dorothy Hall<br />
Mrs Shirley Hallows<br />
Miss V E Harding<br />
Mrs Faye Hare<br />
Mr & Mrs G B Hargreaves<br />
Mrs E Harman<br />
Ms Elise Harper<br />
Mrs Elizabeth Harrison<br />
Mr & Mrs T Hart<br />
Ms Azura Hashim-Arshad<br />
Mrs June Haughton<br />
Mrs Susan Hawes<br />
Mrs Margaret A Hawksworth<br />
Mr Joshua Haywood<br />
Mrs Anne-Marie Healy<br />
Mrs Rosemary Heide<br />
Ms Elizabeth M Heinze<br />
Mrs Susanna Henry<br />
Dr Ian Hewson<br />
Mr & Ms Graeme & Chris Higgs<br />
Mrs Margaret Higgs<br />
Ms Margaret Hill<br />
Ms W E Hirst<br />
Mr Paul Hitchinson<br />
Mr & Mrs Ian & Joy Hodgson<br />
Mrs Jean Hofmaier<br />
Mrs H Holman<br />
Mr Allan Holoyda
Ms Nanette Home<br />
Mrs J Homewood<br />
Mr John Hopper<br />
Mr Julian Hopper<br />
Mr Peter Houghton<br />
Mr L Hughes<br />
Miss L Hughes<br />
Mr Eric Hunter<br />
Mr B Hurst<br />
Dr Andrew Hutchison<br />
Dr Agim Hymer<br />
Ms Marilyn Imbery<br />
Mr Jave Ivanovski<br />
Mrs H E Jackson<br />
Ms Nola Jackson<br />
Mr & Mrs A S Jackson<br />
Mr & Mrs K A & N J Jackson<br />
Ms Therese James<br />
James Bennett Pty Ltd<br />
Miss Jennifer Jamison<br />
Mr Bassim Jebeili<br />
Mr Philip Jefferies<br />
Ms Dianne Jenkins<br />
Ms Helen Jennings<br />
Mrs S Johnstone<br />
Mr Ross J Johnstone<br />
Ms Eunice Jolliffe<br />
Mrs Delys Jolly<br />
Mrs C L Jones<br />
Mr Roger Jones<br />
Ms Leonie Joynson<br />
Mrs Rachel Kalman OAM<br />
Ms Margaret Kaye<br />
Mrs Peg Keast<br />
Ms Maree Keating<br />
Ms Sue Kelly<br />
Ms Belinda Kelly<br />
Mr Andrew Kelly<br />
Ms Jennifer Kelso<br />
Mrs J Kennedy<br />
Ms Heather Kinang<br />
Mr & Mrs John & Margaret King<br />
Mr & Mrs B & V King<br />
Mr G E King<br />
Mrs Joyce Kirk<br />
Mr A J Kirkh AM<br />
Mr M C Kirkland<br />
Mr David Knight<br />
Mrs Pam Knott<br />
Ms Jan Knox<br />
Mr & Mrs Bill & Dianne Koller<br />
Mr P Kolliner OAM<br />
Mr & Mrs L & M Kovacs<br />
Mr & Mrs Kowalski<br />
Dr Jerzy Krupinski<br />
Ms Jane Kunstler<br />
Mr G Kuran<br />
Mr Don Kuruppu<br />
Ms Kathy Lai<br />
Ms Joyce Laing<br />
Mrs Lamberti<br />
Mrs Bella Lamers<br />
Mr John Landy AC CVO MBE<br />
Mr R Lanini<br />
Mrs Rita Lavale<br />
Mr & Mrs J & B Le Boeuf<br />
Mr Hoe Lee<br />
Mr Stephen Leitch<br />
Mr & Mrs G F Lenton<br />
Mrs Barbara Leorke<br />
Drs P S & N G Lewis<br />
Mrs Penny Lewisohn<br />
Ms Mary Lipshut<br />
Mr & Mrs I Little<br />
Rod & Marg Lowther<br />
Mrs Joan Lucas<br />
Lundbeck<br />
Mrs Doreen Lydeamore<br />
Mrs M Lynch<br />
Mr John MacDermott<br />
Mr & Mrs Lindy & Roger MacRaild<br />
Mr & Mrs Mario & Julie Magaten<br />
Mrs S P Maher<br />
Mrs Joan Mann<br />
Mrs M D March<br />
Mr S Marks OAM<br />
Miss M I Marris<br />
Mrs Joy L Marsh<br />
Mr & Mrs D Marshall<br />
Mrs Dymphna Mason<br />
Mrs Carmel Mastwyk<br />
Mrs F M Matthews<br />
Mr & Mrs R & B Mazzucchelli<br />
Mr & Mrs C G & P V McAleer<br />
Mr Brian McAllister<br />
M McBriar<br />
Mrs E M McCann<br />
Mr Sean McCarthy<br />
Mr & Mrs Gwen & Peter McCarthy<br />
Mrs J McCauley<br />
Mr Ben J McConchie<br />
Lindy & Glynn McConnell<br />
Mr John McCormack<br />
Mr & Mrs D McCullough<br />
Mr B J McDonald<br />
Mr John McEncroe<br />
Ms Marion McEwin<br />
Clare McGee<br />
Ms Peta McIver<br />
Ms Judith Mckenzie<br />
Ms Roslyn McKnight<br />
Mr W G McLean<br />
Mr John McLeish<br />
Mrs Theresa McManus<br />
Mrs Janice Medway<br />
A & N Mezzalira<br />
F Miccoli<br />
Mrs K Mills<br />
Mir Bros Group of Companies<br />
Mrs Franca Moffa<br />
Mr K Moller<br />
M Monty<br />
R Monty<br />
Mr John Moody<br />
Miss Kate Moore<br />
Mrs Alison Morgan<br />
Miss J Morgan<br />
Mr N Moulden<br />
Mrs Penelope Mullner<br />
Mr George Mulvey<br />
Munday Des & Son<br />
Mrs A I Murphy<br />
Ms Catherine Murphy<br />
Ms Natalie Murray<br />
Mrs Kate Murtagh<br />
67
Donations <strong>2011</strong><br />
continued<br />
Mr Neetesh Nambiar<br />
Mr Cyrus Nanavati<br />
Mr and Mrs I T & B M Naylor<br />
Ms Alison Nghiem<br />
Mr Gary Nicholls<br />
Mrs Kerry Nicolussi<br />
Mr C A Nilsen<br />
Mr & Mrs RM & D Nossbaum<br />
Ms Jane Novak<br />
Mr Trevor R Nuttall<br />
Mrs Elizabeth Nuzum<br />
Mr Ian T Oakley<br />
Mrs Cynthia O’Brien<br />
Ms Anne O’Brien<br />
Mr Peter O’Brien<br />
R M O’Collins<br />
Mrs R O’Connor<br />
Mr & Mrs Ian & Shirley O’Keefe<br />
Mrs Clarissa O’Meara<br />
Mr L Orback<br />
Mr Gordon Ortmann<br />
Ms Loren Oscari<br />
Mr & Mrs Richard Oxborrow<br />
Mr John S Palmer<br />
Mrs Ella Panes<br />
Mrs Kamala Paramanathan<br />
Mr G Parham<br />
Mrs Jean Parker<br />
Mrs Anne Parker<br />
Mrs F J Parris<br />
Mr Gerald Pascoe<br />
Mrs Greg Paterson<br />
Mr D Patisteas OAM<br />
Mr Peter John Payne<br />
Ms Linda Pearce<br />
Ms Deb Peart<br />
Mrs Mary Pederick<br />
Ms Tanya Penny<br />
Mr S Perelstein<br />
Ms Christine Perkal<br />
Mr Denis Philipatos<br />
Mrs Catherine Philps<br />
Ms Michelle Picker<br />
Miss C A Pickering<br />
Ms Susan Pike<br />
68<br />
Annual report <strong>2011</strong><br />
Dr D M Pinkerton<br />
Mr Roland Pless<br />
Alison & Richard Poole<br />
Mr Alan Powell<br />
Mrs Helen Power<br />
Mr J W R Pratt<br />
Mrs J E Preston<br />
Ms Joan Preston<br />
Ms Elaine Price<br />
VJ & SD Price<br />
Mr Thomas Prince<br />
Mrs Marie Proudlock<br />
Mr J T Prowse<br />
Mrs S Pullen<br />
Miss Sue Pyke<br />
Mr Peter Raad<br />
Ms Carmen Rakic<br />
Mrs Judith Raleigh<br />
Mr Alan Ramsay<br />
Miss Vizma Rasa<br />
Ms Judith Raymond<br />
Ms Patricia Re Sanctis<br />
Ms Estelle Redlich<br />
Mr & Ms I & M Rhodes<br />
Ms Marg Rhodes<br />
Mrs Glenda Rice<br />
Mrs Samantha Rickinson<br />
Ms Fiona Rigg<br />
Mrs Cecilia Rigoni<br />
J Rinaldi<br />
Mr N Rippon<br />
Dr Rachel Robbins<br />
Ms S Robertson<br />
Mrs Marie Robertson<br />
Mr & Mrs S Robertson<br />
Mr & Mrs Arthur and Janet Robertson<br />
Mrs Ann Robertson<br />
Mrs Margaret Robson<br />
Mrs Ivy E Roebuck<br />
Ms Betty Rogers<br />
Ms Kitty Rohan<br />
Mrs L Rosa<br />
Mrs Luciana Rossiani<br />
Mrs A Rossiani<br />
Mrs M Rothman<br />
Mr Alan Rotman<br />
Ms & Mr Cynthia & John Rowe<br />
Mrs Margaret Royston<br />
Mr Logan Russell<br />
Russell Family Trust<br />
Mr Vincent W Sabapro<br />
Ms Vardit Sacks-Davis<br />
Miss Pat Sadler<br />
Mr James W Sadler<br />
Ms Gayle Salisbury<br />
Ms Mary Salispas<br />
Mr Michael Same<br />
Mr Matthew Savage<br />
Ms Mary S Schembri<br />
Mr & Mrs D & W Schieven<br />
Mrs Lilli Schieven<br />
Miss Tahira Scott<br />
Miss Megan Setches<br />
Mrs S Seward<br />
SGI Consulting Group<br />
Mrs Jaya Sharman<br />
Sietel Ltd<br />
Mrs Dorothy Simpson<br />
Mrs M A Sincock<br />
Peter & Einat Singer<br />
Ms Lynne Slade<br />
Ms Sandra Sloane<br />
Ms Justine Sloane-Lees<br />
Dr Maurice Slonim<br />
Small Family Charitable Foundation<br />
MRS Stacey Smith<br />
Ms Heather Smith<br />
Ms Kylie Smith<br />
Mr & Mrs Mike & Maria Smith<br />
Mr Andrew Smith<br />
Mrs Valda Smith<br />
Mr Anthony Smith<br />
Mr Mark Smithies<br />
Mr Samuel Smorgon AO<br />
Mr Barry Smyth<br />
Mr Graham Snell<br />
Ms Liz Somerville<br />
Mr F B Sommervelle<br />
Ms Mavis Sorensen<br />
Mrs Rona Soulsby
Mr & Mrs E Sparrius<br />
Ms Wendy Staal<br />
Mrs Patricia Stallwood<br />
Dr Jan Steel<br />
Ms Katherine Steen<br />
Mr & Mrs Phillip & Genny Steer<br />
Dr & Mrs W B Stephens<br />
Dr P Stephenson<br />
Ms Tracee Stevens<br />
Mrs Margaret Stewart<br />
E Stollery<br />
Ms Caroline Storm<br />
Miss Summer Stott<br />
Mr Stephen Stuart<br />
Mr J N Stucki<br />
Mr & Mrs Anthony Sullivan<br />
Mrs Coral Sundblom<br />
Dr Santhi Devi Suresan<br />
Ms Rene Sutton<br />
Mr & Mrs G & L Swan<br />
Ms Denise Sykes<br />
Mr Stephen Szental<br />
Dr Niv Tadmore<br />
Mr P Taranto<br />
Mr Angelo Taranto<br />
Ms Kathryn Taylor<br />
Mrs Georgina G Taylor<br />
Mr John Taylor<br />
Mr Adam Teeuwsen<br />
Ms Patsy Thatcher<br />
Mrs Sue Thomas<br />
Mr Derek Thompson<br />
Ms Karlene Thompson<br />
Mrs L Thomson<br />
Mr & Mrs A & M Thomson<br />
Mr Dougal Thomson<br />
Mr & Mrs B Tieppo<br />
Ms Gina Tieppo<br />
Mrs Paula Tobias<br />
Mrs V Tolliday<br />
Mr Mitchell Toole<br />
Gabrielle Trainor<br />
Mr & Mrs Ron & Jan Trainor<br />
Mrs E Trevena<br />
Mr & Mrs J & E Treverton<br />
Mr & Mrs Andrew Trimble<br />
Mr & Mrs Vince & Angela Tudini<br />
U3A Melbourne City Inc<br />
Ms M Ullin<br />
Ms Sybil M Ungar<br />
Miss Cinnamon Van Reyk<br />
Mrs R Van Riel<br />
Mrs Lubertha C Van Slageren<br />
Ms Jackie Vandeligt<br />
Mrs Patricia Varga<br />
Mr & Mrs G & A Varrato<br />
Mr Luke Vaughan<br />
Mrs D E Vernon<br />
Ms J.R Vroland<br />
Mr Adam Vujic<br />
Mr John Wagstaff<br />
Ms J Waide<br />
Mr & Mrs Barry & Tina Wakelin<br />
Mrs Adrian Wakenshaw<br />
Mrs J R Walker<br />
Ms Liisa Wallace<br />
Ms Helen Walsh<br />
Mr Stephen Ward<br />
Mr J & R Wardlaw<br />
Mrs Dorothy Warren<br />
Mrs Judith A Waters<br />
Mr Tim Watkin<br />
Mr & Ms Nigel & Stella Watson<br />
Ms Sally Watson<br />
Miss A D Watson<br />
Miss Vanessa Watson<br />
Mr Maxwell Watson<br />
Mrs Norma Watt<br />
Mr Stuart Waugh<br />
Mrs Jill Webber<br />
Ms Brigitte Weber<br />
Ms Sara Weis<br />
Mr Justin Welsh<br />
Mr & Mrs David & Carol West<br />
Ms & Mr Jan & Phil West<br />
Mr Neil M Westaway<br />
Mr Graham Westmore<br />
Mrs Joyce Whistance<br />
Mrs C White<br />
Mr James White<br />
Miss Emily Whitelaw<br />
Mr & Mrs K P & M M Wilks<br />
Ms Carol Willenberg<br />
Toni Williamson<br />
Mrs Judy Wilmot<br />
Mr Ian Wilmoth<br />
Ms Beth Wilson<br />
Mr P Wilson<br />
Yvette Wilson<br />
Miss Doris L L Wisniewski<br />
Mrs June Witheford<br />
Mr Arnold Wittner<br />
Mrs Rosyln Wood<br />
Mr Jon Wood<br />
Mr & Mrs T & M Wood<br />
Dr Philip R Wood<br />
Mrs Brenda Woods<br />
Dr John Woodward<br />
Ms Sandra Wurf<br />
E M Wurf<br />
Mr & Mrs Michael & Lou Yates<br />
Ms Tanya Yi<br />
Mr & Mrs Alan & Linda Young<br />
Ms Kirsty Young<br />
Mr Mario Zaltron<br />
Mr & Mrs G F Zambelli<br />
Mr Victor Ziccone<br />
69
A Brief History<br />
The Kennedy Report of January 1950, identified<br />
the need to upgrade the quality and number<br />
of trained personnel in the Victorian <strong>Mental</strong><br />
<strong>Health</strong> Service sector and set in motion<br />
the establishment of the <strong>Mental</strong> <strong>Health</strong><br />
<strong>Research</strong> <strong>Institute</strong>.<br />
The <strong>Mental</strong> Hygiene Act (1950) created the <strong>Mental</strong> Hygiene<br />
Authority, which became operational in 1952 under the<br />
chairmanship of Dr Eric Cunningham Dax and Deputy<br />
Chairman Dr Charles Brothers. In 1954, Dr Alan Stoller<br />
was appointed as Chief Clinical Officer to the Authority.<br />
Dax, Brothers and Stoller worked together to create the<br />
<strong>Mental</strong> <strong>Health</strong> <strong>Research</strong> <strong>Institute</strong> (MHRI).<br />
The <strong>Mental</strong> <strong>Health</strong> <strong>Research</strong> <strong>Institute</strong> was officially opened on<br />
10 May 1956 by Sir Ian Clunies-Ross, Chairman of the CSIRO.<br />
Dr Stoller had been appointed the inaugural Director. MHRI<br />
became a physical reality within the grounds of the Annex of<br />
the Royal Park Receiving House in pre-fabricated ex-army<br />
buildings. This building subsequently became part of the<br />
Parkville Psychiatric Unit. <strong>Research</strong> was supported by<br />
collaborations with The University of Melbourne and the<br />
<strong>Mental</strong> <strong>Health</strong> Donations Trust Fund (jointly administered by<br />
the University, the Authority and ‘lay representation’).<br />
In 1956, the aims of MHRI were to:<br />
a) act as a focus of research into mental illness in Victoria;<br />
b) study and develop aspects of the prevention of mental<br />
ill-health in Victoria; and<br />
c) promote an informed community understanding of<br />
mental health problems.<br />
The <strong>Mental</strong> <strong>Health</strong> Central Library was part of the MHRI at<br />
the beginning. In 1960, a statistical epidemiological unit was<br />
incorporated. The Charles Brothers Museum and Archives<br />
became an integral part in 1965. In 1966, The Parkville<br />
Psychiatric Unit was opened following the foundation of the<br />
Cato Chair of Psychiatry at The University of Melbourne.<br />
70<br />
Annual report <strong>2011</strong><br />
In 1970, the <strong>Institute</strong> was renamed the <strong>Institute</strong> of <strong>Mental</strong><br />
<strong>Health</strong> <strong>Research</strong> and Postgraduate Training. Dr Richard<br />
Ball became the Chief Clinical Officer of the <strong>Mental</strong> <strong>Health</strong><br />
Authority and also Director of the <strong>Research</strong> <strong>Institute</strong>.<br />
The Neuro-psychiatric Centre at Mont Park Hospital was<br />
incorporated into the <strong>Institute</strong>. In 1974, the Melville Clinic<br />
(an experimental community mental health centre) was<br />
established, and in 1976, a Drug Information Centre was<br />
also established. Both the Clinic and the Drug Information<br />
Centre were associated with the <strong>Institute</strong>. A <strong>Mental</strong> <strong>Health</strong><br />
<strong>Research</strong> Council was established in 1977. From 1978 - 1981,<br />
Dr John Grigor was Chief Clinical Officer and Director of the<br />
<strong>Institute</strong>, followed by Dr Jerzy Krupinski.<br />
The <strong>Health</strong> Commission of Victoria was formed in 1978 arising<br />
from the Syme/Townsend Report. This marked the end of<br />
the <strong>Mental</strong> <strong>Health</strong> Authority. Under the Chairmanship of Dr<br />
Gad Trevaks, the new <strong>Health</strong> Commission promoted mental<br />
health research with two major initiatives. One was to arrange<br />
for Monash University to establish a Chair in Psychological<br />
Medicine situated at Royal Park and the Alfred Hospital<br />
(Professor Bruce Singh was appointed in 1984). The second<br />
initiative started in 1979 when the <strong>Health</strong> Commission, under<br />
the leadership of Dr George Lipton, Director of the <strong>Mental</strong><br />
<strong>Health</strong> Division, convened a Working Party (consisting of D.<br />
Penington, P. Korner, G. Schofield, W. Ironside, R. Scotton,<br />
G. Lipton (chair), W. White, J. Cone and J. Grigor). It presented<br />
its findings in September 1984 and recommended that the<br />
MHRI be further developed, incorporated, be affiliated with<br />
one university and have a close relationship with one or more<br />
mental health services of hospitals. Appropriate funding was<br />
recommended for a new building sited at Royal Park Hospital.<br />
The Commission then sought government approval (from then<br />
Minister David White) for the <strong>Institute</strong> Director position to be<br />
transferred out of the public service and into an independent<br />
entity with academic affiliations.
In September 1985, Professor David Copolov was recruited<br />
as Director of MHRI, to develop independence outside the<br />
structure of the public service. MHRI then relocated to the<br />
grounds of the Royal Park Hospital in February, 1986, with an<br />
initial staff complement of 13 people, and an annual budget<br />
of less than $500K. Professor Copolov, with the assistance<br />
of Dr Trevaks was successful in persuading Mr Richard<br />
Pratt to become the inaugural Chair of the Board of a fully<br />
incorporated ‘MHRI of Victoria’ in March 1987. In 1993/94,<br />
the Board succeeded in raising funds for a new building on<br />
Oak Street partly incorporating an older pre-World War II<br />
kitchen converted into a laboratory. The institute then grew<br />
to a substantial centre which combined clinical research<br />
with neuroscience activity. In November 2000 the <strong>Institute</strong><br />
changed to a company limited by guarantee. In 2010 the<br />
‘of Victoria’ was deleted from the company name.<br />
In <strong>2011</strong>, the MHRI relocated into new facilities in the<br />
Melbourne Neuroscience Centres in Parkville and<br />
Heidelberg.<br />
Brief History of the <strong>Institute</strong> prepared by<br />
Professor Colin Masters. May <strong>2011</strong><br />
Directors of MHRI<br />
1956 – 1969 Dr Alan Stoller<br />
1970 – 1977 Dr Richard Ball<br />
1978 – 1981 Dr John Grigor<br />
1981 – 1985 Dr Jerzy Krupinski<br />
1985 – 2004 Prof David Copolov OAM<br />
2004 – 2006 Prof George Fink<br />
2007 – Prof Colin Masters<br />
Chairs of the Board of the independent MHRI<br />
1987 – 1994 Mr Richard Pratt<br />
1994 – 2002 Dr Ben Lochtenberg<br />
2002 – 2009 Mr Bruce Kean AM<br />
2009 – Dr Sandra Hacker AO<br />
Major Donors to the Melbourne<br />
Neuroscience Project<br />
Commonwealth Government of Australia<br />
Greatorex Foundation<br />
Alison and John Kearney<br />
Ian Potter Foundation<br />
Myer Foundation<br />
David Say<br />
State Government of Victoria<br />
71
Further Information<br />
Donations<br />
Individuals and organisations interested in financially<br />
supporting the <strong>Institute</strong>’s work, or needing to advise a change<br />
of address, should contact Marketing & Communications on<br />
(03) 8344 1828, or via email enquiries@mhri.edu.au<br />
<strong>Institute</strong> publications<br />
The annual report is the main source of information for<br />
our supporters. Supplementing this publication is a free<br />
bi-annual newsletter which outlines recent developments<br />
at the <strong>Institute</strong>. Contact Marketing & Communications on<br />
(03) 8344 1824 for placement on the Towards Understanding<br />
or annual report mailing lists, or simply to notify a change<br />
of address.<br />
72<br />
Annual report <strong>2011</strong><br />
Volunteers to assist with research trials<br />
The <strong>Institute</strong> is always looking for people to assist us with<br />
our research. This assistance can take a number of courses.<br />
For example, sometimes we have new drugs to trial for<br />
Alzheimer’s disease, or we may want to compare responses<br />
in a group of people without mental illness with those<br />
who have a mental illness. Please call the <strong>Institute</strong> on<br />
(03) 9388 1633 if you would like to be directly involved in<br />
our research.<br />
Bequests<br />
The <strong>Institute</strong> has been able to continue its research and<br />
add strength to its work thanks to the people who have<br />
remembered the organisation’s work in their will. For further<br />
information about how to make a bequest to The <strong>Mental</strong><br />
<strong>Health</strong> <strong>Research</strong> <strong>Institute</strong>, please contact the Bequest<br />
Officer or via email enquiries@mhri.edu.au
Why make a Will<br />
Making a Will ensures that your estate is distributed according<br />
to your wishes. After considering the needs of your family<br />
and friends, do think about making a gift in your Will to our<br />
research. Your gift, no matter what the amount, will help<br />
support our efforts to find better treatments for Alzheimer’s<br />
disease, schizophrenia and depressive illnesses. We strongly<br />
recommend you seek the professional advice of a solicitor<br />
when making your Will. However, a general guideline for<br />
wording is as follows:<br />
I Give Devise And Bequeath to the <strong>Mental</strong> <strong>Health</strong><br />
<strong>Research</strong> <strong>Institute</strong> Incorporated of 30 Royal<br />
Parade, Parkville, free of all duties the sum<br />
of……………. (or details of real property,<br />
shares or other assets) to be applied by it for its<br />
general purposes and I direct that the receipt<br />
of its Treasurer or other proper officer shall be<br />
full and sufficient discharge to my Executors.<br />
73
74<br />
Thanks for<br />
your support<br />
To each of our supporters, thank you for your<br />
important contribution supporting our<br />
researchers in their endeavours to find the<br />
missing pieces of the puzzle which will enable<br />
the detection, prevention and treatment of<br />
mental illness and neurodegenerative disease.<br />
Annual report <strong>2011</strong>
Linh<br />
Lam<br />
Dedicated staff<br />
<strong>Research</strong> Assistant<br />
“In <strong>2011</strong>, I was involved in Alzheimer’s disease<br />
research and the oxidation biology of the<br />
Amyloid Precursor Protein (APP) associated<br />
with the disease. The highlight for me was<br />
definitely the time where my group discovered<br />
a possible oxidase function of APP which<br />
resulted in a number of high impact peer-<br />
reviewed scientific journal publications. I look<br />
forward to continuing my research at MHRI.”<br />
75
Kenneth Myer Building<br />
30 Royal Parade (corner Genetics Lane)<br />
Parkville VIC 3052<br />
T: +61 3 9388 1633<br />
F: +61 3 9035 8642<br />
E: enquiries@mhri.edu.au<br />
mhri.edu.au ABN 48 101 228 451